WO2014201409A1 - Phosphatidylinositol 3-kinase inhibitors - Google Patents

Phosphatidylinositol 3-kinase inhibitors Download PDF

Info

Publication number
WO2014201409A1
WO2014201409A1 PCT/US2014/042392 US2014042392W WO2014201409A1 WO 2014201409 A1 WO2014201409 A1 WO 2014201409A1 US 2014042392 W US2014042392 W US 2014042392W WO 2014201409 A1 WO2014201409 A1 WO 2014201409A1
Authority
WO
WIPO (PCT)
Prior art keywords
diamino
oxo
chloro
dihydroquinazolin
carbonitrile
Prior art date
Application number
PCT/US2014/042392
Other languages
French (fr)
Inventor
Jerry Evarts
Joshua Kaplan
Musong Kim
Leena Patel
Stephane Perreault
Gary Phillips
Jennifer A. TREIBERG
Joshua Van Veldhuizen
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES14738957.1T priority Critical patent/ES2667173T3/en
Priority to CA2915129A priority patent/CA2915129C/en
Priority to EP14738957.1A priority patent/EP3008053B1/en
Priority to MX2015017192A priority patent/MX347988B/en
Priority to PL14738957T priority patent/PL3008053T3/en
Priority to SG11201509910YA priority patent/SG11201509910YA/en
Priority to KR1020157035901A priority patent/KR101709436B1/en
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Priority to EA201592182A priority patent/EA028319B1/en
Priority to SI201430672T priority patent/SI3008053T1/en
Priority to CN201480033119.7A priority patent/CN105308034B/en
Priority to AU2014277950A priority patent/AU2014277950B2/en
Priority to JP2015563142A priority patent/JP6030783B2/en
Priority to NZ714710A priority patent/NZ714710A/en
Priority to BR112015031475A priority patent/BR112015031475A2/en
Publication of WO2014201409A1 publication Critical patent/WO2014201409A1/en
Priority to IL242677A priority patent/IL242677B/en
Priority to AU2016201584A priority patent/AU2016201584B2/en
Priority to HK16108969.2A priority patent/HK1220968A1/en
Priority to HK16110710.0A priority patent/HK1223911A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Definitions

  • the present disclosure relates generally to inhibitors of phosphatidylinositol 3- kinase (PI3K) activity and to novel compounds that are selective inhibitors of PI3K delta activity.
  • PI3K phosphatidylinositol 3- kinase
  • PI3K originally was identified as a protein associated with viral oncoproteins and growth factor receptor tyrosine kinases that phosphorylate phosphatidylinositol (PI) and its phosphorylated derivatives at the 3 '-hydroxyl of the inositol ring. See Panayotou et al , Trends Cell Biol 2:358-60 (1992).
  • Class I PI3Ks phosphorylate phosphatidylinositol (PI), phosphatidylinositol-4- phosphate, and phosphatidylinositol-4,5-biphosphate (PIP 2 ) to produce phosphatidylinositol- 3-phosphate (PIP), phosphatidylinositol-3,4-biphosphate, and phosphatidylinositol-3,4,5- triphosphate, respectively.
  • Class II PI3Ks phosphorylate PI and phosphatidylinositol-4- phosphate
  • Class III PI3Ks phosphorylate PI.
  • PI 3-kinase The initial purification and molecular cloning of PI 3-kinase revealed that it was a heterodimer consisting of p85 and pi 10 subunits. See Otsu et al , Cell, 65:91-104 (1991); Hiles et al , Cell, 70:419-29 (1992). Since then, four distinct Class I PI3Ks have been identified, designated as PI3K ⁇ , ⁇ , ⁇ , and ⁇ isomers, each consisting of a distinct 110 kDa catalytic subunit and a regulatory subunit. More specifically, three of the catalytic subunits, i.e.
  • pi 10a, pi 10 ⁇ , and pi 105 each interact with the same regulatory subunit, i.e. , p85, whereas pi 10 ⁇ interacts with a distinct pi 01 regulatory subunit.
  • the patterns of expression of each of these PI3Ks in human cells and tissues also are distinct.
  • the present application provides novel compounds that are inhibitors of PI3K isoforms, such as PI3K5.
  • the application also provides compositions, including
  • compositions, kits that include the compounds, and methods of using and making the compounds.
  • the compounds provided herein are useful in treating diseases, disorders, or conditions that are mediated by PI3K isoforms, such as PI3K5.
  • the application also provides the compounds for use in therapy.
  • the application further provides compounds for use in a method of treating a disease, disorder, or condition that is mediated by PI3K isoforms.
  • the application provides uses of the compounds in the manufacture of a medicament for the treatment of a disease, disorder or condition that is mediated by PI3K isoforms.
  • the PI3K inhibitor is a compound having the structure of formula
  • n 0, 1, 2, or 3;
  • each R 2 is independently halo, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl;
  • R 3 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, or optionally substituted heterocycloalkyl;
  • R 4 is cyano
  • n 0, 1, 2 or 3;
  • each R 1 is independently selected from halogen, cyano, alkyl, or alkylsulfonyl, wherein the alkyl moiety may be optionally substituted with 1 to 3 halogen;
  • n 0, 1, 2 or 3;
  • each R 2 is independently selected from halogen, alkoxy, alkyl, or cycloalkyl, wherein the alkyl moiety may be optionally substituted with 1 to 3 halogen;
  • R 3 is hydrogen, alkyl, or cycloalkyl, wherein the alkyl moiety may be optionally substituted with cycloalkyl;
  • R 4 is cyano
  • the compounds have the structure of formula (I) wherein each R 1 is independently selected from halogen, cyano, Ci ⁇ alkyl, Ci-4 haloalkyl, or C1-4 alkylsulfonyl.
  • each R 1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or
  • each R 2 is independently selected from halogen, C1-4 alkoxy, C1-4 alkyl, Ci-4 haloalkyl, or C3-6 cycloalkyl.
  • each R 2 is independently selected from fluoro, chloro, iodo, bromo, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • the compounds have the structure of formula (I) wherein R 3 is selected from hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl.
  • R 3 is selected from hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C3-6 cycloalkylCi-4 alkyl.
  • R 3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl.
  • n 0, 1, 2, 3, or 4;
  • each R 1 is independently halo, cyano, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optional substituted alkoxy, or S0 2 R lx wherein R lx is optionally substituted alkyl;
  • n 0, 1, 2, or 3;
  • each R 2 is independently halo, -NH 2 , optionally substituted alkoxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl;
  • R 3 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxyalkyl, or optionally substituted heterocycloalkyl ;
  • R 4 is selected from halo, cyano, and -CONH 2 .
  • n 0, 1, 2, 3, or 4;
  • each R 1 is independently selected from halo, cyano, alkyl, or alkylsulfonyl, wherein the alkyl moiety may be optionally substituted with 1 to 3 halogen;
  • n 0, 1, 2, or 3;
  • each R 2 is independently selected from halo, -NH 2 , alkoxy, alkyl, or cycloalkyl, wherein the alkyl moiety may be optionally substituted with 1 to 3 halogen;
  • R 3 is hydrogen, alkyl, or cycloalkyl, wherein the alkyl moiety may be optionally substituted with cycloalkyl;
  • R 4 is cyano, halo, or -CONH 2 .
  • the compounds having the structure of formula (I) wherein R 4 is selected from the group consisting of fluoro, chloro, bromo, iodo, cyano, and -CONH 2 .
  • the compounds have the structure of formula (I) wherein n is 1 or 2. In another embodiment, n is 1. In yet another embodiment, n is 2.
  • the compounds have the structure of formula (I) wherein m is 0, 1 , or 2. In another embodiment, m is 0. In other embodiment, m is 1. In yet another embodiment, m is 2.
  • the compounds have the structure of formula (I), wherein:
  • n 1 or 2;
  • each R 1 is independently selected from halogen, cyano, alkylsulfonyl, or alkyl, wherein the alkyl moiety is optionally substituted with halogen;
  • n 0, 1, or 2;
  • each R 2 is independently selected from halo, alkoxy, alkyl, or cycloalkyl, wherein the alkoxy, alkyl or cycloalkyl moieties are optionally substituted with halogen, alkyl, or cycloalkyl;
  • R 3 is hydrogen, alkyl, or cycloalkyl, wherein the alkyl or cycloalkyl moieties are optionally substituted with halogen or cycloalkyl;
  • R 4 is cyano
  • the compounds have the structure of formula (I), wherein: n is 1 or 2;
  • each R 1 is independently selected from halogen, cyano, Ci ⁇ alkyl, Ci-4 haloalkyl, or C 1-4 alkylsulfonyl;
  • n 0, 1, or 2;
  • each R 2 is independently selected from halogen, C 1-4 alkoxy, d ⁇ alkyl, Ci-4 haloalkyl, or C3-6 cycloalkyl.
  • R 3 is selected from hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C3_6cycloalkylCi_4alkyl;
  • R 4 is cyano
  • the compounds have the structure of formula (I), wherein: n is 1 or 2; each R 1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
  • n 0, 1, or 2;
  • each R 2 is independently selected from fluoro, chloro, iodo, bromo, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
  • R 3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl;
  • R 4 is cyano
  • the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
  • n 2 and m is 2;
  • each R 1 is independently selected from halogen, cyano, C 1-4 alkylsulfonyl, C 1-4 alkyl, or Ci_4 haloalkyl;
  • each R 2 is independently selected from halogen, C 1-4 alkoxy, C 1-4 alkyl, Ci-4 haloalkyl, or C3-6 cycloalkyl;
  • R 3 is selected from hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C 1-4 cycloalkylCi-4 alkyl;
  • R 4 is cyano
  • the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
  • R 1 is independently selected from halogen, cyano, C 1-4 alkylsulfonyl, C 1-4 alkyl, or Ci_ 4 haloalkyl;
  • each R 2 is independently selected from halogen, C 1-4 alkoxy, C 1-4 alkyl, Ci_ 4 haloalkyl, or C3-6 cycloalkyl;
  • R 3 is selected from hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C 1-4 cycloalkylCi_ 4 alkyl; and R 4 is cyano.
  • the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
  • n 2 and m is 1 ;
  • each R 1 is independently selected from halogen, cyano, C 1-4 alkylsulfonyl, C 1-4 alkyl, or Ci_ 4 haloalkyl;
  • R 2 is selected from halogen, C 1-4 alkoxy, C 1-4 alkyl, C 1-4 haloalkyl, or C3-6 cycloalkyl;
  • R 3 is selected from hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C 1-4 cycloalkylCi-4 alkyl;
  • R 4 is cyano
  • the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
  • n i and m is 1 ;
  • R 1 is selected from halogen, cyano, Ci_ 4 alkylsulfonyl, C 1-4 alkyl, or Ci_ 4 haloalkyl
  • R 2 is selected from halogen, C 1-4 alkoxy, C 1-4 alkyl, C 1-4 haloalkyl, or C3-6 cycloalkyl
  • R 3 is selected from hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C 1-4 cycloalkylCi_ 4 alkyl;
  • R 4 is cyano
  • the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
  • R 1 is selected from halogen, cyano, C 1-4 alkylsulfonyl, C 1-4 alkyl, or C 1-4 haloalkyl
  • R 3 is selected from hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C 1-4 cycloalkylCi_ 4 alkyl
  • the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
  • n 2 and m is 0;
  • each R 1 is independently selected from halogen, cyano, C 1-4 alkylsulfonyl, C 1-4 alkyl, or Ci_4 haloalkyl;
  • R 3 is selected from hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C 1-4 cycloalkylCi-4 alkyl;
  • R 4 is cyano
  • the compounds have the structure of formula (I), wherein:
  • n 1 or 2;
  • each R 1 is independently selected from halo, cyano, alkylsulfonyl, or alkyl, wherein the alkyl moiety is optionally substituted with halogen;
  • n 0, 1, or 2;
  • each R 2 is independently selected from halo, -NH 2 , alkoxyalkyl, alkyl, or cycloalkyl, wherein the alkyl or cycloalkyl moieties are optionally substituted with halogen, alkyl, or cycloalkyl;
  • R 3 is hydrogen, alkyl, or cycloalkyl, wherein the alkyl or cycloalkyl moieties are optionally substituted with halogen or cycloalkyl;
  • R 4 is cyano, halo, or -CONH 2 .
  • the compounds have the structure of formula (I), wherein: n is 1 or 2;
  • each R 1 is independently selected from halo, cyano, C 1-4 alkyl, Ci-4 haloalkyl, or Ci_ 4 alkylsulfonyl;
  • n 0, 1, or 2;
  • each R 2 is independently selected from halo, -NH 2 , C ⁇ alkyl, d ⁇ haloalkyl, or C3-6 cycloalkyl.
  • R 3 is selected from hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C3_6cycloalkylCi_4alkyl;
  • R 4 is cyano, halo, or -CONH 2 .
  • the compounds have the structure of formula (I), wherein: n is 1 or 2;
  • each R 1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
  • n 0, 1, or 2;
  • each R 2 is independently selected from fluoro, chloro, iodo, -NH 2 , bromo, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
  • R 3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl;
  • R 4 is cyano, halo, or -CONH 2 .
  • the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
  • n 2 and m is 2;
  • each R 1 is independently selected from halo, cyano, C 1-4 alkylsulfonyl, C 1-4 alkyl, or Ci_ 4 haloalkyl;
  • each R 2 is independently selected from halo, -NH 2 , C 1-4 alkyl, Ci ⁇ haloalkyl, or C3-6 cycloalkyl;
  • R 3 is selected from hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C 1-4 cycloalkylCi-4 alkyl;
  • R 4 is cyano, halo, or -CONH 2 .
  • the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
  • R 1 is independently selected from halo, cyano, Ci_ 4 alkylsulfonyl, Ci_ 4 alkyl, or Ci_ 4 haloalkyl;
  • each R 2 is independently selected from halo, -NH 2 , C 1-4 alkoxy, C 1-4 alkyl, C 1-4 haloalkyl, or C3-6 cycloalkyl;
  • R 3 is selected from hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C 1-4 cycloalkylCi-4 alkyl;
  • R 4 is cyano, halo, or -CONH 2 .
  • the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
  • n 2 and m is 1 ;
  • each R 1 is independently selected from halo, cyano, C 1-4 alkylsulfonyl, C 1-4 alkyl, or Ci_ 4 haloalkyl;
  • R 2 is selected from halo, -NH 2 , C 1-4 alkyl, Ci ⁇ haloalkyl, or C 3-6 cycloalkyl;
  • R 3 is selected from hydrogen, C 1-4 alkyl, C 3 _6 cycloalkyl, or C 1-4 cycloalkylCi-4 alkyl;
  • R 4 is cyano, halo, or -CONH 2 .
  • the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
  • n i and m is 1 ;
  • R 1 is selected from halo, cyano, C 1-4 alkylsulfonyl, C 1-4 alkyl, or C 1-4 haloalkyl;
  • R 2 is selected from halo, -NH 2 , C 1-4 alkyl, C 1-4 haloalkyl, or C 3-6 cycloalkyl;
  • R 3 is selected from hydrogen, C 1-4 alkyl, C 3 _6 cycloalkyl, or C 1-4 cycloalkylCi-4 alkyl;
  • R 4 is cyano, halo, or -CONH 2 .
  • the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
  • R 1 is selected from halo, cyano, C 1-4 alkylsulfonyl, C 1-4 alkyl, or C 1-4 haloalkyl;
  • R 3 is selected from hydrogen, C 1-4 alkyl, C 3 _6 cycloalkyl, or C 1-4 cycloalkylCi-4 alkyl;
  • the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
  • n 2 and m is 0;
  • each R 1 is independently selected from halo, cyano, C 1-4 alkylsulfonyl, C 1-4 alkyl, or Ci_ 4 haloalkyl;
  • R 3 is selected from hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C 1-4 cycloalkylCi-4 alkyl;
  • R 4 is cyano, halo, or -CONH 2 .
  • the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
  • n 1 ;
  • m 1 ;
  • R 1 is selected from halo, cyano, C 1-4 alkylsulfonyl, C 1-4 alkyl, or C 1-4 haloalkyl;
  • R 2 is -NH 2 ;
  • R 3 is selected from hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C 1-4 cycloalkylCi-4 alkyl;
  • R 4 is cyano, halo, or -CONH 2 .
  • the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
  • n 2;
  • m 1 ;
  • each R 1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
  • each R 2 is -NH 2 ;
  • R 3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl;
  • R 4 is cyano, halo, or -CONH 2 .
  • the PI3K inhibitors are the compounds selected from Table 1, or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof.
  • the compounds are the atropisomers.
  • the compounds are the (S)-enantiomer.
  • the compounds are the (R)-enantiomer.
  • the compounds are atropisomers.
  • the application also provides a pharmaceutical composition that includes a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof, together with at least one pharmaceutically acceptable vehicle.
  • pharmaceutically acceptable vehicle may be selected from carriers, adjuvants, and excipients.
  • Also provided herein is a method of treating a disease or condition in a human in need thereof by administering to the human a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof.
  • a compound of formula (I) for use in a method of treating a disease, disorder or condition that is mediated by PI3K isoforms is also provides the use of a compounds of formula (I) in the manufacture of a medicament for the treatment of a disease, disorder or condition that is mediated by PI3K isoforms.
  • the disease or condition is associated or mediated by PI3K.
  • the disease or condition is an inflammatory disorder, an autoimmune disease, or a cancer. In certain other embodiments, the disease or condition is an inflammatory disorder. In other embodiments, the disease or condition is an autoimmune disease. In additional embodiments, the disease or condition is a cancer.
  • Also provided herein is a method of inhibiting kinase activity of a
  • phosphatidylinositol 3-kinase delta polypeptide by contacting the polypeptide with a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof.
  • a method of inhibiting kinase activity of a phosphatidylinositol 3-kinase beta polypeptide by contacting the polypeptide with a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof.
  • a method of inhibiting excessive or destructive immune reactions comprising administering an effective amount of a compound of formula (I) described herein or a pharmaceutically acceptable salt, isomer, a mixture of isomers, or prodrug thereof such as asthma, rheumatoid arthritis, multiple sclerosis, and lupus.
  • a method of inhibiting excess or destructive immune reactions comprising administering an effective amount of a compound of formula (I) described herein or a pharmaceutically acceptable salt, isomer, a mixture of isomers, or prodrug thereof such as psoriasis, or chronic obstructive pulmonary disease (COPD).
  • a compound of formula (I) described herein or a pharmaceutically acceptable salt, isomer, a mixture of isomers, or prodrug thereof such as psoriasis, or chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • Also provided is a method of disrupting leukocyte function comprising contacting the leukocytes with an effective amount of a compound of formula (I) described herein or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof.
  • a method of inhibiting a growth or a proliferation of cancer cells comprising contacting the cancer cells with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof.
  • the cancer cells are of hematopoietic origin.
  • the cancer is lymphoma, leukemia, or solid tumor.
  • kits that includes a compound of formula (I) or a
  • kits may further comprise a label and/or instructions for use of the compound in the treatment of a disease or condition in a human in need thereof.
  • the disease or condition may be associated or mediated by PI3K5 activity.
  • the disease or condition may be associated or mediated by PI3K5 and/or ⁇ 3 ⁇ activity.
  • articles of manufacture that include a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof, and a container.
  • the container may be a vial, jar, ampoule, preloaded syringe, or an intravenous bag.
  • a dash (“-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent.
  • -CONH2 is attached through the carbon atom.
  • Reference to "about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.
  • description referring to "about X” includes description of "X”.
  • the term “about” includes the indicated amount + 10%.
  • the term “about” includes the indicated amount ⁇ 5%.
  • alkyl refers to a monoradicai unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has i to 20 carbon atoms (i.e. , Ci- ? .o alkyl), i to 8 carbon atoms (? ' . ⁇ ;. , Ci-8 alkyl), 1 to 6 carbon atoms (i. e. , Ci-e alkyl), or 1 to 4 carbon atoms (i.e. , C1.4 alkyl).
  • alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyi, sec-butyl, iso- butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3- methylpentyl.
  • butyl can include n-butyl, sec -butyl, isobutyl and t-butyl
  • propyl can include n-propyi and isopropyl
  • Cycloalkyl refers to a cyclic alkyl group.
  • cycloalkyl has from 3 to 20 ring carbon atoms (i.e. , C3-20 cycloalkyl), or 3 to 12 ring carbon atoms (i.e. , C3..12 cycloalkyl), 3 to 8 ring carbon atoms (i.e. , C3.8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e. , ( ' ! , ⁇ , cycloalkyl).
  • Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • Heterocycloalkyl refers to a cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur.
  • heterocycloalkyl has 2 to 20 ring carbon atoms (i.e. , C2-2 0 heterocycloalkyl), 2 to 12 ring carbon atoms (i.e. , C 2-12 heterocycloalkyl), or 2 to 8 ring carbon atoms (i. e. , C2-8 heterocycloalkyl); and 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 or 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur or oxygen.
  • heterocycloalkyl groups may include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidinyl, and morpholinyl.
  • Alkoxy refers to the group “alkyl-O-”. Examples of alkoxy groups may include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n- hexoxy, and 1 ,2-dimethylbutoxy.
  • Aryl refers to an aromatic carbocyclic group having a single ring (e.g. , phenyl), multiple rings (e.g. , biphenyl), or multiple fused rings (e.g. , naphthyl, fluorenyl, and anthryl).
  • aryl groups may include 6 to 20 ring carbon atoms (i.e. , C & . 2 o aryl), or 6 to 12 carbon ring atoms (i.e. , Ce-iz ary )- Aryl, however, does not encompass or overlap in any way with heteroaryl, separately defined below. If one or more aryl groups are fused with a heteroaryi ring, the resulting ring system is heteroaryl.
  • Heteroaryl refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. Heteroaryl may be an aromatic, monocyclic or bicyclic ring containing one or more heteroatoms independently selected from nitrogen, oxygen and sulfur with the remaining ring atoms being carbon. As used herein, heteroaryi include 1 to 20 ring carbon atoms (i.e. , ⁇ ? ⁇ heteroaryl), 1 to 12 ring carbon atoms (i.e. , C .n heteroaryl), or 1 to 8 carbon ring atoms (i.e.
  • heteroaryl groups include pyridyl, pyridazinyi, pyrimidinyl, benzothiazolyi, and pyrazoiyl. Heteroaryi does not encompass or overlap with aryl as defined above.
  • substituted means that any one or more hydrogen atoms on the designated atom or group is replaced with a moiety other than hydrogen, provided that the designated atom's normal valence is not exceeded.
  • Substituted alky refers to an alkyl group having one or more substituents including, for example, hydroxy], haloaikyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cyano, halo, carboxyl, and NR 2» where each R is independently hydrogen, alkyl, haloaikyl, alkylC(O)-, aikylOC(O)-, or H 2 NC(0)-.
  • a substituted alkyl may have 1 to 5 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent.
  • a substituted alkyl may have 1 to 4 substituents.
  • a substituted alkyl is haloaikyl, cycloalkylalkyl, or heterocycloalkylalkyl.
  • a substituted alkyl is Ci- haloaikyl, d-e cycloalkyl, C . heterocycloalkyl, C1- haloaikyl. CM cycloalkyl, or C 1-4 heterocycloalkyl.
  • a substituted alkyl is Ci_e haloaikyl, Ci-6 cycloalkylalkyl, Ci-6 heterocycloalkylalkyl, C haloaikyl, C M.
  • cycloalkylalkyl or C heterocycloalkylalkyl.
  • substituted alkyl group may include - O N ' . -CHF 2 , CF 3 , -CH 2 FCH 3 , -CHF 2 CH 3 , -CH 2 CH 2 F, -CH 2 CF 3 ,
  • cyclopropylmethyi cyclopropylethyl , cyclopropylpropyl, cyclobuty knetbyl, cyciobutyiethyl , or cyclobutylpropyl.
  • Substituted cycloalkyl refers to a cycloalkyl group having one or more substituents including, for example, alkyl, haloaikyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, cyano, halo, carboxyl, hydroxyl, and -N 2 , where each R is independently hydrogen, alkyl, haloaikyl, alkylC(O)-, alkylOC(O)-, or H 2 NC(0)-.
  • a substituted cycloalkyl may have 1 to 5 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent.
  • a substituted cycloalkyl may have 1 to 4 substituents.
  • a substituted alkyl is haloaikyl, cycloalkylalkyl, or heterocycloalkylalkyl.
  • a substituted alkyl is Ci-e haloaikyl, C3-6 cycloalkyl, Ci-6 heterocycloalkyl, C haloaikyl, C3.4 cycloalkyl, or C 1-4 heterocycloalkyl .
  • a substituted cycloalkyl is halocycloalkyl, or alkylcycloalkyl,.
  • a substituted cycloalkyl is C 3 -j halocycloalkyl , Cs-iocycloalkyl, C2-10 heterocycloalkyl, C3-6 halocycloalkyl, C3..6 cycloalkyl, or C2-5 heterocycloalkyl .
  • Substituted heterocycloalkyl refers to a heterocycloalkyl group having one or more substituents including, for example, alkyl, haloaikyl, cycloalkyl, aryl, heteroaryl, alkoxy, cyano, halo, carboxyl, hydroxy!, and -NR 2 , where each R is independently hydrogen, alkyl, haloaikyl, alkylC(O)-, alkylOC(O)-, or H 2 NC(0) ⁇ .
  • a substituted heterocycloalkyl may have 1 to 5 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent.
  • a substituted heterocycloalkyl may have 1 to 4
  • a substituted heterocycloalkyl may contain 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • Substituted aryl refers to an aryl group having one or more substituents including, for example, halo, -OR . -NR 2 , -C(0)NR' 2 , -SO > ⁇ ' k ⁇ >. alkyl, haloalkyl, heterocycloalkyl, heteroaryl, alkoxy, amino, cyano, and carboxyl, where each R is independently hydrogen, alkyl, haloalkyl, alkylC(O)-, a!kvK K ' ; ( ⁇ ;-. or H 2 NC(0)- and each R' is independently hydrogen, alkyl, haloalkyl.
  • a substituted aryl may have 1 to 5 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent.
  • Substituted heteroaryl refers to a heteroaryl group having one or more substituents including, for example, alkyl, haloalkyl, halo, -NR 2 , -OR, -C(0)OR,
  • heterocycloalkyl, aryl, and cyano where each R is independently hydrogen, alky], haloalkyl, alkyiCYO)-, alkylOC(O)-, or H 2 NC(0)-.
  • a substituted heteroaryl may have 1 to 5 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent.
  • a substituted heteroaryl may have 1 to 4 substituents.
  • a substituted heteroaryl may contain 1 , 2 or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • Substituted sulfonyl refers to the group “S0 2 R” where R refers to a substituent including, for example, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, and aryl and R is further substituted with alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, or aryl.
  • Sulfonyl refers to the group “-S0 2 R” where R refers to a substituent including, for example, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, and aryl.
  • the sulfonyl group is alkylsulfonyl, in which R is alkyl.
  • examples of the sulfonyl groups may include S0 2 CH 3 , S0 2 CH 2 CH 3 , or S0 2 Ph.
  • halogen or “halo” includes fluoro, chio.ro, bromo, and iodo, and the term “halogen” includes fluorine, chlorine, bromine, and iodine.
  • Haloalkyl refers to an unbranched or branched chain alkyl group as defined above, wherein one or more hydrogen atoms are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached.
  • dihaloaryl, dihaloalkyl, and trihaloaryl refer to aryl and alkyl substituted with two ("di") or three ("tri") halo groups, which may be, but are not necessarily, the same halogen; thus, for example, 3,5-difluorophenyl, 3-chloro-5-fluorophenyl, 4-chloro- 3-fluorophenyl, and 3,5-difluoro-4-chlorophenyl is within the scope of dihaloaryl.
  • a haloalkyl group include difluoromethyl (-CHF 2 ) and trifluoromethyl (-CF 3 ).
  • a divalent group such as a divalent "alkyl” group, a divalent “aryl” group, etc., may also be referred to as an "alkylene” group or an "alkylenyl” group, an "arylene” group or an
  • arylenyl group, respectively. Also, unless defined otherwise, where combinations of groups are referred to herein as one moiety, e.g. arylalkyl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule.
  • PI3K inhibitors are the compound having formula (II):
  • A is N or CH
  • n 0, 1, 2, 3, or 4;
  • R lx is independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, alkylene-N(R lx ) 2 , optionally substituted aryl, arylalkyl, alkylenearyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, or alkyleneheteroaryl, or two R lx groups are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom,
  • R ly is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, arylalkyl, heteroarylalkyl, alkylenearyl, and
  • n 0, 1, 2, 3, or 4;
  • each R 2 is independently selected from hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, or NR 2x R 2y , wherein each R 2x and R 2y is independently hydrogen, C(0)R 2s or C(0)OR 2s , wherein R 2s is optionally substituted alkyl;
  • R 3 is hydrogen, optionally substituted cycloalkyl, or optionally substituted alkyl; and R 4 is hydrogen, cyano, CON(R 4a ) 2 , S0 2 -alkyl, halo, or haloalkyl, where each R 4a is independently hydrogen or optionally substituted alkyl.
  • the application provides the compounds having the structure of formula (I) that function as inhibitors of PI3K isoforms, such as PI3K5.
  • the structure of formula (I) is shown below:
  • n 0, 1, 2, 3, or 4;
  • each R 1 is independently halo, cyano, optionally substituted alkylsulfonyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted alkoxy;
  • n 0, 1, 2, 3, or 4;
  • each R 2 is independently halo, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl;
  • R 3 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, or optionally substituted heterocycloalkyl;
  • R 4 is cyano
  • n 1, 2, or 3;
  • each R 1 is independently halo, cyano, Ci_ 6 alkylsulfonyl, or Ci_ 6 alkyl, wherein the alkyl moiety is optionally substituted with halogen or cycloalkyl;
  • n 0, 1, 2, or 3;
  • each R 2 is independently halo, Ci_ 6 alkoxy, Ci_ 6 alkyl, or C3_ 6 cycloalkyl, wherein the alkoxy, alkyl, or cycloalkyl moieties are optionally substituted with halogen, alkyl, or cycloalkyl;
  • R 3 is hydrogen, Ci_6 alkyl, or C3-6 cycloalkyl, wherein the alkyl or cycloalkyl moieties are optionally substituted with halogen, alkyl, or cycloalkyl;
  • R 4 is cyano
  • n 1 or 2;
  • each R 1 is independently selected from halogen, cyano, C 1-4 alkyl, Ci-4 haloalkyl, C 1-4 alkylsulfonyl, or C3_6 cycloalkylCi_4alkyl;
  • n 0, 1, or 2;
  • each R 2 is independently selected from halogen, C1-4 alkoxy, C 1-4 alkyl, C 1-4 haloalkyl, C3-6 cycloalkyl, or C3-6 cycloalkylC ⁇ alkyl;
  • R 3 is selected from hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C3_6 cycloalkylCi_4alkyl;
  • R 4 is cyano
  • n 1 or 2;
  • each R 1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
  • n 0, 1, or 2;
  • each R 2 is independently selected from fluoro, chloro, iodo, bromo, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
  • R 3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl;
  • R 4 is cyano
  • n 0, 1, 2, 3, or 4;
  • each R 2 is independently halo, -NH 2 , optionally substituted alkoxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl;
  • R 3 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxyalkyl, or optionally substituted heterocycloalkyl;
  • R 4 is cyano, halo or -CONH 2 .
  • n 1, 2, or 3;
  • each R 1 is independently halo, cyano, Ci_ 6 alkylsulfonyl, or Ci_ 6 alkyl, wherein the alkyl moiety is optionally substituted with halogen or cycloalkyl;
  • n 0, 1, 2, or 3;
  • each R 2 is independently halo, -NH 2 , Ci_ 6 alkoxy, Ci_ 6 alkyl, or C3_ 6 cycloalkyl, wherein the alkoxy, alkyl, or cycloalkyl moieties are optionally substituted with halogen, alkyl, or cycloalkyl;
  • R 3 is hydrogen, Ci_6 alkyl, or C3-6 cycloalkyl, wherein the alkyl or cycloalkyl moieties are optionally substituted with halogen, alkyl, or cycloalkyl;
  • R 4 is cyano, halo or -CONH 2 .
  • n 1 or 2;
  • each R 1 is independently selected from halo, cyano, C1-4 alkyl, Ci ⁇ haloalkyl, C1-4 alkylsulfonyl, or C3_6 cycloalkylCi_4alkyl;
  • n 0, 1, or 2;
  • each R 2 is independently selected from halo, -NH 2 , C1-4 alkoxy, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, or C3_6 cycloalkylCi_4alkyl;
  • R 3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C3_6 cycloalkylCi_4alkyl;
  • R 4 is cyano, halo or -CONH 2 .
  • n 1 or 2;
  • each R 1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
  • n 0, 1, or 2;
  • each R 2 is independently selected from fluoro, chloro, iodo, bromo, -NH 2 , methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
  • R 3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl;
  • R 4 is cyano, halo or -CONH 2 .
  • n 1 or 2;
  • each R 1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
  • n 0, 1, or 2;
  • each R 2 is independently selected from fluoro, chloro, iodo, bromo, -NH 2 , methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
  • R 3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl;
  • R 4 is cyano
  • n is 1 or 2; each R 1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
  • n 0, 1, or 2;
  • each R 2 is independently selected from fluoro, chloro, iodo, bromo, -NH 2 , methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
  • R 3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl;
  • R 4 is fluoro, chloro, or bromo.
  • n 1 or 2;
  • each R 1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
  • n 0, 1, or 2;
  • each R 2 is independently selected from fluoro, chloro, iodo, bromo, -NH 2 , methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
  • R 3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl;
  • R 4 is -CONH 2 .
  • n is 0. In some embodiments, n is 1, 2, 3, or 4. In other embodiments, n is 1, 2 or 3. In certain embodiments, n is 1 or 2. In one
  • n is 1.
  • the R 1 moiety may be located on any position of the quinazolinone ring, as depicted below.
  • n is 2. In embodiments where n is 2, both R may be the same or different. Two R 1 moieties may be located on any two positions of the
  • R 1 moieties may be in para-, meta- or ortho-positio
  • n is 3.
  • all R 1 may be the same or different, or two R 1 may be the same and different from the third R 1 .
  • Three R 1 moieties may be located on any three positions of the quinazolinone ring as depicted below.
  • the first R 1 may be ortho to the second R 1
  • the first R 1 may be para to the third R 1 .
  • n is 4. In embodiments where n is 4, all R 1 may be the same or different, three R 1 may be the same and different from the fourth R 1 , two R 1 may be the same and different from the third and the fourth R 1 .
  • each R 1 is independently halo, cyano, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, or optionally substituted alkylsulfonyl. In certain embodiments, each R 1 is independently halo, cyano, optionally substituted alkyl, or optionally substituted alkylsulfonyl.
  • each R 1 is independently halo, cyano, optionally substituted C 1-4 alkyl, optionally substituted C 1-4 haloalkyl, optionally substituted Ci-4 alkoxy, hydroxy, optionally substituted C3-6 cycloalkyl, or optionally substituted Ci_6 alkylsulfonyl.
  • each R 1 is independently halo, cyano, optionally substituted C 1-4 alkyl, optionally substituted C 3 -6 alkoxy, optionally substituted C3-6 cycloalkyl, or optionally substituted C 1-4 alkylsulfonyl.
  • each R 1 is independently halo, cyano, C 1-4 haloalkyl, C 1-4 alkyl, or C 1-4 alkylsulfonyl.
  • each R 1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl.
  • each R 1 is independently fluoro, chloro, iodo, cyano, methyl, difluoromethyl (-CHF 2 ), trifluoromethyl (-CF 3 ), ethyl, methoxy,
  • each R 1 is independently fluoro, chloro, cyano, methylsulfonyl, methyl, or trifluoromethyl.
  • R 1 is halo, cyano, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, hydroxy, optionally substituted alkylsulfonyl, or optionally substituted cycloalkyl.
  • R 1 is independently halo, cyano, C 1-4 haloalkyl, Ci-4 alkyl, or C 1-4 alkylsulfonyl.
  • R 1 is fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, -CHF2, -CF 3 , fluoroethyl, fluoropropyl, methylsulfonyl, or ethylsulfonyl.
  • R 1 is fluoro, chloro, cyano, methyl, trifluoromethyl (-CF 3 ), or methylsulfonyl (-SO2CH 3 ).
  • R 1 is fluoro, chloro, bromo, cyano, methyl, trifluoromethyl (-CF 3 ), or methylsulfonyl (-SO2CH 3 ).
  • the R 1 moiety may be located on any position of the quinazolinone ring.
  • both R 1 are independently halo, which may be the same (e.g. , both R 1 are fluoro, chloro, or iodo) or different (e.g. , one R 1 is fluoro and the other R 1 is chloro).
  • n 2
  • one R 1 is halo and the other R 1 is optionally substituted alkyl.
  • one R 1 is halo and the other R is optionally substituted cycloalkyl.
  • each R 1 is independently selected from fluoro, chloro, bromo, cyano, methyl, trifluoromethyl (-CF 3 ), or methylsulfonyl (-SO 2 CH 3 ).
  • one R 1 is bromo and the other R 1 is fluoro.
  • both R 1 are chloro, or both R 1 are fluoro.
  • one R 1 is chloro and the other R 1 is fluoro; one R 1 is chloro and the other R 1 is methyl; one R 1 is fluoro and the other R 1 is methyl; one R 1 is fluoro and the other R 1 is cyano; one R 1 is chloro and the other R 1 is cyano.
  • n 2; one R 1 is bromo and the other R 1 is fluoro.
  • the two R 1 moieties may be located at any two positions of the quinazolinone ring as depicted below.
  • n and R 1 may be combined with each and every variation of m, R 2 and R 3 as described for formula (I), as if each and every combination is individually described.
  • m is 0. In certain embodiments, m is 1 , 2, 3, or 4. In other embodiments, m is 1, 2 or 3. In yet other embodiments, m is 1 or 2. In one embodiment, m is 1.
  • the R 2 moiety may be located on any position of the pyridinyl ring, as depicted below.
  • n is 2.
  • both R 2 may be the same or different.
  • the two R 2 moieties may be located on any two positions of the pyridinyl ring, as depicted below.
  • m is 3. In embodiments where m is 3, all R 2 may be the same or different, or two R 2 may be the same and different from the third R 2 . The three R 2 moi low.
  • m is 4. In embodiments where m is 4, all R 2 may be the same or different, three R 2 may be the same and different from the fourth R 2 , or two R 2 may be the same and different from the third and the fourth R 2 .
  • each R 2 is independently halo, cyano, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, or optionally substituted cycloalkyl.
  • each R 2 is independently halo, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted haloalkyl, or optionally substituted cycloalkyl.
  • each R 2 is independently halo, cyano, optionally substituted Ci_6 alkyl, optionally substituted Ci_6 haloalkyl, optionally substituted Ci_6 alkoxy, or optionally substituted C3-8 cycloalkyl.
  • each R 2 is independently halo, -NH 2 , cyano, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, or optionally substituted cycloalkyl.
  • each R 2 is independently halo, -NH 2 , cyano, optionally substituted Ci_6 alkyl, optionally substituted Ci_6 haloalkyl, optionally substituted Ci_6 alkoxy, or optionally substituted C3-8 cycloalkyl.
  • each R 2 is independently halo, -NH 2 , cyano, optionally substituted C1-4 alkyl, optionally substituted C1-4 haloalkyl, optionally substituted C1-4 alkoxy, or optionally substituted C3-6 cycloalkyl.
  • each R 2 is independently fluoro, chloro, iodo, bromo, -NH 2 , methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, - CHF 2 , -CF 3 , fluoroethyl, difluoroethyl, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • each R 2 is independently fluoro, chloro, methoxy, methyl, -NH 2 , -CHF 2 , -CF 3 , or cyclopropyl.
  • each R 2 is independently halo, cyano, optionally substituted Ci_ 4 alkyl, optionally substituted Ci_ 4 haloalkyl, optionally substituted Ci-4 alkoxy, or optionally substituted C3-6 cycloalkyl.
  • each R 2 is independently fluoro, chloro, iodo, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, - CHF 2 , -CF 3 , fluoroethyl, difluoroethyl, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • each R 2 is independently fluoro, chloro, methoxy, methyl, -CHF 2 , -CF 3 , or cyclopropyl.
  • R 2 is halo, cyano, optionally substituted haloalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted alkoxy.
  • R 2 is fluoro, chloro, iodo, cyano, Ci_ 4 alkyl, Ci_ 4 haloalkyl, Ci_ 4 alkoxy, or C3-6 cycloalkyl.
  • R 2 is fluoro, chloro, methoxy, methyl, ethoxy, propoxy, butoxy, pentoxy, hexoxy, -CHF 2 , -CF 3 , fluoroethyl, difluoroethyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • R 2 is fluoro, chloro, methoxy, methyl, difluoromethyl (-CHF 2 ), trifluoromethyl (-CF 3 ), or cyclopropyl.
  • R 2 may be located on any position of the pyridinyl ring.
  • R 2 is fluoro, chloro, iodo, bromo, -NH 2 , cyano, Ci_ 4 alkyl, Ci_ 4 haloalkyl, Ci ⁇ alkoxy, or C3-6 cycloalkyl.
  • R 2 is fluoro, chloro, methoxy, methyl, ethoxy, propoxy, butoxy, pentoxy, hexoxy, -NH 2 , -CHF 2 , -CF 3 , fluoroethyl, difluoroethyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • R 2 is fluoro, chloro, -NH 2 , methoxy, methyl, difluoromethyl (-CHF 2 ), trifluoromethyl (-CF 3 ), or cyclopropyl.
  • the R 2 moiety may be located on any position of the pyridinyl ring.
  • both R 2 are independently halo, which may be the same (e.g. , both R 2 are fluoro or chloro) or different (e.g. , one R 2 is fluoro and the other R 2 is chloro).
  • both R 2 are independently optionally substituted alkyl, which may be the same (e.g. , both R 2 are methyl) or which may be different (e.g. , one R 2 is methyl and the other R 2 is ethyl).
  • both R 2 are independently optionally substituted haloalkyl, which may the same (e.g.
  • both R are -CF 3 ) or which may be different (e.g. , one R 2 is -CF 3 and the other R 2 is -CHF 2 ).
  • both R 2 are independently optionally substituted alkoxy, which may be the same (e.g. , both R 2 are methoxy) or which may be different (e.g. , one R 2 is methoxy and the other R 2 is ethoxy).
  • both R 2 are independently optionally substituted cycloalkyl, which may the same (e.g. , both R 2 are cyclopropyl) or which may be different (e.g.
  • one R 2 is methylcyclopropyl and the other R 1 is cyclopropyl).
  • one R 2 is halo and the other R 2 is cyano
  • one R 2 is halo and the other R 2 is optionally substituted haloalkyl
  • one R 2 is halo and the other R 2 is optionally substituted alkyl
  • one R 2 is halo and the other R 2 is optionally substituted alkoxy
  • one R 2 is halo and the other R 2 is optionally substituted cycloalkyl
  • one R 2 is optionally substituted alkyl and the other R 2 is optionally substituted cycloalkyl
  • one R 2 is optionally substituted alkyl and the other R 2 is optionally substituted cycloalkyl
  • one R 2 is optionally substituted alkyl and the other R 2 is optionally substituted alkoxy.
  • each R 2 is independently selected from fluoro, chloro, -NH 2 , methoxy, methyl, difluoromethyl (-CHF 2 ), trifluoromethyl (-CF 3 ), or cyclopropyl.
  • m is 2
  • one R 2 is -NH 2 and the other R 2 is optionally substituted alkyl.
  • both R 2 are fluoro, both R 2 are chloro, both R 2 are methoxy, both R 2 is methyl, or both R 2 is cyclopropyl.
  • one R 2 is fluoro and the other R 2 is chloro
  • one R 2 is fluoro and the other R 2 is cyano
  • one R 2 is chloro and the other R 2 is cyano
  • one R 2 is fluoro and the other R 2 is -CF 3
  • one R 2 is fluoro and the other R 2 is -CHF 2
  • one R 2 is chloro and the other R 2 is -CF 3
  • one R 2 is chloro and the other R 2 is -CHF 2
  • one R 2 is cyano and the other R 2 is -CF 3
  • one R 2 is cyano and the other R 2 is -CHF 2i one R 2 is fluoro and the other R 2 is methyl, one R 2 is chloro
  • R 2 are independently halo, which may be the same (e.g. , two R 2 are fluoro) or which may be different (e.g. , one R 2 is fluoro and another R 2 is chloro), the third R 2 is optionally substituted alkoxy (e.g. , third R 2 is methoxy).
  • the third R 2 is halo.
  • the three R 2 moieties may be located on any three positions of the pyridinyl ring.
  • Each and every variation of m and R 2 may be combined with each and every variation of n, R 1 and R 3 as described for formula (I), as if each and every combination is individually described.
  • R 3 is hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted heterocycloalkyl, or optionally substituted cycloalkyl.
  • R 3 is hydrogen, optionally substituted Ci_6 alkyl, optionally substituted C3-8 cycloalkylCi-6 alkyl or optionally substituted C3-8 cycloalkyl.
  • R 3 is hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C3-6 cycloalkylCi-4 alkyl.
  • R 3 is hydrogen, methyl, ethyl, propyl, butyl, cyclopropylmethyl, cyclopropylbutyl, cyclobutylmethyl, or cyclopropylethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • R 3 is methyl, ethyl, cyclopropylmethyl, or cyclopropyl.
  • R 3 is methyl, ethyl, propyl, butyl, cyclopropylmethyl, or cyclopropyl.
  • R 3 may be combined with each and every variation of n, R 1 , m and R 2 as described for formula (I), as if each and every combination is individually described.
  • R 4 is hydrogen, cyano, -C(0)N(R 4a ) 2 , or halo, wherein each R 4a is independently hydrogen or optionally substituted Ci_6 alkyl.
  • R 4 is cyano, halo, -C(0)N(R 4a ) 2 wherein each R 4a is independently hydrogen or Ci-4 alkyl.
  • R 4 is cyano, fluoro, bromo, chloro, or - C(0)NH 2 .
  • R 4 is cyano, chloro, or -C(0)NH 2 .
  • n 1 or 2;
  • each R 1 is independently halo, cyano, C3-6 alkylsulfonyl, C1-4 haloalkyl, or Ci ⁇ alkyl; m is 0, 1 or 2;
  • each R 2 is independently halo, C1-4 alkoxy, C1-4 alkyl, C 1-4 haloalkyl, or C3-6 cycloalkyl;
  • R 3 is hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C3-6 cycloalkylCi-4 alkyl;
  • R 4 is cyano
  • n 1 or 2;
  • each R 1 is independently selected from fluoro, chloro, methylsulfonyl, cyano, methyl, trifluoromethyl;
  • n 0, 1 or 2;
  • each R 2 is independently selected from fluoro, chloro, methoxy, methyl,
  • R 3 is methyl, ethyl, cyclopropyl, or cyclopropylmethyl
  • R 4 is cyano
  • n 1 or 2;
  • each R 1 is independently halo, cyano, C3-6 alkylsulfonyl, C 1-4 haloalkyl, or C 1-4 alkyl; m is 0, 1 or 2;
  • each R 2 is independently halo, -NH 2 , Ci_ 4 alkoxy, Ci_ 4 alkyl, Ci_ 4 haloalkyl, or C3_ 6 cycloalkyl;
  • R 3 is hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C3-6 cycloalkylCi_ 4 alkyl;
  • R 4 is cyano, halo or -CONH 2
  • n 1 or 2;
  • each R 1 is independently selected from fluoro, chloro, methylsulfonyl, cyano, methyl, trifluoromethyl;
  • n 0, 1 or 2;
  • each R 2 is independently selected from fluoro, chloro, -NH 2 , methoxy, methyl, difluoromethyl, trifluoromethyl, or cyclopropyl;
  • R 3 is methyl, ethyl, cyclopropyl, or cyclopropylmethyl
  • R 4 is cyano, halo or -CONH 2 .
  • n 1 or 2;
  • each R 1 is independently halo, cyano, C3-6 alkylsulfonyl, C 1-4 haloalkyl, or C 1-4 alkyl; m is 0, 1 or 2;
  • each R 2 is independently halo, -NH 2 , Ci_ 4 alkoxy, Ci_ 4 alkyl, Ci_ 4 haloalkyl, or C 3 _ 6 cycloalkyl;
  • R 3 is hydrogen, C 1-4 alkyl, C3-6 cycloalkyl, or C3-6 cycloalkylCi_ 4 alkyl;
  • R 4 is halo or -CONH 2 .
  • n 1 or 2;
  • each R 1 is independently selected from fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, and methylsulfonyl;
  • n 0, 1, or 2;
  • each R 2 is independently selected from fluoro, chloro, bromo, methoxy, methyl, difluoromethyl, trifluoromethyl, and cyclopropyl;
  • R 3 is selected from methyl, ethyl, propyl, butyl, cyclopropyl, and cyclopropylmethyl;
  • R 4 is chloro, fluoro, bromo, or -CONH 2 .
  • each R la and R lb can be independently selected from the moieties defined for R 1 of formula (I);
  • each R 2a and R 2b can be independently selected from the moieties defined for R 2 of formula (I);
  • R 3 is as defined for formula (I). [00115] In other embodiments of formula (I) where n is 1, m is 2, and R 4 is cyano, the compounds have the structure of formula (IB):
  • R 1 is as defined for formula (I);
  • each R 2a and R 2b can be independently selected from the moieties defined for R 2 of formula (I);
  • R 3 is as defined for formula (I).
  • each R la and R lb can be independently selected from the moieties defined for R 1 of formula (I);
  • R 2 is as defined for formula (I);
  • R 3 is as defined for formula (I). [00117] In another embodiments where n is 1, m is 1, and R 4 is cyano, the compounds have the structure of formula (ID):
  • R 1 is as defined for formula (I);
  • R 2 is as defined for formula (I);
  • R 3 is as defined for formula (I).
  • R 1 is as defined for formula (I);
  • R 3 is as defined for formula (I). [00119] In another embodiments where n is 2, m is 0, and R 4 is cyano, the compounds have the structure of formula (IF):
  • each R la and R lb can be selected from the moieties defined for R 1 of formula (I); and R 3 is as defined for formula (I).
  • each unique stereoisomer has an unique compound number.
  • the structure below bearing one chiral center can be resolved into the (S) and (R) enantiomer.
  • the compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof is the (S)- enantiomer.
  • the compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof is the (R)- enantiomer.
  • the application also provides a composition containing a mixture of enantiomers of the compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof.
  • the composition contains the (S)-enantiomer of the compound and is substantially free of its corresponding (R)-enantiomer.
  • a composition substantially free of the (R)-enantiomer has less than or about 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1 %, 0.05%, or 0.01 % of the (R)-enantiomer.
  • the composition containing the (S)-enantiomer of a compound according to any of formulae described herein or a pharmaceutically acceptable salt thereof predominates over its corresponding ( ?)-enantiomer by a molar ratio of at least or about 9: 1 , at least or about 19: 1 , at least or about 40: 1 , at least or about 80: 1 , at least or about 160: 1 , or at least or about 320: 1.
  • composition containing a compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof may also contain the compound in enantiomeric excess (e.e.).
  • a compound with 95% ( ⁇ -isomer and 5% ( ?)-isomer will have an e.e. of 90%.
  • the compound has an e.e. of at least or about 60%, 75%, 80%, 85%, 90%, 95%, 98% or 99%.
  • the compound is enantiomerically-enriched in the (S) -isomer of compound according to any of the formula described herein.
  • composition comprising a mixture of the (S)-enantiomer and the (R)-enantiomer of a compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof.
  • the mixture is a racemic mixture.
  • the composition comprises the (S)-enantiomer of a compound according to any of formulae described herein or a pharmaceutically acceptable salt thereof, wherein the (S)-enantiomer of the compound is present in excess of over the corresponding the (R)-enantiomer of the compound, or a pharmaceutically acceptable salt thereof.
  • the compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof is an atropisomer.
  • a composition containing a mixture of atropisomers of the compound of any of the formulae described herein or a pharmaceutically acceptable salt thereof, is also provided herein.
  • Atropisomers refers to conformational stereoisomers which occur when rotation about a single bond in the molecule is prevented, or greatly hindered, as a result of steric interactions with other parts of the molecule and the substituents at both ends of the single bond are asymmetrical, i.e. , they do not require a stereocenter. Where the rotational barrier about the single bond is high enough, and interconversion between conformations is slow enough, separation and isolation of the isomeric species may be permitted. Atropisomers are enantiomers without a single asymmetric atom. In some embodiments, the compounds described herein may contain a mixture of diastereomers.
  • the compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof is the atropisomer.
  • the atropisomer is the atropisomer.
  • Table 1 Representative compounds of the present application are listed in Table 1 below.
  • the compounds in Table 1 are named using ChemBioDraw Ultra 12.0 and it should be understood that other names may be used to identify compounds of the same structure.
  • Other compounds or radicals may be named with common names, or systematic or non-systematic names.
  • the compounds may also be named using other nomenclature systems and symbols that are commonly recognized in the art of chemistry including, for example, Chemical Abstract Service (CAS) and International Union of Pure and Applied Chemistry (IIJPAC).
  • CAS Chemical Abstract Service
  • IIJPAC International Union of Pure and Applied Chemistry Table 1 shows the naming and numbering of the compounds that represent the formulae described herein.
  • the compounds provided in Table 1 may be a single enantiomer (e.g.
  • the present application provides the compounds according to any of the formulae described herein or pharmaceutically acceptable salts, tautomers, isomers, prodrugs, or solvates thereof, in which from 1 to n hydrogen atoms attached to a carbon atom may be replaced by a deuterium atom or D, in which n is the number of hydrogen atoms in the molecule. It is known that the deuterium atom is a non-radioactive isotope of the hydrogen atom. Such compounds may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds of any of the formulae described herein or pharmaceutically acceptable salts, isomers, prodrugs, or solvates thereof, when administered to a mammal.
  • the present application also provides pharmaceutically acceptable salts, hydrates, solvates, tautomeric forms, polymorphs, and prodrugs of the compounds of any of the formulae described herein.
  • “Pharmaceutically acceptable” or “physiologically acceptable” refer to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.
  • “Pharmaceutically acceptable salts” or “physiologically acceptable salts” refer to salts of pharmaceutical compounds that retain the biological effectiveness and properties of the underlying compound, and which are not biologically or otherwise undesirable.
  • Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Acids and bases useful for reaction with an underlying compound to form pharmaceutically acceptable salts (acid addition or base addition salts respectively) are known to one of skill in the art.
  • “Pharmaceutically acceptable salts” include, for example, salts with inorganic acids and salts with an organic acid.
  • the free base can be obtained by basifying a solution of the acid salt.
  • an addition salt, particularly a pharmaceutically acceptable addition salt may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds.
  • salts include, but are not limited to salts with inorganic acids, such as hydrochlorate, phosphate, diphosphate, hydrobromate, sulfate, sulfinate, nitrate; as well as salts with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, benzoate, salicylate, stearate, and alkanoate such as acetate, HOOC-(CH 2 ) n -COOH where n is 0-4.
  • inorganic acids such as hydrochlorate, phosphate, diphosphate, hydrobromate, sulfate, sulfinate, nitrate
  • organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate,
  • pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium, and ammonium.
  • the free base can be obtained by basifying a solution of the acid salt.
  • a "solvate” is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds of any of the formulae described herein are also provided. Hydrates of the compounds of any of the formulae are also provided.
  • a "prodrug” includes any compound that becomes a compound of the formulae described herein when administered to a subject, e.g. , upon metabolic processing of the prodrug.
  • prodrug includes any compound that becomes a compound of the formulae described herein when administered to a subject, e.g. , upon metabolic processing of the prodrug.
  • the single enantiomer or diastereomer, i. e. , optically active form can be obtained by asymmetric synthesis or by resolution of the racemate. Resolution of racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high pressure liquid chromatography (HPLC) column.
  • HPLC high pressure liquid chromatography
  • Z- and E- forms (or cis- and trans- forms) of the compounds of the formulae described herein or pharmaceutically acceptable salts, prodrugs, or solvates thereof with carbon-carbon double bonds Provided are also all tautomeric forms of the compounds of any of the formulae or pharmaceutically acceptable salts, isomers, prodrugs, or solvates thereof.
  • provided herein are the free base forms of the compounds of the formulae described herein or pharmaceutically acceptable salts, isomers, or mixture of isomers, prodrugs or solvates thereof.
  • provided herein are the (S)- enantiomers of the compounds of the formulae described herein or pharmaceutically acceptable salts, isomers, or mixture of isomers, prodrugs or solvates thereof.
  • provided herein are the (R)-enantiomers of the compounds of the formulae described herein or pharmaceutically acceptable salts, isomers, or mixture of isomers, prodrugs or solvates thereof.
  • provided herein are the atropisomers of the compounds of the formulae described herein or pharmaceutically acceptable salts, isomers, or mixture of isomers, prodrugs or solvates thereof.
  • compositions provided herein that include a compound of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof may include racemic mixtures, or mixtures containing an enantiomeric excess of one enantiomer or single diastereomers or diastereomeric mixtures. All such isomeric forms of these compounds are expressly included herein the same as if each and every isomeric form were specifically and individually listed.
  • provided herein are also crystalline and amorphous forms of the compounds of the formulae described herein or pharmaceutically acceptable salts, isomer, a mixture of isomers, prodrugs, or solvates thereof.
  • provided are also chelates, non-covalent complexes, and mixtures thereof, of the compounds of the formula described herein or pharmaceutically acceptable salts, prodrugs, or solvates thereof.
  • a "chelate” is formed by the coordination of a compound to a metal ion at two (or more) points.
  • a “non-covalent complex” is formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule. For example, complexation can occur through van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding).
  • the compounds of the formulae described herein or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof may be used for the treatment of diseases and/or conditions mediated by PI3K isomers, such as PI3K5.
  • PI3K isomers such as PI3K5.
  • methods for inhibiting one or more PI3K isomers such as PI3K ⁇ , ⁇ , ⁇ , and ⁇ .
  • 'ITie PI3K isomers may be selectively or specifically inhibited.
  • the compounds may be used to inhibit PI3K activity therapeutically or prophylactically.
  • the compounds according to the present application may be used in combination with other therapeutic agents.
  • the therapeutic agents may be in the forms of compounds, antibodies, polypeptides, or polynucleotides.
  • the application provides a product comprising a compound described herein and an additional therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy, e.g. a method of treating a disease, disorder, or condition that is mediated by PI3K isoforms.
  • the therapeutic agents may be those that inhibit or modulate the activities of Bruton's tyrosine kinase, spleen tyrosine kinase, apoptosis signal-regulating kinase, Janus kinase, lysyl oxidase, lysyl oxidase-like proteins, or matrix metallopeptidase.
  • the therapeutic agents may be those that inhibit or modulate the activites of bromodomain-containing protein, adenosine A2B receptor, isocitrate dehydrogenase, serine/threonine kinase TPL2, discoidin domain receptor, serine/threonine-protein kinase, IKK, MEK, EGFR, histone deacetylase, protein kinase C, or any combination thereof.
  • the methods include administering a compound of the formula described herein or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof, in a therapeutically effective amount to a human in need thereof.
  • the method can be employed to treat a patient who has or is believed to have a disease or condition whose symptoms or pathology is mediated by PI3K5 expression or activity. Additionally, the method can be employed to treat a patient who has or is believed to have a disease or condition whose symptoms or pathology is mediated by ⁇ 3 ⁇ expression or activity.
  • the patient may be a mammal or a human.
  • certain compounds of any of the formulae described herein or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof have one or more properties selected from: (i) selectivity to any PI3K isoforms, such as PI3K5; (ii) hepatocyte stability; and (iii) potency in a cellular assay.
  • certain compounds of the formulae or a pharmaceutically acceptable salt, prodrug, isomers, or solvate thereof have selectivity to any PI3K isoforms, such as PI3K5.
  • certain compounds of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof have selectivity to at least PI3K5.
  • certain compounds of the formulae or a pharmaceutically acceptable salt, prodrug, isomers, or solvate thereof have selectivity to PI3K5 and/or ⁇ 3 ⁇ .
  • certain compounds of the formulae or a pharmaceutically acceptable salt, prodrug, or solvate thereof have one of the properties selected from: (i) selectivity to PI3K5; (ii) hepatocyte stability; and (iii) potency in a cellular assay.
  • certain compounds of the formulas according to the present application or a pharmaceutically acceptable salt, prodrug, or solvate thereof have: selectivity to PI3K5 and hepatocyte stability; or selectivity to PI3K5 and potency in a cellular assay; or hepatocyte stability and potency in a cellular assay.
  • certain compounds of the formulae or a pharmaceutically acceptable salt, prodrug, or solvate thereof have selectivity to PI3K5, hepatocyte stability, and potency in a cellular assay.
  • certain compounds of the formulae described herein or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof have hepatocyte stability.
  • Hepatocyte stability of a compound can be determined using any methods currently known in the art, including the methods described in the Examples below.
  • hepatocyte stability may be characterized based on half-life. In some embodiments, the half- life is greater than or about 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 1 1 hours, 12 hours, or 15 hours when incubated in human hepatocytes.
  • certain compounds of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof have potency in a cellular assay.
  • Potency in a cellular assay can be determined using any methods currently known in the art, including the methods described in the Examples below.
  • the activity in the cellular assay is less than 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, InM, 0.1 nM, or 0.01 nM.
  • certain compounds inhibit at least one PI3K isomer, including PI3K5.
  • the compounds have an EC 50 in the described cellular assay less than 10 nM, and have a half life in hepatocytes of greater than 3 hours.
  • Treatment is an approach for obtaining beneficial or desired results including clinical results.
  • beneficial or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (e.g. , decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g. , stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and/or preventing or delaying the spread (e.g. , metastasis) of the disease or condition); and/or
  • clinical symptoms e.g. , ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival.
  • Prevention means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop.
  • Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.
  • Subject refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment.
  • the methods described herein may be useful in human therapy and/or veterinary applications.
  • the subject is a mammal.
  • the subject is a human.
  • Human in need thereof refers to a human who may have or is suspect to have diseases or conditions that would benefit from certain treatment; for example, being treated with the PI3K inhibitor of the compounds according to the present application.
  • a therapeutically effective amount of a compound of the present application or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof means an amount sufficient to effect treatment when administered to a subject, to provide a therapeutic benefit such as amelioration of symptoms or slowing of disease progression.
  • a therapeutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition responsive to inhibition of PI3K5 activity.
  • the therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one or ordinary skill in the art.
  • inhibitortion indicates a decrease in the baseline activity of a biological activity or process.
  • inhibitor of activity of PI3K isomers or variants thereof refer to a decrease in activity in any PI3K isomer (e.g.
  • alpha, beta, gamma, or delta as a direct or indirect response to the presence of a compound of any of the formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (II) or a pharmaceutically acceptable salt, isomer, a mixture of isomers, prodrug, or solvent thereof, relative to the activity of PI3K isomer in the absence of such compound or a pharmaceutically acceptable salt, isomer, a mixture of isomers, prodrug, or solvent thereof.
  • “Inhibition of PI3K5 activity” or variants thereof refer to a decrease in PI3K5 activity as a direct or indirect response to the presence of a compound of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (II) or a pharmaceutically acceptable salt, isomer, a mixture of isomers, prodrug, or solvate thereof, relative to the activity of PI3K5 in the absence of such compound.
  • the inhibition of PI3K5 activity may be compared in the same subject prior to treatment, or other subjects not receiving the treatment.
  • the compounds inhibit PI3K5 activity also inhibit PI3K ⁇ activity.
  • the decrease in PI3K5 activity may be due to the direct interaction of the compound with PI3K5, or due to the interaction of the compounds described herein with one or more other factors that in turn affect PI3K5 activity.
  • the presence of the compounds of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof may decrease PI3K5 activity by directly binding to the PI3K5, by causing (directly or indirectly) another factor to decrease PI3K5 activity, or by (directly or indirectly) decreasing the amount of PI3K5 present in the cell or organism.
  • a compound of the present application refers to a compound having the structure of any of the formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (II).
  • the PI3K inhibitors are the compounds having the structure of the formula (I).
  • the PI3K inhibitors are the compounds having the structure of the formula (IA).
  • the PI3K inhibitors are the compounds having the structure of the formula (IB).
  • the PI3K inhibitors are the compounds having the structure of the formula (IC).
  • the PI3K inhibitors are the compound having the structure of formula (ID).
  • the PI3K inhibitors are the compounds having the structure of formula (IE).
  • the PI3K inhibitors are the compound having the structure of formula (IF).
  • PI3K inhibitor or variant thereof refers to a compound that inhibits the activity of PI3K.
  • PI3K isoform selective inhibitor or variant thereof refers to a compound that inhibits the activity of one or more PI3K isoforms more effectively than the other remaining PI3K isoforms.
  • PI3K5 selective inhibitor generally refers to a compound that inhibits the activity of the PI3K5 isoform more effectively than other isoforms of the PI3K family (e.g. , PI3K ⁇ , ⁇ , or ⁇ ).
  • PI3Ka selective inhibitor generally refers to a compound that inhibits the activity of the PI3Ka isoform more effectively than other isoforms of the PI3K family (e.g. , PI3K ⁇ , ⁇ , or ⁇ ).
  • ⁇ 3 ⁇ selective inhibitor generally refers to a compound that inhibits the activity of the ⁇ 3 ⁇ isoform more effectively than other isoforms of the PI3K family (e.g. , PI3K ⁇ , ⁇ , or ⁇ ).
  • the term "dual ⁇ 3 ⁇ / ⁇ selective inhibitor generally refers to a compound that inhibits the activity of the PI3Ka and ⁇ 3 ⁇ isoforms more effectively than other isoforms of the PI3K family (e.g. , PI3K ⁇ or ⁇ ).
  • the relative efficacies of compounds as inhibitors of an enzyme activity can be established by determining the concentrations at which each compound inhibits the activity to a predefined extent and then comparing the results.
  • the efficacy of a compound as an inhibitor of one or more PI3K isoforms can be measured by the concentration that inhibits 50% of the activity in a biochemical assay, i.e. , the 50% inhibitory concentration or "IC 50 ".
  • IC 50 determinations can be accomplished using conventional techniques known in the art, including the techniques describes in the Examples below. In general, an IC 50 can be determined by measuring the activity of a given enzyme in the presence of a range of concentrations of the compound under study.
  • the experimentally obtained values of enzyme activity may then be plotted against the compound concentrations used.
  • concentration of the inhibitor that shows 50% enzyme activity is taken as the IC 50 value.
  • other inhibitory concentrations can be defined through appropriate determinations of activity. For example, in some settings it may be desirable to establish a 90% inhibitory concentration, i.e. ,
  • a PI3K5 selective inhibitor is a compound that exhibits a 50% inhibitory concentration (IC 50 ) with respect to PI3K5 that is at least 10-fold, in another aspect at least 20-fold, and in another aspect at least 30-fold, lower than the IC 50 value with respect to any or all of the other Class I PI3K family members.
  • a PI3K5 selective inhibitor is a compound that exhibits an IC 50 with respect to PI3K5 that is at least 50-fold, in another aspect at least 100-fold, in an additional aspect at least 200-fold, and in yet another aspect at least 500-fold, lower than the IC 50 with respect to any or all of the other PI3K Class I family members.
  • a PI3K5 selective inhibitor is typically administered in an amount such that it selectively inhibits PI3K5 activity, as described above.
  • a PI3Ka selective inhibitor is a compound that exhibits a 50% inhibitory concentration (IC 50 ) with respect to PI3Kot that is at least 10-fold, in another aspect at least 20-fold, and in another aspect at least 30-fold, lower than the IC 50 value with respect to any or all of the other Class I PI3K family members.
  • a PI3Ka selective inhibitor is a compound that exhibits an IC 50 with respect to PI3Ka that is at least 50-fold, in another aspect at least 100-fold, in an additional aspect at least 200-fold, and in yet another aspect at least 500-fold, lower than the IC 50 with respect to any or all of the other PI3K Class I family members.
  • a PI3Ka selective inhibitor is typically administered in an amount such that it selectively inhibits PI3Ka activity, as described above [0159]
  • a ⁇ 3 ⁇ selective inhibitor is a compound that exhibits a 50% inhibitory concentration (IC 50 ) with respect to ⁇ 3 ⁇ that is at least 10-fold, in another aspect at least 20-fold, and in another aspect at least 30-fold, lower than the IC 50 value with respect to any or all of the other Class I PI3K family members.
  • a ⁇ 3 ⁇ selective inhibitor is a compound that exhibits an IC 50 with respect to ⁇ 3 ⁇ that is at least 50-fold, in another aspect at least 100-fold, in an additional aspect at least 200-fold, and in yet another aspect at least 500-fold, lower than the IC 50 with respect to any or all of the other PI3K Class I family members.
  • a ⁇ 3 ⁇ selective inhibitor is typically administered in an amount such that it selectively inhibits ⁇ 3 ⁇ activity, as described above.
  • a dual ⁇ 3 ⁇ / ⁇ selective inhibitor is a compound that exhibits a 50% inhibitory concentration (IC 50 ) with respect to PI3Ka and ⁇ 3 ⁇ that is at least 10- fold, in another aspect at least 20-fold, and in another aspect at least 30-fold, lower than the IC 50 value with respect to any or all of the other Class I PI3K family members.
  • IC 50 inhibitory concentration
  • a dual ⁇ 3 ⁇ / ⁇ selective inhibitor is a compound that exhibits an IC 50 with respect to PI3Ka and ⁇ 3 ⁇ that is at least 50-fold, in another aspect at least 100-fold, in an additional aspect at least 200-fold, and in yet another aspect at least 500-fold, lower than the IC 50 with respect to any or all of the other PI3K Class I family members.
  • a ⁇ 3 ⁇ / ⁇ selective inhibitor is a compound that exhibits an IC 50 with respect to ⁇ 3 ⁇ and PI3K5 that is at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 200-fold, at least 300-fold, at least 400-fold, and at least 500-fold, lower than the IC 50 with respect to either PI3Ka or ⁇ 3 ⁇ or to both PI3Ka and ⁇ 3 ⁇ .
  • a dual ⁇ 3 ⁇ / ⁇ selective inhibitor is typically administered in an amount such that it selectively inhibits PI3Ka and ⁇ 3 ⁇ activity, as described above.
  • the methods described herein may be applied to cell populations in vivo or ex vivo.
  • “In vivo” means within a living individual, as within an animal or human. In this context, the methods described herein may be used therapeutically in an individual.
  • "Ex vivo” means outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. Such samples may be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and biopsies thereof. In this context, the invention may be used for a variety of purposes, including therapeutic and experimental purposes.
  • the invention may be used ex vivo to determine the optimal schedule and/or dosing of administration of a PI3K5 selective inhibitor for a given indication, cell type, individual, and other parameters. Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for in vivo treatment. Other ex vivo uses for which the invention may be suited are described below or will become apparent to those skilled in the art.
  • the selected compounds of the formula described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof may be further characterized to examine the safety or tolerance dosage in human or non-human subjects. Such properties may be examined using commonly known methods to those skilled in the art.
  • PI3K5 is generally expressed in hematopoietic cells. Consequently, the direct effects of selective inhibitors of PI3K5 can be observed in hematopoietic cells.
  • Hematopoietic cells typically differentiate into either lymphoid progenitor cells or myeloid progenitor cells, both of which ultimately differentiate into various mature cell types including leukocytes. Aberrant proliferation of hematopoietic cells of one type often interferes with the production or survival of other hematopoietic cell types, which can result in compromised immunity, anemia, and/or thrombocytopenia.
  • the methods described herein may treat aberrant proliferation of hematopoietic cells by inhibiting aberrant proliferation of hematopoietic cells. As a result, these methods may also ameliorate the symptoms and secondary conditions that result from a primary effect such as excessive system or localized levels of leukocytes or lymphocytes.
  • the compounds described herein may be used to treat subjects having various disease states, disorders, and conditions (also collectively referred to as "indications") involving aberrant proliferation of hematopoietic cells (including excessive production of lymphoid progenitor cell-derived cells and/or myeloid progenitor cell-derived cells).
  • indications may include, for example, leukemias, lymphomas,
  • the compounds described herein may be used to treat hematologic malignancies, inflammation, autoimmune disorders, allergic conditions, cardiovascular disease, and autoimmune diseases.
  • allergic conditions may include all forms of hypersensitivity.
  • the compounds described herein may be used to treat cancers that are mediated by, dependent on or associated with PI3K activity, such as PI3K5 activity.
  • the disease is a hematologic malignancy.
  • the hematologic malignancy is leukemia or lymphoma.
  • the disease is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), indolent non-Hodgkin' s lymphoma (iNHL), refractory iNHL, non-Hodgkin' s lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldestrom' s macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma, and diffuse large B-cell lymphoma (DLBCL).
  • ALL acute lymphocytic leukemia
  • AML acute myeloid leukemia
  • CLL chronic lymphocytic leukemia
  • SLL small lympho
  • the disease is T-cell acute lymphoblastic leukemia (T-ALL), or B-cell acute lymphoblastic leukemia (B-ALL).
  • T-ALL T-cell acute lymphoblastic leukemia
  • B-ALL B-cell acute lymphoblastic leukemia
  • the non- Hodgkin lymphoma encompasses the indolent B-cell diseases that include, for example, follicular lymphoma, lymphoplasmacytic lymphoma, Waldenstrom macroglobulinemia, and marginal zone lymphoma, as well as the aggressive lymphomas that include, for example, Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
  • follicular lymphoma follicular lymphoma
  • lymphoplasmacytic lymphoma Waldenstrom macroglobulinemia
  • MCL mantle cell lymphoma
  • the disease is a solid tumor.
  • the solid tumor is from pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors (e.g. , glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, or soft tissue sarcoma.
  • the solid tumor is from non-small cell lung cancer, small- cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, or breast cancer.
  • the disease is an autoimmune disease.
  • the autoimmune disease is systemic lupus erythematosus (SLE), myestenia gravis, rheumatoid arthritis (RA), acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis (MS), Sjoegren' s syndrome, or autoimmune hemolytic anemia.
  • the disease is inflammation.
  • the disease is excessive or destructive immune reactions, such as asthma, rheumatoid arthritis, multiple sclerosis, and lupus.
  • the disease is excessive or destructive immune reactions, such as psoriasis or chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the present application also provides a method for treating a subject, who has or is suspected of having a disease or condition responsive or believed to be responsive to the inhibition of PI3K5 activity by administering to the subject a compound of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
  • the application provides a method of inhibiting kinase activity of a phosphatidylinositol 3-kinase delta polypeptide by contacting the polypeptide with a compound of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
  • a method of disrupting leukocyte function comprising contacting the leukocytes with an effective amount of a compound of any of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, in a subject in need thereof (e.g. , a human).
  • a method of inhibiting a growth or a proliferation of cancer cells of hematopoietic origin comprising contacting the cancer cells with an effective amount of a compound of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
  • kits that include a compound of the formulae of the present application or a pharmaceutically acceptable salt, prodrug, or solvate thereof, and suitable packaging.
  • a kit further includes instructions for use.
  • a kit includes a compound of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, and a label and/or instructions for use of the compounds in the treatment of the indications, including the diseases or conditions, described herein.
  • articles of manufacture that include a compound of any of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, in a suitable container.
  • the container may be a vial, jar, ampoule, preloaded syringe, and intravenous bag.
  • compositions that contain one or more of the compounds of any of the formulae, including (I), (IA), (IB), (IC), (ID), (IE), (IF), or (II), or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof, and one or more pharmaceutically acceptable vehicles selected from carriers, adjuvants and excipients.
  • suitable pharmaceutically acceptable vehicles may include, for example, inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
  • compositions are prepared in a manner well known in the pharmaceutical art. See, e.g. , Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T.
  • the pharmaceutical compositions may be administered in either single or multiple doses.
  • the pharmaceutical composition may be administered by various methods including, for example, rectal, buccal, intranasal and transdermal routes.
  • the pharmaceutical composition may be administered by intra- arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.
  • Oral administration may be another route for administration of the compounds described herein. Administration may be via, for example, capsule or enteric coated tablets.
  • the active ingredient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container.
  • the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose.
  • the formulations can additionally include lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • compositions that include at least one compound of any of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the subject by employing procedures known in the art.
  • Controlled release drug delivery systems for oral administration include osmotic pump systems and
  • transdermal delivery devices Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds described herein in controlled amounts.
  • the construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent Nos. 5,023,252, 4,992,445 and 5,001,139.
  • patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
  • the principal active ingredient may be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of any of the above formulae or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
  • a pharmaceutical excipient When referring to these preformulation compositions as homogeneous, the active ingredient may be dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • the tablets or pills of the compounds described herein may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach.
  • the tablet or pill can include an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • compositions for inhalation or insufflation may include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • compositions in pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
  • a dosage may be expressed as a number of milligrams of a compound of the formula per kilogram of the subject's body weight (mg/kg). Dosages of between about 0.01 and 150 mg/kg may be appropriate. Dosages of between about 0.001 and 10 mg/kg, between about 0.005 and 5mg/kg, and between about 0.01 and 50 mg/kg may be appropriate.
  • a dosage of between 0.05 and 60 mg/kg may be appropriate. Normalizing according to the subject's body weight is particularly useful when adjusting dosages between subjects of widely disparate size, such as occurs when using the drug in both children and adult humans or when converting an effective dosage in a non-human subject such as dog to a dosage suitable for a human subject.
  • the daily dosage may also be described as a total amount of a compound of the formulae administered per dose or per day.
  • Daily dosage of a compound may be between about 1 mg and 2,000 mg, between about 1,000 to 2,000 mg/day, between about 1 to 1,000 mg/day, between about 1 to 500 mg/day, between about 5 to 400 mg/day, between about 10 to 300 mg/day, between about 25 to 250 mg/day, between about 50 to 225 mg/day, between about 75 to 200 mg/day, between about 100 to 150 mg/day, between about 1 to 100 mg/day between about between about 1 to 75 mg/day, between about 1 to 50 mg/day, between about 1 to 25 mg/day, between about 1 to 20 mg/day, between about 1 to 15 mg/day, between about 1 to 10 mg/day, between about 1 to 5 mg/day, between about 5 to 100 mg/day, between about between about 5 to 75 mg/day, between about 5 to 50 mg/day, between about 5 to 25 mg/day, between about 5 to 15 mg/day, between about 5 to
  • daily dosage of a compound may be between about 0.01 mg and 1,000 mg, between about 0.05 mg and 500 mg, between about 0.075 mg and 250 mg, between about 0.1 mg and 100 mg, between about 0.5 mg and 50 mg, between about 0.75 mg and 25mg, between about 1 mg and 10 mg, [0184]
  • the total daily dosage for a human subject may be between 1 mg and 1,000 mg, between about 1 to 100 mg/day, between about 1 to 50 mg/day, between about 5 to 50 mg/day, between 5 to 25 mg/day, between about 5 to 75 mg/day, between about 10-500 mg/day, between about 10 to 150 mg/day, between about 10 to 200 mg/day, between about 50-300 mg/day, between about 75-200 mg/day, between about 75 to 150 mg/day, or between about 100-150 mg/day.
  • daily dosage for a human may be administered between about 0.01 mg and 1,000 mg, between about 0.05 mg and 500 mg, between about 0.075 mg and 250 mg, between about 0.1 mg and 100 mg, between about 0.5 mg and 50 mg, between about 0.75 mg and 25mg, between about 1 mg and 10 mg,
  • the compounds of the present application or the compositions thereof may be administered once, twice, three, or four times daily, using any suitable mode described above. Also, administration or treatment with the compounds according to any of the formulae described herein may be continued for a number of days; for example, commonly treatment would continue for at least 7 days, 14 days, or 28 days, for one cycle of treatment. In some embodiments, the compounds or the composition thereof may be administered continuously, i.e. every day. Treatment cycles are well known in cancer chemotherapy, and are frequently alternated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in other embodiments, may also be continuous.
  • the method comprises administering to the subject an initial daily dose of about 1 to 500 mg of a compound of the above formula and increasing the dose by increments until clinical efficacy is achieved. Increments of about 5, 10, 25, 50, or 100 mg can be used to increase the dose.
  • the methods comprising administering to the subject an initial daily dose of about 0.01 to 100 mg of the compound described herein and increasing the dose by increments of about 0.01, 0.05, 0.1, 0.5, 1, 2, 2.5, 5, 10, 25, 50, or 100 mg.
  • the dosage can be increased daily, every other day, twice per week, or once per week.
  • the compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (II) may be prepared using the methods disclosed herein and routine modifications thereof, which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein. The synthesis of typical compounds described herein may be accomplished as described in the following examples. If available, reagents may be purchased commercially, e.g. , from Sigma Aldrich or other chemical suppliers.
  • Typical embodiments of compounds described herein may be synthesized using the general reaction schemes described below. It will be apparent given the description herein that the general schemes may be altered by substitution of the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Given a desired product for which the substituent groups are defined, the necessary starting materials generally may be determined by inspection. Starting materials are typically obtained from commercial sources or synthesized using published methods. For synthesizing compounds which are embodiments described in the present disclosure, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group. The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein. In general, compounds described herein are typically stable and isolatable at room temperature and pressure.
  • solvent refers to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like).
  • solvents used in the reactions of the present invention are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen.
  • the compound of formula (1) can be made by combining compounds (A), (B) and (C) in the presence of a dehydrating agent.
  • Compounds (A), (B) and (C) are commercially available or can be made by the methods that are commonly known or used by one skilled in the art.
  • R 1 , R 2 , and R 3 are defined as in the formula (I).
  • Compound (A) is mixed with Compound (B) in the presence of a coupling agent such as diphenyl phosphite in a solvent such as pyridine. After stirring at a temperature between ambient and 100°C for 1 to 5 hours, compound (C) is added. The mixture is further stirred at a temperature between ambient and 100°C for 5 to 24 hours and cooled to room temperature.
  • an organic solvent such as ethyl acetate (EtOAc) is added. Then the reaction is washed with mild acid, water, and brine. The organic phase is concentrated to obtain the compound of formula (1).
  • the compound of formula (1) is purified by any suitable methods known in the art, such as chromatography on silica gel. Alternatively, the compound of formula (1) is used in the next step without purification. In some instance, the compound of formula (1) is purified directly without an aqueous work-up. In cases where an R 1 is a cyano, the corresponding bromide can be converted to a nitrile by methods known in the art.
  • the compound of formula (2) can be made by removing the protecting group(s) from the compound of formula (1).
  • the compound of formula (1) is dissolved in a suitable solvent and treated with a suitable acid.
  • suitable solvents include dichloromethane or dioxane
  • suitable acids include trifluoroacetic acid, hydrochloric acid, or boron tribromide (BBr 3 ).
  • the reaction is carried out at temperatures between -78°C to ambient temperature. After the reaction is complete, solvent is removed to obtain the compound of formula (2).
  • the compound of formula (3) can be made by treating 5-substituted-2,4,6- trihalopyrimidine with ammonium hydroxide in a suitable solvent such as dioxane, where the halo is either chloro or fluoro.
  • a suitable solvent such as dioxane, where the halo is either chloro or fluoro.
  • the reaction is carried out at an elevated temperature between 30 and 80°C between 2 and 8 hours or when the reaction was complete. Then, water is added to the cooled solution, and the precipitate is collected by filtration. If necessary, separation of regiosiomers is accomplished by standard methods, such as chromatography. The nitrile can be converted to the carboxamide under standard conditions.
  • Step 4 Preparation of a compound of formula (I)
  • the compound of formula (I) can generally be prepared by coupling compound of formula (2) and compound of formula (3) in the presence of a suitable base in a suitable solvent.
  • a suitable base is diisopropylethylamine.
  • An example of a suitable solvent is N-methylpyrrolidone (NMP), DMF, DMSO, or isopropanol.
  • NMP N-methylpyrrolidone
  • DMF DMF
  • DMSO dimethylpyrrolidone
  • an additive such as potassium fluoride may be used.
  • the reaction is typically performed at a temperature between 50°C to 150°C for about 30 minutes to 24 hours. Alternatively the reaction can be performed in a microwave at a temperature between 100°C to 150°C for about 30 minutes to 24 hours.
  • the product can be isolated by methods known in the art, for example by removal of solvent under reduced pressure.
  • the product can be purified using any suitable methods known in the art, for example, chromatography of the residue on a silica column. In certain instance, the product can be purified using recrystallization or precipitation.
  • Enzymatic activity of PI3K isoforms was measured to determine the inhibitory activities to the PI3K isoforms selectivity of the compounds tested, including the activities against PI3K5.
  • a cellular assay measuring the inhibition of basophil activation was used to assess the potency of the compounds in a cellular assay. Stability in human hepatocytes was also measured to assess the half-life of the tested compounds in human subjects. i. Enzymatic activity ofPI3K isoforms
  • Enzymatic activity of the class I PI3K isoforms in the presence of the compounds of Table 1 and Compounds X, Y and Z was measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.
  • TR-FRET time-resolved fluorescence resonance energy transfer
  • the TR-FRET assay was used to monitor formation of the product 3,4,5-inositol triphosphate molecule (PIP3) as it competed with fluorescently labeled PIP3 for binding to the GRP- 1 pleckstrin homology domain protein.
  • An increase in phosphatidylinositide 3-phosphate product results in a decrease in TR-FRET signal as the labeled fluorophore is displaced from the GRP- 1 protein binding site.
  • Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2 X Km ATP (75-500 ⁇ ), 2 ⁇ PIP2, 5% glycerol, 5 mM MgC12, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1 % (v/v) DMSO at the following concentrations for each isoforms: ⁇ 3 ⁇ , ⁇ 3 ⁇ , and PI3K5 between 25 and 50 pM, and ⁇ 3 ⁇ at 2 nM.
  • Table 2 summarizes the IC 50 values (nM) that were collected for PI3K5 for compounds in the Example.
  • Table 2a summarizes the IC 50 (nM) values for ⁇ 3 ⁇ and half life (hours) values in cryopreserved human hepatocytes.
  • Table 2 The PI3K5 IC 50 Values for Representive Compounds
  • erythrocytes were lysed and fixed by the addition of 2 mL of lysing solution (B-BAT-LYR) for 10 minutes at room temperature. Cells were pelleted by centrifugation at 1200 rpm for 10 minutes at room temperature in a swing- out rotor. Supernatant was aspirated and cell pellet resuspended in 400 ⁇ L ⁇ of wash buffer. Flow cytometric analysis of the basophil activation was performed on a FC500MPL flow cytometer (Beckman Coulter Inc., Fullerton, CA).
  • CCR3-staining and side scatter were applied to gate at least 200 basophils that expressed a high density of CCR3.
  • the percent CD63 positive cells within the gated basophil population were determined in different treatment groups and normalized to the vehicle control (0.3% DMSO) with anti-FceRI mAb of fMLP stimulus as 100%. Final compound concentration was adjusted to correct for dilution effect of added reagents.
  • the EC 50 values were calculated from the analysis of the dose-response curves to a four-parameter equation. All EC 50 values represented geometric mean values and were reported in units of nM. Table 3 below summarizes the EC 50 data collected in the Example.
  • This assay was used to evaluate the metabolic stability of test articles (TA) following incubation in cryopreserved hepatocytes by monitoring parent drug disappearance via LC/MC.
  • the TA was incubated with 1 million hepatocytes/mL at 2 ⁇ substrate in duplicate. The incubation was carried out at 37°C with 5% C0 2 and saturating humidity. Samples were taken at 0, 1 , 2, and 4 hours to monitor the disappearance of TA and a half-life (t 2 ) was determined.
  • Table 3 summarizes the human hepatocyte t 2 values (hours) collected in the Example. [0470] The symbols used in Table 3 below are as follows:

Abstract

The present disclosure provides phosphatidylinositol 3 -kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts or isomers thereof, in which n, m, R1, R2, R4, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3Kδ. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts or isomers thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3Kδ.

Description

PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
FIELD
[0001] The present disclosure relates generally to inhibitors of phosphatidylinositol 3- kinase (PI3K) activity and to novel compounds that are selective inhibitors of PI3K delta activity.
BACKGROUND
[0002] Cell signaling via 3 '-phosphorylated phosphoinosi tides has been implicated in a variety of cellular processes, e.g. , malignant transformation, growth factor signaling, inflammation, and immunity. See generally Rameh et al , J. Biol. Chem. , 274:8347-8350 (1999). Phosphatidylinositol 3-kinase (PI 3-kinase; PI3K) is responsible for generating these phosphorylated signaling products. PI3K originally was identified as a protein associated with viral oncoproteins and growth factor receptor tyrosine kinases that phosphorylate phosphatidylinositol (PI) and its phosphorylated derivatives at the 3 '-hydroxyl of the inositol ring. See Panayotou et al , Trends Cell Biol 2:358-60 (1992).
[0003] Three classes of the PI 3-kinase (PI3K) are proposed, based on their substrate specificities. Class I PI3Ks phosphorylate phosphatidylinositol (PI), phosphatidylinositol-4- phosphate, and phosphatidylinositol-4,5-biphosphate (PIP2) to produce phosphatidylinositol- 3-phosphate (PIP), phosphatidylinositol-3,4-biphosphate, and phosphatidylinositol-3,4,5- triphosphate, respectively. Class II PI3Ks phosphorylate PI and phosphatidylinositol-4- phosphate, and Class III PI3Ks phosphorylate PI.
[0004] The initial purification and molecular cloning of PI 3-kinase revealed that it was a heterodimer consisting of p85 and pi 10 subunits. See Otsu et al , Cell, 65:91-104 (1991); Hiles et al , Cell, 70:419-29 (1992). Since then, four distinct Class I PI3Ks have been identified, designated as PI3K α, β, δ, and γ isomers, each consisting of a distinct 110 kDa catalytic subunit and a regulatory subunit. More specifically, three of the catalytic subunits, i.e. , pi 10a, pi 10β, and pi 105, each interact with the same regulatory subunit, i.e. , p85, whereas pi 10γ interacts with a distinct pi 01 regulatory subunit. As described below, the patterns of expression of each of these PI3Ks in human cells and tissues also are distinct.
[0005] Identification of the pi 105 isoform of PI 3-kinase is described in Chantry et al. , J. Biol. Chem. , 272: 19236-41 (1997). It was observed that the human pi 105 isoform is expressed in a tissue-restricted fashion. It is expressed at high levels in lymphocytes and lymphoid tissues, suggesting that the protein might play a role in PI 3-kinase-mediated signaling in the immune system. The pi 105 isoform is described in U.S. Patent Nos.
5,858,753; 5,882,910; and 5,985,589, each of which is incorporated herein by reference. See also Vanhaesebroeck ei a/. , Proc. Natl. Acad. Sci. USA, 94:4330-5 (1997); and WO
97/46688.
[0006] Therefore, there is a need for therapeutic agents that inhibit PI3K isomers to treat disorders or diseases that are mediated by PI3K.
SUMMARY
[0007] The present application provides novel compounds that are inhibitors of PI3K isoforms, such as PI3K5. The application also provides compositions, including
pharmaceutical compositions, kits that include the compounds, and methods of using and making the compounds. The compounds provided herein are useful in treating diseases, disorders, or conditions that are mediated by PI3K isoforms, such as PI3K5. The application also provides the compounds for use in therapy. The application further provides compounds for use in a method of treating a disease, disorder, or condition that is mediated by PI3K isoforms. Moreover, the application provides uses of the compounds in the manufacture of a medicament for the treatment of a disease, disorder or condition that is mediated by PI3K isoforms.
[0008] In one aspect, the PI3K inhibitor is a compound having the structure of formula
(I):
Figure imgf000003_0001
or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug thereof; wherein:
n is 0, 1, 2 or 3; each R1 is independently halo, cyano, optionally substituted alkylsulfonyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optional substituted alkoxy;
m is 0, 1, 2, or 3;
each R2 is independently halo, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl;
R3 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, or optionally substituted heterocycloalkyl; and
R4 is cyano.
[0009] In one aspect, the compounds having the structure of formula (I) wherein:
n is 0, 1, 2 or 3;
each R1 is independently selected from halogen, cyano, alkyl, or alkylsulfonyl, wherein the alkyl moiety may be optionally substituted with 1 to 3 halogen;
m is 0, 1, 2 or 3;
each R2 is independently selected from halogen, alkoxy, alkyl, or cycloalkyl, wherein the alkyl moiety may be optionally substituted with 1 to 3 halogen;
R3 is hydrogen, alkyl, or cycloalkyl, wherein the alkyl moiety may be optionally substituted with cycloalkyl; and
R4 is cyano.
[0010] In some embodiments, the compounds have the structure of formula (I) wherein each R1 is independently selected from halogen, cyano, Ci^ alkyl, Ci-4 haloalkyl, or C1-4 alkylsulfonyl. In certain embodiments, each R1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or
propylsulfonyl.
[0011] In other embodiments, the compounds have the structure of formula (I) wherein each R2 is independently selected from halogen, C1-4 alkoxy, C1-4 alkyl, Ci-4 haloalkyl, or C3-6 cycloalkyl. In yet other embodiments, each R2 is independently selected from fluoro, chloro, iodo, bromo, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. [0012] In certain embodiments, the compounds have the structure of formula (I) wherein R3 is selected from hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl. In other embodiments, R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C3-6 cycloalkylCi-4 alkyl. In yet other embodiments, R3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl.
[0013] In additional embodiments, the compound having the structure of formula (I) wherein
n is 0, 1, 2, 3, or 4;
each R1 is independently halo, cyano, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optional substituted alkoxy, or S02Rlx wherein Rlx is optionally substituted alkyl;
m is 0, 1, 2, or 3;
each R2 is independently halo, -NH2, optionally substituted alkoxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl;
R3 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxyalkyl, or optionally substituted heterocycloalkyl ; and
R4 is selected from halo, cyano, and -CONH2.
[0014] In one additional embodiment, the compound having the structure of formula (I), wherein:
n is 0, 1, 2, 3, or 4;
each R1 is independently selected from halo, cyano, alkyl, or alkylsulfonyl, wherein the alkyl moiety may be optionally substituted with 1 to 3 halogen;
m is 0, 1, 2, or 3;
each R2 is independently selected from halo, -NH2, alkoxy, alkyl, or cycloalkyl, wherein the alkyl moiety may be optionally substituted with 1 to 3 halogen;
R3 is hydrogen, alkyl, or cycloalkyl, wherein the alkyl moiety may be optionally substituted with cycloalkyl; and
R4 is cyano, halo, or -CONH2.
[0015] In other additional embodiments, the compounds having the structure of formula (I) wherein R4 is selected from the group consisting of fluoro, chloro, bromo, iodo, cyano, and -CONH2. [0016] In some embodiment, the compounds have the structure of formula (I) wherein n is 1 or 2. In another embodiment, n is 1. In yet another embodiment, n is 2.
[0017] In other embodiments, the compounds have the structure of formula (I) wherein m is 0, 1 , or 2. In another embodiment, m is 0. In other embodiment, m is 1. In yet another embodiment, m is 2.
[0018] In certain embodiments, the compounds have the structure of formula (I), wherein:
n is 1 or 2;
each R1 is independently selected from halogen, cyano, alkylsulfonyl, or alkyl, wherein the alkyl moiety is optionally substituted with halogen;
m is 0, 1, or 2;
each R2 is independently selected from halo, alkoxy, alkyl, or cycloalkyl, wherein the alkoxy, alkyl or cycloalkyl moieties are optionally substituted with halogen, alkyl, or cycloalkyl;
R3 is hydrogen, alkyl, or cycloalkyl, wherein the alkyl or cycloalkyl moieties are optionally substituted with halogen or cycloalkyl; and
R4 is cyano.
[0019] In other embodiments, the compounds have the structure of formula (I), wherein: n is 1 or 2;
each R1 is independently selected from halogen, cyano, Ci^alkyl, Ci-4 haloalkyl, or C 1-4 alkylsulfonyl;
m is 0, 1, or 2;
each R2 is independently selected from halogen, C1-4 alkoxy, d^alkyl, Ci-4 haloalkyl, or C3-6 cycloalkyl.
R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C3_6cycloalkylCi_4alkyl; and
R4 is cyano.
[0020] In another embodiment, the compounds have the structure of formula (I), wherein: n is 1 or 2; each R1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
m is 0, 1, or 2;
each R2 is independently selected from fluoro, chloro, iodo, bromo, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
R3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl; and
R4 is cyano.
[0021] In some embodiments, the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
n is 2 and m is 2;
each R1 is independently selected from halogen, cyano, C1-4 alkylsulfonyl, C1-4 alkyl, or Ci_4 haloalkyl;
each R2 is independently selected from halogen, C1-4 alkoxy, C1-4 alkyl, Ci-4 haloalkyl, or C3-6 cycloalkyl;
R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C1-4 cycloalkylCi-4 alkyl; and
R4 is cyano.
[0022] In other embodiments, the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
n is 1 and m is 2;
R1 is independently selected from halogen, cyano, C1-4 alkylsulfonyl, C1-4 alkyl, or Ci_ 4 haloalkyl;
each R2 is independently selected from halogen, C1-4 alkoxy, C1-4 alkyl, Ci_4 haloalkyl, or C3-6 cycloalkyl;
R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C1-4 cycloalkylCi_4 alkyl; and R4 is cyano.
[0023] In some embodiments, the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
n is 2 and m is 1 ;
each R1 is independently selected from halogen, cyano, C1-4 alkylsulfonyl, C1-4 alkyl, or Ci_4 haloalkyl;
R2 is selected from halogen, C1-4 alkoxy, C1-4 alkyl, C1-4 haloalkyl, or C3-6 cycloalkyl; R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C1-4 cycloalkylCi-4 alkyl; and
R4 is cyano.
[0024] In some embodiments, the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
n is i and m is 1 ;
R1 is selected from halogen, cyano, Ci_4 alkylsulfonyl, C1-4 alkyl, or Ci_4 haloalkyl; R2 is selected from halogen, C1-4 alkoxy, C1-4 alkyl, C1-4 haloalkyl, or C3-6 cycloalkyl; R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C1-4 cycloalkylCi_4 alkyl; and
R4 is cyano.
[0025] In some embodiments, the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
n is 1 and m is 0;
R1 is selected from halogen, cyano, C1-4 alkylsulfonyl, C1-4 alkyl, or C1-4 haloalkyl; R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C1-4 cycloalkylCi_4 alkyl; and
R4 is cyano. [0026] In some embodiments, the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
n is 2 and m is 0;
each R1 is independently selected from halogen, cyano, C1-4 alkylsulfonyl, C1-4 alkyl, or Ci_4 haloalkyl;
R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C1-4 cycloalkylCi-4 alkyl; and
R4 is cyano.
[0027] In additional embodiments, the compounds have the structure of formula (I), wherein:
n is 1 or 2;
each R1 is independently selected from halo, cyano, alkylsulfonyl, or alkyl, wherein the alkyl moiety is optionally substituted with halogen;
m is 0, 1, or 2;
each R2 is independently selected from halo, -NH2, alkoxyalkyl, alkyl, or cycloalkyl, wherein the alkyl or cycloalkyl moieties are optionally substituted with halogen, alkyl, or cycloalkyl;
R3 is hydrogen, alkyl, or cycloalkyl, wherein the alkyl or cycloalkyl moieties are optionally substituted with halogen or cycloalkyl; and
R4 is cyano, halo, or -CONH2.
[0028] In other embodiments, the compounds have the structure of formula (I), wherein: n is 1 or 2;
each R1 is independently selected from halo, cyano, C1-4alkyl, Ci-4 haloalkyl, or Ci_ 4alkylsulfonyl;
m is 0, 1, or 2;
each R2 is independently selected from halo, -NH2, C^alkyl, d^ haloalkyl, or C3-6 cycloalkyl.
R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C3_6cycloalkylCi_4alkyl; and
R4 is cyano, halo, or -CONH2. [0029] In another embodiment, the compounds have the structure of formula (I), wherein: n is 1 or 2;
each R1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
m is 0, 1, or 2;
each R2 is independently selected from fluoro, chloro, iodo, -NH2, bromo, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
R3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl; and
R4 is cyano, halo, or -CONH2.
[0030] In some embodiments, the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
n is 2 and m is 2;
each R1 is independently selected from halo, cyano, C1-4 alkylsulfonyl, C1-4 alkyl, or Ci_4 haloalkyl;
each R2 is independently selected from halo, -NH2, C1-4 alkyl, Ci^ haloalkyl, or C3-6 cycloalkyl;
R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C1-4 cycloalkylCi-4 alkyl; and
R4 is cyano, halo, or -CONH2.
[0031] In other embodiments, the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
n is 1 and m is 2;
R1 is independently selected from halo, cyano, Ci_4 alkylsulfonyl, Ci_4 alkyl, or Ci_4 haloalkyl;
each R2 is independently selected from halo, -NH2, C1-4 alkoxy, C1-4 alkyl, C1-4 haloalkyl, or C3-6 cycloalkyl; R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C1-4 cycloalkylCi-4 alkyl; and
R4 is cyano, halo, or -CONH2.
[0032] In some embodiments, the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
n is 2 and m is 1 ;
each R1 is independently selected from halo, cyano, C1-4 alkylsulfonyl, C1-4 alkyl, or Ci_4 haloalkyl;
R2 is selected from halo, -NH2, C1-4 alkyl, Ci^ haloalkyl, or C3-6 cycloalkyl;
R3 is selected from hydrogen, C1-4 alkyl, C3_6 cycloalkyl, or C1-4 cycloalkylCi-4 alkyl; and
R4 is cyano, halo, or -CONH2.
[0033] In some embodiments, the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
n is i and m is 1 ;
R1 is selected from halo, cyano, C1-4 alkylsulfonyl, C1-4 alkyl, or C1-4 haloalkyl;
R2 is selected from halo, -NH2, C1-4 alkyl, C1-4 haloalkyl, or C3-6 cycloalkyl;
R3 is selected from hydrogen, C1-4 alkyl, C3_6 cycloalkyl, or C1-4 cycloalkylCi-4 alkyl; and
R4 is cyano, halo, or -CONH2.
[0034] In some embodiments, the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
n is 1 and m is 0;
R1 is selected from halo, cyano, C1-4 alkylsulfonyl, C1-4 alkyl, or C1-4 haloalkyl;
R3 is selected from hydrogen, C1-4 alkyl, C3_6 cycloalkyl, or C1-4 cycloalkylCi-4 alkyl; and
R4 is cyano, halo, or -CONH2. [0035] In some embodiments, the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
n is 2 and m is 0;
each R1 is independently selected from halo, cyano, C1-4 alkylsulfonyl, C1-4 alkyl, or Ci_4 haloalkyl;
R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C1-4 cycloalkylCi-4 alkyl; and
R4 is cyano, halo, or -CONH2.
[0036] In some embodiments, the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
n is 1 ;
m is 1 ;
R1 is selected from halo, cyano, C1-4 alkylsulfonyl, C1-4 alkyl, or C1-4 haloalkyl;
R2 is -NH2;
R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C1-4 cycloalkylCi-4 alkyl; and
R4 is cyano, halo, or -CONH2.
[0037] In some embodiments, the PI3K inhibitor is a compound having the structure of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
n is 2;
m is 1 ;
each R1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
each R2 is -NH2;
R3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl; and
R4 is cyano, halo, or -CONH2. [0038] In certain embodiments, the PI3K inhibitors are the compounds selected from Table 1, or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof. In some embodiments, the compounds are the atropisomers. In other embodiments, the compounds are the (S)-enantiomer. In some other embodiments, the compounds are the (R)-enantiomer. In other additional embodiments, the compounds are atropisomers.
[0039] The application also provides a pharmaceutical composition that includes a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof, together with at least one pharmaceutically acceptable vehicle. Examples of pharmaceutically acceptable vehicle may be selected from carriers, adjuvants, and excipients.
[0040] Also provided herein is a method of treating a disease or condition in a human in need thereof by administering to the human a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof. Further provided is a compound of formula (I) for use in a method of treating a disease, disorder or condition that is mediated by PI3K isoforms. The application also provides the use of a compounds of formula (I) in the manufacture of a medicament for the treatment of a disease, disorder or condition that is mediated by PI3K isoforms. In certain embodiments, the disease or condition is associated or mediated by PI3K. In some embodiments, the disease or condition is an inflammatory disorder, an autoimmune disease, or a cancer. In certain other embodiments, the disease or condition is an inflammatory disorder. In other embodiments, the disease or condition is an autoimmune disease. In additional embodiments, the disease or condition is a cancer.
[0041] Also provided herein is a method of inhibiting kinase activity of a
phosphatidylinositol 3-kinase delta polypeptide by contacting the polypeptide with a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof. Additionally provided herein is a method of inhibiting kinase activity of a phosphatidylinositol 3-kinase beta polypeptide by contacting the polypeptide with a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof. [0042] Further provided is a method of inhibiting excessive or destructive immune reactions, comprising administering an effective amount of a compound of formula (I) described herein or a pharmaceutically acceptable salt, isomer, a mixture of isomers, or prodrug thereof such as asthma, rheumatoid arthritis, multiple sclerosis, and lupus.
Moreover, provided is a method of inhibiting excess or destructive immune reactions, comprising administering an effective amount of a compound of formula (I) described herein or a pharmaceutically acceptable salt, isomer, a mixture of isomers, or prodrug thereof such as psoriasis, or chronic obstructive pulmonary disease (COPD).
[0043] Also provided is a method of disrupting leukocyte function comprising contacting the leukocytes with an effective amount of a compound of formula (I) described herein or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof.
[0044] Also provided is a method of inhibiting a growth or a proliferation of cancer cells comprising contacting the cancer cells with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof. In some embodiments, the cancer cells are of hematopoietic origin. In certain embodiment, the cancer is lymphoma, leukemia, or solid tumor.
[0045] Also provided is a kit that includes a compound of formula (I) or a
pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof. The kit may further comprise a label and/or instructions for use of the compound in the treatment of a disease or condition in a human in need thereof. In some embodiments, the disease or condition may be associated or mediated by PI3K5 activity. In some other embodiments, the disease or condition may be associated or mediated by PI3K5 and/or ΡΙ3Κβ activity.
[0046] Also provided are articles of manufacture that include a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof, and a container. In one embodiment, the container may be a vial, jar, ampoule, preloaded syringe, or an intravenous bag.
DETAILED DESCRIPTION
[0047] The following description sets forth exemplary methods, parameters and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.
[0048] As used in the present specification, the following words, phrases and symbols are generally intended to have the meanings as set forth below, except to the extent that the contex in which they are used indicates otherwise.
[0049] A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CONH2 is attached through the carbon atom.
[0050] Reference to "about" a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to "about X" includes description of "X". In some embodiments, the term "about" includes the indicated amount + 10%. In other embodiments, the term "about" includes the indicated amount ± 5%.
[0051] "Alkyl" refers to a monoradicai unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has i to 20 carbon atoms (i.e. , Ci-?.o alkyl), i to 8 carbon atoms (?'.<;. , Ci-8 alkyl), 1 to 6 carbon atoms (i. e. , Ci-e alkyl), or 1 to 4 carbon atoms (i.e. , C1.4 alkyl). Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyi, sec-butyl, iso- butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3- methylpentyl. When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons may be encompassed; thus, for example, "butyl" can include n-butyl, sec -butyl, isobutyl and t-butyl; "propyl" can include n-propyi and isopropyl.
[0052] "Cycloalkyl" refers to a cyclic alkyl group. As used herein, cycloalkyl has from 3 to 20 ring carbon atoms (i.e. , C3-20 cycloalkyl), or 3 to 12 ring carbon atoms (i.e. , C3..12 cycloalkyl), 3 to 8 ring carbon atoms (i.e. , C3.8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e. , ( ' ! ,·, cycloalkyl). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0053] "Heterocycloalkyl" refers to a cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur. As used herein, heterocycloalkyl has 2 to 20 ring carbon atoms (i.e. , C2-20 heterocycloalkyl), 2 to 12 ring carbon atoms (i.e. , C2-12 heterocycloalkyl), or 2 to 8 ring carbon atoms (i. e. , C2-8 heterocycloalkyl); and 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 or 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur or oxygen. Examples of heterocycloalkyl groups may include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidinyl, and morpholinyl.
[0054] "Alkoxy" refers to the group "alkyl-O-". Examples of alkoxy groups may include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n- hexoxy, and 1 ,2-dimethylbutoxy.
[0055] "Aryl" refers to an aromatic carbocyclic group having a single ring (e.g. , phenyl), multiple rings (e.g. , biphenyl), or multiple fused rings (e.g. , naphthyl, fluorenyl, and anthryl). Examples of aryl groups may include 6 to 20 ring carbon atoms (i.e. , C&.2o aryl), or 6 to 12 carbon ring atoms (i.e. , Ce-iz ary )- Aryl, however, does not encompass or overlap in any way with heteroaryl, separately defined below. If one or more aryl groups are fused with a heteroaryi ring, the resulting ring system is heteroaryl.
[0056] "Heteroaryl" refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. Heteroaryl may be an aromatic, monocyclic or bicyclic ring containing one or more heteroatoms independently selected from nitrogen, oxygen and sulfur with the remaining ring atoms being carbon. As used herein, heteroaryi include 1 to 20 ring carbon atoms (i.e. , ί ?ο heteroaryl), 1 to 12 ring carbon atoms (i.e. , C .n heteroaryl), or 1 to 8 carbon ring atoms (i.e. , Cj-g heteroaryl); and 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 ring heteroatoms, 1 or 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include pyridyl, pyridazinyi, pyrimidinyl, benzothiazolyi, and pyrazoiyl. Heteroaryi does not encompass or overlap with aryl as defined above.
[0057] As used herein, the term "substituted" means that any one or more hydrogen atoms on the designated atom or group is replaced with a moiety other than hydrogen, provided that the designated atom's normal valence is not exceeded.
[0058] The terms "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. Also, the term "optionally substituted" refers to any one or more hydrogen atoms on the designated atom or group may or may not be replaced by a moiety other than hydrogen.
[0059] "Substituted alky!" refers to an alkyl group having one or more substituents including, for example, hydroxy], haloaikyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cyano, halo, carboxyl, and NR2» where each R is independently hydrogen, alkyl, haloaikyl, alkylC(O)-, aikylOC(O)-, or H2NC(0)-. In some embodiments, a substituted alkyl may have 1 to 5 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent. In other embodiment, a substituted alkyl may have 1 to 4 substituents. For example, a substituted alkyl is haloaikyl, cycloalkylalkyl, or heterocycloalkylalkyl. In some embodiments, a substituted alkyl is Ci- haloaikyl, d-e cycloalkyl, C . heterocycloalkyl, C1- haloaikyl. CM cycloalkyl, or C1-4 heterocycloalkyl. In some other embodiments, a substituted alkyl is Ci_e haloaikyl, Ci-6 cycloalkylalkyl, Ci-6 heterocycloalkylalkyl, C haloaikyl, C M.
cycloalkylalkyl, or C heterocycloalkylalkyl. Examples of the substituted alkyl group may include - O N '. -CHF2, CF3, -CH2FCH3, -CHF2CH3, -CH2CH2F, -CH2CF3,
cyclopropylmethyi , cyclopropylethyl , cyclopropylpropyl, cyclobuty knetbyl, cyciobutyiethyl , or cyclobutylpropyl.
[0060] "Substituted cycloalkyl" refers to a cycloalkyl group having one or more substituents including, for example, alkyl, haloaikyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, cyano, halo, carboxyl, hydroxyl, and -N 2, where each R is independently hydrogen, alkyl, haloaikyl, alkylC(O)-, alkylOC(O)-, or H2NC(0)-. In some embodiments, a substituted cycloalkyl may have 1 to 5 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent. In other embodiment, a substituted cycloalkyl may have 1 to 4 substituents. For example, a substituted alkyl is haloaikyl, cycloalkylalkyl, or heterocycloalkylalkyl. In some embodiments, a substituted alkyl is Ci-e haloaikyl, C3-6 cycloalkyl, Ci-6 heterocycloalkyl, C haloaikyl, C3.4 cycloalkyl, or C 1-4 heterocycloalkyl . In other example, a substituted cycloalkyl is halocycloalkyl, or alkylcycloalkyl,. In some embodiments, a substituted cycloalkyl is C3-j halocycloalkyl , Cs-iocycloalkyl, C2-10 heterocycloalkyl, C3-6 halocycloalkyl, C3..6 cycloalkyl, or C2-5 heterocycloalkyl .
[0061] "Substituted heterocycloalkyl" refers to a heterocycloalkyl group having one or more substituents including, for example, alkyl, haloaikyl, cycloalkyl, aryl, heteroaryl, alkoxy, cyano, halo, carboxyl, hydroxy!, and -NR2, where each R is independently hydrogen, alkyl, haloaikyl, alkylC(O)-, alkylOC(O)-, or H2NC(0)~. In some embodiments, a substituted heterocycloalkyl may have 1 to 5 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent. In other embodiment, a substituted heterocycloalkyl may have 1 to 4
substituents. In certain embodiments, a substituted heterocycloalkyl may contain 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0062] "Substituted aryl" refers to an aryl group having one or more substituents including, for example, halo, -OR . -NR2, -C(0)NR'2, -SO >\'k\>. alkyl, haloalkyl, heterocycloalkyl, heteroaryl, alkoxy, amino, cyano, and carboxyl, where each R is independently hydrogen, alkyl, haloalkyl, alkylC(O)-, a!kvK K '; ( } ;-. or H2NC(0)- and each R' is independently hydrogen, alkyl, haloalkyl. In some embodiments, a substituted aryl may have 1 to 5 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent.
[0063] "Substituted heteroaryl" refers to a heteroaryl group having one or more substituents including, for example, alkyl, haloalkyl, halo, -NR2, -OR, -C(0)OR,
heterocycloalkyl, aryl, and cyano, where each R is independently hydrogen, alky], haloalkyl, alkyiCYO)-, alkylOC(O)-, or H2NC(0)-. In some embodiments, a substituted heteroaryl may have 1 to 5 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent. In other embodiment, a substituted heteroaryl may have 1 to 4 substituents. In certain embodiments, a substituted heteroaryl may contain 1 , 2 or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0064] "Substituted sulfonyl" refers to the group "S02R" where R refers to a substituent including, for example, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, and aryl and R is further substituted with alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, or aryl. "Sulfonyl" refers to the group "-S02R" where R refers to a substituent including, for example, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, and aryl. In some embodiments, the sulfonyl group is alkylsulfonyl, in which R is alkyl. Examples of the sulfonyl groups may include S02CH3, S02CH2CH3, or S02Ph.
[0065] The term "halogen" or "halo" includes fluoro, chio.ro, bromo, and iodo, and the term "halogen" includes fluorine, chlorine, bromine, and iodine. "Haloalkyl" refers to an unbranched or branched chain alkyl group as defined above, wherein one or more hydrogen atoms are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached. For example, dihaloaryl, dihaloalkyl, and trihaloaryl refer to aryl and alkyl substituted with two ("di") or three ("tri") halo groups, which may be, but are not necessarily, the same halogen; thus, for example, 3,5-difluorophenyl, 3-chloro-5-fluorophenyl, 4-chloro- 3-fluorophenyl, and 3,5-difluoro-4-chlorophenyl is within the scope of dihaloaryl. Other examples of a haloalkyl group include difluoromethyl (-CHF2) and trifluoromethyl (-CF3).
[0066] Certain commonly used alternative chemical names may be used. For example, a divalent group such as a divalent "alkyl" group, a divalent "aryl" group, etc., may also be referred to as an "alkylene" group or an "alkylenyl" group, an "arylene" group or an
"arylenyl" group, respectively. Also, unless defined otherwise, where combinations of groups are referred to herein as one moiety, e.g. arylalkyl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule.
PI3K Inhibitor Compounds
[0067] The present application provides the compounds that function as inhibitors of PI3K isoforms, such as PI3K5. In one aspect, the PI3K inhibitors are the compound having formula (II):
Figure imgf000019_0001
or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein:
A is N or CH;
n is 0, 1, 2, 3, or 4;
each R1 is independently selected from hydrogen, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted aryl, optionally substituted heteroaryl, halo, cyano, NHC(=0)alkylene-N(Rlx)2, N02, ORlx, OCF3, N(Rlx)2, OC(=0)Rlx, C(=0)Rlx, C(=0)ORlx, aryl-ORly, Het, NRlxC(=0)alkylene-C(=0)ORlx, aryl-0-alkylene-N(Rlx)2, aryl- 0-C(=0)Rlx, alkylene-C(=0)ORlx, 0-alkylene-C(=0)ORlx, alkylene-O-alkylene- C(=0)ORlx, C(=0)NRlxS02Rlx, alkylene-N(Rlx)2, alkenylene-N(Rlx)2, C(=0)NRlx-alkylene- ORlx, C(=0)NRlxalkylene-Het, 0-alkylene-N(Rlx)2, 0-alkylene-CH(ORly)CH2N(Rlx)2, O- alkylene-Het, 0-alkylene-ORlx, 0-alkylene-NRlxC(=0)ORlx, NRlx-alkylene-N(Rlx)2, NRlxC(=0)Rlx, NRlxC(=0)N(Rlx)2, N(S02-alkyl)2, NRlx(S02-alkyl), S02Rlx, S02N(Rlx)2, OSO2CF3, alkylene-aryl, alkylene-Het, alkylene-ORly, alkylene-N(Rlx)2, C(=0)N(Rlx)2, NHC(=0)alkylene-aryl, optionally substituted cycloalkyl, optionally substituted
heterocycloalkyl, aryl-0-alkylene-N(Rlx)2, aryl-OC(=0)Rly, NHC(=0)alkylene- heterocycloalkyl, NHC(=0)alkylene-Het, 0-alkylene-0-alkylene-C(=0)ORly,
C(=0)alkylene-Het, or NHC(=0)halo-alkyl,
wherein Het is a 5- or 6-membered heterocyclic ring containing at least one heteroatom selected from the group consisting of oxygen, nitrogen and sulfur, wherein the 5- or 6-membered heterocyclic ring is saturated, partially unsaturated or fully unsaturated, and wherein Het is optionally substituted with alkyl or C(=0)ORlx,
wherein Rlx is independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, alkylene-N(Rlx)2, optionally substituted aryl, arylalkyl, alkylenearyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, or alkyleneheteroaryl, or two Rlx groups are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom,
wherein Rly is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, arylalkyl, heteroarylalkyl, alkylenearyl, and
alkyleneheteroaryl;
m is 0, 1, 2, 3, or 4;
each R2 is independently selected from hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, or NR2xR2y, wherein each R2x and R2y is independently hydrogen, C(0)R2sor C(0)OR2s, wherein R2s is optionally substituted alkyl;
R3 is hydrogen, optionally substituted cycloalkyl, or optionally substituted alkyl; and R4 is hydrogen, cyano, CON(R4a)2, S02-alkyl, halo, or haloalkyl, where each R4a is independently hydrogen or optionally substituted alkyl.
[0068] In one embodiment, the application provides the compounds having the structure of formula (I) that function as inhibitors of PI3K isoforms, such as PI3K5. The structure of formula (I) is shown below:
Figure imgf000021_0001
or a pharmaceutically acceptable salt, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein each of n, R1, m, R2, R3 and R4 are as defined for formula (II).
[0069] In other embodiments, the compound having the structure of formula (I) wherein: n is 0, 1, 2, 3, or 4;
each R1 is independently halo, cyano, optionally substituted alkylsulfonyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted alkoxy;
m is 0, 1, 2, 3, or 4;
each R2 is independently halo, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl;
R3 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, or optionally substituted heterocycloalkyl; and
R4 is cyano.
[0070] In other embodiments, the compounds having the structure of formula (I), wherein:
n is 1, 2, or 3;
each R1 is independently halo, cyano, Ci_6 alkylsulfonyl, or Ci_6 alkyl, wherein the alkyl moiety is optionally substituted with halogen or cycloalkyl;
m is 0, 1, 2, or 3;
each R2 is independently halo, Ci_6 alkoxy, Ci_6 alkyl, or C3_6 cycloalkyl, wherein the alkoxy, alkyl, or cycloalkyl moieties are optionally substituted with halogen, alkyl, or cycloalkyl; R3 is hydrogen, Ci_6 alkyl, or C3-6 cycloalkyl, wherein the alkyl or cycloalkyl moieties are optionally substituted with halogen, alkyl, or cycloalkyl; and
R4 is cyano.
[0071] In yet other embodiments, the compounds having the structure of formula (I), wherein:
n is 1 or 2;
each R1 is independently selected from halogen, cyano, C1-4 alkyl, Ci-4 haloalkyl, C1-4 alkylsulfonyl, or C3_6 cycloalkylCi_4alkyl;
m is 0, 1, or 2;
each R2 is independently selected from halogen, C1-4 alkoxy, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, or C3-6 cycloalkylC^alkyl;
R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C3_6 cycloalkylCi_4alkyl; and
R4 is cyano.
[0072] In another embodiment, the compounds having the structure of formula (I), wherein:
n is 1 or 2;
each R1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
m is 0, 1, or 2;
each R2 is independently selected from fluoro, chloro, iodo, bromo, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
R3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl; and
R4 is cyano.
[0073] In other embodiments, the compound having the structure of formula (I) wherein: n is 0, 1, 2, 3, or 4; each R1 is independently halo, cyano, optionally substituted alkylsulfonyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted alkoxy;
m is 0, 1, 2, 3, or 4;
each R2 is independently halo, -NH2, optionally substituted alkoxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl;
R3 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxyalkyl, or optionally substituted heterocycloalkyl; and
R4 is cyano, halo or -CONH2.
[0074] In other embodiments, the compounds having the structure of formula (I), wherein:
n is 1, 2, or 3;
each R1 is independently halo, cyano, Ci_6 alkylsulfonyl, or Ci_6 alkyl, wherein the alkyl moiety is optionally substituted with halogen or cycloalkyl;
m is 0, 1, 2, or 3;
each R2 is independently halo, -NH2, Ci_6 alkoxy, Ci_6 alkyl, or C3_6 cycloalkyl, wherein the alkoxy, alkyl, or cycloalkyl moieties are optionally substituted with halogen, alkyl, or cycloalkyl;
R3 is hydrogen, Ci_6 alkyl, or C3-6 cycloalkyl, wherein the alkyl or cycloalkyl moieties are optionally substituted with halogen, alkyl, or cycloalkyl; and
R4 is cyano, halo or -CONH2.
[0075] In yet other embodiments, the compounds having the structure of formula (I), wherein:
n is 1 or 2;
each R1 is independently selected from halo, cyano, C1-4 alkyl, Ci^ haloalkyl, C1-4 alkylsulfonyl, or C3_6 cycloalkylCi_4alkyl;
m is 0, 1, or 2;
each R2 is independently selected from halo, -NH2, C1-4 alkoxy, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, or C3_6 cycloalkylCi_4alkyl;
R3 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C3_6 cycloalkylCi_4alkyl; and
R4 is cyano, halo or -CONH2. [0076] In another embodiment, the compounds having the structure of formula (I), wherein:
n is 1 or 2;
each R1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
m is 0, 1, or 2;
each R2 is independently selected from fluoro, chloro, iodo, bromo, -NH2, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
R3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl; and
R4 is cyano, halo or -CONH2.
[0077] In another embodiment, the compounds having the structure of formula (I), wherein:
n is 1 or 2;
each R1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
m is 0, 1, or 2;
each R2 is independently selected from fluoro, chloro, iodo, bromo, -NH2, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
R3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl; and
R4 is cyano.
[0078] In another embodiment, the compounds having the structure of formula (I), wherein:
n is 1 or 2; each R1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
m is 0, 1, or 2;
each R2 is independently selected from fluoro, chloro, iodo, bromo, -NH2, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
R3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl; and
R4 is fluoro, chloro, or bromo.
[0079] In another embodiment, the compounds having the structure of formula (I), wherein:
n is 1 or 2;
each R1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl;
m is 0, 1, or 2;
each R2 is independently selected from fluoro, chloro, iodo, bromo, -NH2, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
R3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl; and
R4 is -CONH2.
[0080] In one embodiment of formula (I), n is 0. In some embodiments, n is 1, 2, 3, or 4. In other embodiments, n is 1, 2 or 3. In certain embodiments, n is 1 or 2. In one
embodiment, n is 1. In the embodiment where n is 1 , the R1 moiety may be located on any position of the quinazolinone ring, as depicted below.
Figure imgf000025_0001
[0081] In another embodiment, n is 2. In embodiments where n is 2, both R may be the same or different. Two R1 moieties may be located on any two positions of the
quinazolinone ring as depicted below. For example, two R1 moieties may be in para-, meta- or ortho-positio
Figure imgf000026_0001
[0082] In yet another embodiment, n is 3. In embodiments where n is 3, all R1 may be the same or different, or two R1 may be the same and different from the third R1. Three R1 moieties may be located on any three positions of the quinazolinone ring as depicted below. For example, the first R1 may be ortho to the second R1, and the first R1 may be para to the third R1.
Figure imgf000026_0002
[0083] In yet another embodiment, n is 4. In embodiments where n is 4, all R1 may be the same or different, three R1 may be the same and different from the fourth R1, two R1 may be the same and different from the third and the fourth R1.
Figure imgf000026_0003
[0084] In some embodiments of formula (I), each R1 is independently halo, cyano, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, or optionally substituted alkylsulfonyl. In certain embodiments, each R1 is independently halo, cyano, optionally substituted alkyl, or optionally substituted alkylsulfonyl.
[0085] In some other embodiments of formula (I), each R1 is independently halo, cyano, optionally substituted C1-4 alkyl, optionally substituted C1-4 haloalkyl, optionally substituted Ci-4 alkoxy, hydroxy, optionally substituted C3-6 cycloalkyl, or optionally substituted Ci_6 alkylsulfonyl. In certain embodiments, each R1 is independently halo, cyano, optionally substituted C1-4 alkyl, optionally substituted C3-6 alkoxy, optionally substituted C3-6 cycloalkyl, or optionally substituted C1-4 alkylsulfonyl. In other embodiments, each R1 is independently halo, cyano, C1-4 haloalkyl, C1-4 alkyl, or C1-4 alkylsulfonyl.
[0086] In certain embodiments of formula (I), each R1 is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl. In some embodiments, each R1 is independently fluoro, chloro, iodo, cyano, methyl, difluoromethyl (-CHF2), trifluoromethyl (-CF3), ethyl, methoxy,
methylsulfonyl (-SO2CH3), cyclopropylmethyl, or cyclopropyl. In one embodiment, each R1 is independently fluoro, chloro, cyano, methylsulfonyl, methyl, or trifluoromethyl.
[0087] In some embodiments of formula (I) where n is 1 , R1 is halo, cyano, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, hydroxy, optionally substituted alkylsulfonyl, or optionally substituted cycloalkyl. In other embodiments of formula (I) wherein n is 1 , R1 is independently halo, cyano, C1-4 haloalkyl, Ci-4 alkyl, or C1-4 alkylsulfonyl. In certain embodiments where n is 1 , R1 is fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, -CHF2, -CF3, fluoroethyl, fluoropropyl, methylsulfonyl, or ethylsulfonyl. In another embodiment where n is 1 , R1 is fluoro, chloro, cyano, methyl, trifluoromethyl (-CF3), or methylsulfonyl (-SO2CH3). In another embodiment where n is 1 , R1 is fluoro, chloro, bromo, cyano, methyl, trifluoromethyl (-CF3), or methylsulfonyl (-SO2CH3). The R1 moiety may be located on any position of the quinazolinone ring.
[0088] In other embodiments of formula (I) where n is 2, both R1 are independently halo, which may be the same (e.g. , both R1 are fluoro, chloro, or iodo) or different (e.g. , one R1 is fluoro and the other R1 is chloro). In other embodiments where n is 2, one R1 is halo and the other R1 is optionally substituted alkyl. In other embodiments where n is 2, one R1 is halo and the other R is optionally substituted cycloalkyl. In other embodiments where n is 2, one R1 is halo and the other R1 is cyano.In additional embodiments, each R1 is independently selected from fluoro, chloro, bromo, cyano, methyl, trifluoromethyl (-CF3), or methylsulfonyl (-SO2CH3). In other embodiments of formula (I) where n is 2, one R1 is bromo and the other R1 is fluoro.
[0089] In certain embodiments where n is 2, both R1 are chloro, or both R1 are fluoro. In other embodiments where n is 2, one R1 is chloro and the other R1 is fluoro; one R1 is chloro and the other R1 is methyl; one R1 is fluoro and the other R1 is methyl; one R1 is fluoro and the other R1 is cyano; one R1 is chloro and the other R1 is cyano. In certain other
embodiments where n is 2; one R1 is bromo and the other R1 is fluoro. The two R1 moieties may be located at any two positions of the quinazolinone ring as depicted below.
[0090] In some embodiments, the moiety
Figure imgf000028_0001
of formula (I) is:
Figure imgf000028_0002
In certain embodiments, the moiety of formula (I) is:
Figure imgf000029_0001
Figure imgf000030_0001
[0092] Each and every variation of n and R1 may be combined with each and every variation of m, R2 and R3 as described for formula (I), as if each and every combination is individually described.
[0093] In some embodiments of formula (I), m is 0. In certain embodiments, m is 1 , 2, 3, or 4. In other embodiments, m is 1, 2 or 3. In yet other embodiments, m is 1 or 2. In one embodiment, m is 1. The R2 moiety may be located on any position of the pyridinyl ring, as depicted below.
Figure imgf000030_0002
[0094] In another embodiment, m is 2. In embodiments where m is 2, both R2 may be the same or different. The two R2 moieties may be located on any two positions of the pyridinyl ring, as depicted below.
Figure imgf000031_0001
[0095] In yet another embodiment, m is 3. In embodiments where m is 3, all R2 may be the same or different, or two R2 may be the same and different from the third R2. The three R2 moi low.
Figure imgf000031_0002
[0096] In certain embodiment, m is 4. In embodiments where m is 4, all R2 may be the same or different, three R2 may be the same and different from the fourth R2, or two R2 may be the same and different from the third and the fourth R2.
Figure imgf000031_0003
[0097] In some embodiments of formula (I), each R2 is independently halo, cyano, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, or optionally substituted cycloalkyl. In other embodiments of formula (I), each R2 is independently halo, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted haloalkyl, or optionally substituted cycloalkyl. In certain embodiments of formula (I), each R2 is independently halo, cyano, optionally substituted Ci_6 alkyl, optionally substituted Ci_6 haloalkyl, optionally substituted Ci_6 alkoxy, or optionally substituted C3-8 cycloalkyl. In some embodiments of formula (I), each R2 is independently halo, -NH2, cyano, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, or optionally substituted cycloalkyl. In certain embodiments of formula (I), each R2 is independently halo, -NH2, cyano, optionally substituted Ci_6 alkyl, optionally substituted Ci_6 haloalkyl, optionally substituted Ci_6 alkoxy, or optionally substituted C3-8 cycloalkyl. In certain embodiments of formula (I), each R2 is independently halo, -NH2, cyano, optionally substituted C1-4 alkyl, optionally substituted C1-4 haloalkyl, optionally substituted C1-4 alkoxy, or optionally substituted C3-6 cycloalkyl. In some embodiments, each R2 is independently fluoro, chloro, iodo, bromo, -NH2, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, - CHF2, -CF3 , fluoroethyl, difluoroethyl, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In one embodiment, each R2 is independently fluoro, chloro, methoxy, methyl, -NH2, -CHF2, -CF3, or cyclopropyl.
[0098] In certain embodiments of formula (I), each R2 is independently halo, cyano, optionally substituted Ci_4 alkyl, optionally substituted Ci_4 haloalkyl, optionally substituted Ci-4 alkoxy, or optionally substituted C3-6 cycloalkyl. In some embodiments, each R2 is independently fluoro, chloro, iodo, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, - CHF2, -CF3 , fluoroethyl, difluoroethyl, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In one embodiment, each R2 is independently fluoro, chloro, methoxy, methyl, -CHF2, -CF3, or cyclopropyl.
[0099] In some embodiments of formula (I) where m is 1 , R2 is halo, cyano, optionally substituted haloalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted alkoxy. In certain embodiments where m is 1, R2 is fluoro, chloro, iodo, cyano, Ci_4 alkyl, Ci_4 haloalkyl, Ci_4 alkoxy, or C3-6 cycloalkyl. In other embodiments where m is 1, R2 is fluoro, chloro, methoxy, methyl, ethoxy, propoxy, butoxy, pentoxy, hexoxy, -CHF2, -CF3, fluoroethyl, difluoroethyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In one embodiment where m is 1, R2 is fluoro, chloro, methoxy, methyl, difluoromethyl (-CHF2), trifluoromethyl (-CF3), or cyclopropyl. The R2 moiety may be located on any position of the pyridinyl ring. In certain embodiments where m is 1 , R2 is fluoro, chloro, iodo, bromo, -NH2, cyano, Ci_4 alkyl, Ci_4 haloalkyl, Ci^ alkoxy, or C3-6 cycloalkyl. In other embodiments where m is 1, R2 is fluoro, chloro, methoxy, methyl, ethoxy, propoxy, butoxy, pentoxy, hexoxy, -NH2, -CHF2, -CF3, fluoroethyl, difluoroethyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In one embodiment where m is 1 , R2 is fluoro, chloro, -NH2, methoxy, methyl, difluoromethyl (-CHF2), trifluoromethyl (-CF3), or cyclopropyl. The R2 moiety may be located on any position of the pyridinyl ring.
[00100] In some embodiments of formula (I) where m is 2, both R2 are independently halo, which may be the same (e.g. , both R2 are fluoro or chloro) or different (e.g. , one R2 is fluoro and the other R2 is chloro). In other embodiments where m is 2, both R2 are independently optionally substituted alkyl, which may be the same (e.g. , both R2 are methyl) or which may be different (e.g. , one R2 is methyl and the other R2 is ethyl). In other embodiments where m is 2, both R2 are independently optionally substituted haloalkyl, which may the same (e.g. , both R are -CF3) or which may be different (e.g. , one R2 is -CF3 and the other R2 is -CHF2). In yet other embodiments where m is 2, both R2 are independently optionally substituted alkoxy, which may be the same (e.g. , both R2 are methoxy) or which may be different (e.g. , one R2 is methoxy and the other R2 is ethoxy). In some embodiments where m is 2, both R2 are independently optionally substituted cycloalkyl, which may the same (e.g. , both R2 are cyclopropyl) or which may be different (e.g. , one R2 is methylcyclopropyl and the other R1 is cyclopropyl). In other embodiments where m is 2, one R2 is halo and the other R2 is cyano, one R2 is halo and the other R2 is optionally substituted haloalkyl, one R2 is halo and the other R2 is optionally substituted alkyl, one R2 is halo and the other R2 is optionally substituted alkoxy, one R2 is halo and the other R2 is optionally substituted cycloalkyl, one R2 is optionally substituted alkyl and the other R2 is optionally substituted cycloalkyl, or one R2 is optionally substituted alkyl and the other R2 is optionally substituted alkoxy. In further embodiments, each R2 is independently selected from fluoro, chloro, -NH2, methoxy, methyl, difluoromethyl (-CHF2), trifluoromethyl (-CF3), or cyclopropyl. In yet other embodiments where m is 2, one R2 is -NH2 and the other R2 is optionally substituted alkyl.
[00101] In certain embodiments of formula (I) where m is 2, both R2 are fluoro, both R2 are chloro, both R2 are methoxy, both R2 is methyl, or both R2 is cyclopropyl. In yet other embodiments where m is 2, one R2 is fluoro and the other R2 is chloro, one R2 is fluoro and the other R2 is cyano, one R2 is chloro and the other R2 is cyano, one R2 is fluoro and the other R2 is -CF3, one R2 is fluoro and the other R2 is -CHF2, one R2 is chloro and the other R2 is -CF3, one R2 is chloro and the other R2 is -CHF2, one R2 is cyano and the other R2 is -CF3, one R2 is cyano and the other R2 is -CHF2i one R2 is fluoro and the other R2 is methyl, one R2 is chloro and the other R2 is methyl, one R2 is fluoro and the other R2 is cyclopropyl, or one R2 is chloro and the other R2 is cyclopropyl. In additional embodiments, one R2 is -NH2 and the other R2 is methyl. The two R2 moieties may be located on any two positions of the pyridinyl ring.
[00102] In yet other embodiments of formula (I) where m is 3, one or two of R2 are independently halo, which may be the same (e.g. , two R2 are fluoro) or which may be different (e.g. , one R2 is fluoro and another R2 is chloro), the third R2 is optionally substituted alkoxy (e.g. , third R2 is methoxy). In another embodiment where m is 3, one R2 is optionally substituted alkyl, another R2 is optionally substituted alkoxy, and the third R2 is halo. The three R2 moieties may be located on any three positions of the pyridinyl ring.
Figure imgf000034_0001
[00104] Each and every variation of m and R2 may be combined with each and every variation of n, R1 and R3 as described for formula (I), as if each and every combination is individually described.
[00105] In some embodiments of formula (I), R3 is hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted heterocycloalkyl, or optionally substituted cycloalkyl. In other embodiments of formula (I), R3 is hydrogen, optionally substituted Ci_6 alkyl, optionally substituted C3-8 cycloalkylCi-6 alkyl or optionally substituted C3-8 cycloalkyl. In one embodiment, R3 is hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C3-6 cycloalkylCi-4 alkyl. In some embodiments, R3 is hydrogen, methyl, ethyl, propyl, butyl, cyclopropylmethyl, cyclopropylbutyl, cyclobutylmethyl, or cyclopropylethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In other embodiments, R3 is methyl, ethyl, cyclopropylmethyl, or cyclopropyl. In other embodiments, R3 is methyl, ethyl, propyl, butyl, cyclopropylmethyl, or cyclopropyl.
[00106] Each and every variation of R3 may be combined with each and every variation of n, R1, m and R2 as described for formula (I), as if each and every combination is individually described.
[00107] In additional embodiments, R4 is hydrogen, cyano, -C(0)N(R4a)2, or halo, wherein each R4a is independently hydrogen or optionally substituted Ci_6 alkyl. In some additional embodiments, R4 is cyano, halo, -C(0)N(R4a)2 wherein each R4a is independently hydrogen or Ci-4 alkyl. In certain additional embodiments, R4 is cyano, fluoro, bromo, chloro, or - C(0)NH2. In certain embodiments, R4 is cyano, chloro, or -C(0)NH2. It is understood by those skilled in the art that "-C(=0)NH2", "-C(0)NH2", and "-CONH2" are equivalent and used interchangeably. Each and every variation of R4 may be combined with each and every variation of n, R1, m, R2, and R3 as described herein, as if each and every combination is individually described.
[00108] In some embodiments of formula (I),
n is 1 or 2;
each R1 is independently halo, cyano, C3-6 alkylsulfonyl, C1-4 haloalkyl, or Ci^ alkyl; m is 0, 1 or 2;
each R2 is independently halo, C1-4 alkoxy, C1-4 alkyl, C 1-4 haloalkyl, or C3-6 cycloalkyl; R3 is hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C3-6 cycloalkylCi-4 alkyl; and
R4 is cyano.
[00109] In one embodiment of formula (I),
n is 1 or 2;
each R1 is independently selected from fluoro, chloro, methylsulfonyl, cyano, methyl, trifluoromethyl;
m is 0, 1 or 2;
each R2 is independently selected from fluoro, chloro, methoxy, methyl,
difluoromethyl, trifluoromethyl, or cyclopropyl;
R3 is methyl, ethyl, cyclopropyl, or cyclopropylmethyl; and
R4 is cyano.
[00110] In some other embodiments of formula (I),
n is 1 or 2;
each R1 is independently halo, cyano, C3-6 alkylsulfonyl, C1-4 haloalkyl, or C1-4 alkyl; m is 0, 1 or 2;
each R2 is independently halo, -NH2, Ci_4 alkoxy, Ci_4 alkyl, Ci_4 haloalkyl, or C3_6 cycloalkyl;
R3 is hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C3-6 cycloalkylCi_4 alkyl; and
R4 is cyano, halo or -CONH2
[00111] In one other embodiment of formula (I),
n is 1 or 2;
each R1 is independently selected from fluoro, chloro, methylsulfonyl, cyano, methyl, trifluoromethyl;
m is 0, 1 or 2;
each R2 is independently selected from fluoro, chloro, -NH2, methoxy, methyl, difluoromethyl, trifluoromethyl, or cyclopropyl;
R3 is methyl, ethyl, cyclopropyl, or cyclopropylmethyl; and
R4 is cyano, halo or -CONH2.
[00112] In some other embodiments of formula (I),
n is 1 or 2;
each R1 is independently halo, cyano, C3-6 alkylsulfonyl, C1-4 haloalkyl, or C1-4 alkyl; m is 0, 1 or 2;
each R2 is independently halo, -NH2, Ci_4 alkoxy, Ci_4 alkyl, Ci_4 haloalkyl, or C3_6 cycloalkyl;
R3 is hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or C3-6 cycloalkylCi_4 alkyl; and
R4 is halo or -CONH2.
[00113] In yet another embodiment of formula (I),
n is 1 or 2;
each R1 is independently selected from fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, and methylsulfonyl;
m is 0, 1, or 2;
each R2 is independently selected from fluoro, chloro, bromo, methoxy, methyl, difluoromethyl, trifluoromethyl, and cyclopropyl;
R3 is selected from methyl, ethyl, propyl, butyl, cyclopropyl, and cyclopropylmethyl; and
R4 is chloro, fluoro, bromo, or -CONH2.
[00114] In some embodiments of formula (I) where n is 2, m is 2, and R4 is cyano, the compounds have the structure of formula (IA):
Figure imgf000037_0001
(IA),
or a pharmaceutically acceptable salt, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
each Rla and Rlb can be independently selected from the moieties defined for R1 of formula (I);
each R2a and R2b can be independently selected from the moieties defined for R2 of formula (I); and
R3 is as defined for formula (I). [00115] In other embodiments of formula (I) where n is 1, m is 2, and R4 is cyano, the compounds have the structure of formula (IB):
Figure imgf000038_0001
(IB),
or a pharmaceutically acceptable salt, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
R1 is as defined for formula (I);
each R2a and R2b can be independently selected from the moieties defined for R2 of formula (I); and
R3 is as defined for formula (I).
[00116] In another embodiments where n is 2, m is 1, and R4 is cyano, the compounds have the structure of formula IC):
Figure imgf000038_0002
(IC),
or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, prodrug, or solvate thereof, wherein:
each Rla and Rlb can be independently selected from the moieties defined for R1 of formula (I);
R2 is as defined for formula (I); and
R3 is as defined for formula (I). [00117] In another embodiments where n is 1, m is 1, and R4 is cyano, the compounds have the structure of formula (ID):
Figure imgf000039_0001
(ID),
or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof, wherein:
R1 is as defined for formula (I);
R2 is as defined for formula (I); and
R3 is as defined for formula (I).
[00118] In another embodiments where n is 1, m is 0, and R4 is cyano, the compounds have the structure of formula (IE):
Figure imgf000039_0002
or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof, wherein:
R1 is as defined for formula (I); and
R3 is as defined for formula (I). [00119] In another embodiments where n is 2, m is 0, and R4 is cyano, the compounds have the structure of formula (IF):
Figure imgf000040_0001
(IF),
or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof, wherein:
each Rla and Rlb can be selected from the moieties defined for R1 of formula (I); and R3 is as defined for formula (I).
[00120] It should be understood that the embodiments and structures as described herein with respect to formula (I) are suitable for compounds of any formulae detailed herein where applicable.
[00121] For compounds of the present application bearing one or more chiral centers, each unique stereoisomer has an unique compound number. As an example, the structure below bearing one chiral center can be resolved into the (S) and (R) enantiomer.
Figure imgf000040_0002
[0122] In any one of the foregoing embodiments, the compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof, is the (S)- enantiomer.
[0123] In any one of the foregoing embodiments, the compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof, is the (R)- enantiomer. [0124] The application also provides a composition containing a mixture of enantiomers of the compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the composition contains the (S)-enantiomer of the compound and is substantially free of its corresponding (R)-enantiomer. In certain embodiments, a composition substantially free of the (R)-enantiomer has less than or about 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1 %, 0.05%, or 0.01 % of the (R)-enantiomer. In other embodiments, the composition containing the (S)-enantiomer of a compound according to any of formulae described herein or a pharmaceutically acceptable salt thereof, predominates over its corresponding ( ?)-enantiomer by a molar ratio of at least or about 9: 1 , at least or about 19: 1 , at least or about 40: 1 , at least or about 80: 1 , at least or about 160: 1 , or at least or about 320: 1.
[0125] The composition containing a compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof, may also contain the compound in enantiomeric excess (e.e.). For instance, a compound with 95% (^-isomer and 5% ( ?)-isomer will have an e.e. of 90%. In some embodiments, the compound has an e.e. of at least or about 60%, 75%, 80%, 85%, 90%, 95%, 98% or 99%. In some of the foregoing embodiments, the compound is enantiomerically-enriched in the (S) -isomer of compound according to any of the formula described herein.
[0126] Provided is also a composition comprising a mixture of the (S)-enantiomer and the (R)-enantiomer of a compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof. In one embodiment, the mixture is a racemic mixture. In other embodiments, the composition comprises the (S)-enantiomer of a compound according to any of formulae described herein or a pharmaceutically acceptable salt thereof, wherein the (S)-enantiomer of the compound is present in excess of over the corresponding the (R)-enantiomer of the compound, or a pharmaceutically acceptable salt thereof.
[0127] In any one of the foregoing embodiments, the compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof, is an atropisomer. A composition containing a mixture of atropisomers of the compound of any of the formulae described herein or a pharmaceutically acceptable salt thereof, is also provided herein.
"Atropisomers" refers to conformational stereoisomers which occur when rotation about a single bond in the molecule is prevented, or greatly hindered, as a result of steric interactions with other parts of the molecule and the substituents at both ends of the single bond are asymmetrical, i.e. , they do not require a stereocenter. Where the rotational barrier about the single bond is high enough, and interconversion between conformations is slow enough, separation and isolation of the isomeric species may be permitted. Atropisomers are enantiomers without a single asymmetric atom. In some embodiments, the compounds described herein may contain a mixture of diastereomers.
[0128] In any one of the foregoing embodiments, the compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof, is the atropisomer. As an example,
Figure imgf000042_0001
[0129] Representative compounds of the present application are listed in Table 1 below. The compounds in Table 1 are named using ChemBioDraw Ultra 12.0 and it should be understood that other names may be used to identify compounds of the same structure. Other compounds or radicals may be named with common names, or systematic or non-systematic names. The compounds may also be named using other nomenclature systems and symbols that are commonly recognized in the art of chemistry including, for example, Chemical Abstract Service (CAS) and International Union of Pure and Applied Chemistry (IIJPAC). Table 1 shows the naming and numbering of the compounds that represent the formulae described herein. The compounds provided in Table 1 may be a single enantiomer (e.g. , (S)- enantiomer, (R) -enantiomer), or the compounds may be present in a composition having an enantiomeric mixture. Additional representative compounds are listed in Table la below. As those in Table 1, the compounds in Table la are named using ChemBioDraw Ultra 12.0. The compounds provided in Table la may be a single enantiomer (e.g. , (S)-enantiomer, (R)- enantiomer), or the compounds may be present in a composition having an enantiomeric mixture. In some embodiments, the compounds provided in Tables 1 and la are
atropisomers.
Table 1. Representative Compounds - - -
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Table la. Re resentative Compounds
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
(S)-2,4-diamino-6-((l- (S)-2,4-diamino-6-(((3- (5-chloro-8-fluoro-3- (6 -aminopyridin-3 -yl) -
Λ Νώ (5-fluoro-4- 5-chloro-8-fluoro-4- methylpyridin-3-yl)-4- oxo-3,4-
73 107
oxo-3,4- dihydroquinazolin-2- dihydroquinazolin-2- yl) (cyclopropyl)methyl) yl)ethyl)amino)pyrimi amino)pyrimidine-5 - dine-5 -carbonitrile carbonitrile
(S)-2,4-diamino-6-((l- (5-chloro-8-fluoro-3- (S)-2,4-diamino-6-((l -
(5-fluoro-4- (3 -(5 -aminopyridin-3 - methylpyridin-3-yl)-4- yl)-5-chloro-4-oxo-3,4-
74 108
oxo-3,4- dihydroquinazolin-2-
AfN dihydroquinazolin-2- yl)ethyl)amino)pyrimid yl)ethyl)amino)pyrimi ine-5 -carbonitrile dine-5 -carbonitrile
(S)-2,4-diamino-6-((l-
(S)-4-amino-6-((l-(3- (6 -fluoro-3 -(5 -fluoro- (5 -aminopyridin-3 -yl) - 4-methylpyridin-3-yl)- 5-chloro-4-oxo-3,4-
75 4-oxo-3,4- 109
ΗΝγΝγ dihydroquinazolin-2- dihydroquinazolin-2-
NH2 yl)ethyl)amino)pyrimid
T yl)ethyl)amino)pyrimi
ine-5 -carbonitrile dine-5 -carbonitrile
(S)-2,4-diamino-6-((l- (R)-2,4-Diamino-6-((l- (6 -fluoro-3 -(5 -fluoro- (5-chloro-8-fluoro-4- 4-methylpyridin-3-yl)- oxo-3-(pyridin-3-yl)-
76 4-oxo-3,4- 110 "*γ«γ 3 ,4 -dihydroquinazolin- dihydroquinazolin-2- 2- yl)ethyl)amino)pyrimi
Figure imgf000051_0001
ΝΛ*Ν yl)ethyl)amino)pyrimid dine-5 -carbonitrile ine-5 -carbonitrile
(S)-2,4-diamino-6-((l- (R)-2,4-Diamino-6-((l- ci o (5-chloro-3-(4,5- dimethylpyridin-3 -yl)- ΛΛΝΌ (5-chloro-8-fluoro-4- oxo-3-(pyridin-3-yl)-
77 4-oxo-3,4- 111 3 ,4 -dihydroquinazolin- dihydroquinazolin-2- 2- yl)ethyl)amino)pyrimi A T TN>
yl)propyl)amino)pyrimi dine-5 -carbonitrile dine-5 -carbonitrile
(R)-2,4-Diamino-6-
(S)-2,4-diamino-6-((l- (((5-chloro-8-fluoro-4-
(5-chloro-3-(4,5- oxo-3-(pyridin-3-yl)- dimethylpyridin-3 -yl)- 3 ,4 -dihydroquinazolin-
78 4-oxo-3,4- 112
2- dihydroquinazolin-2- yl) (cyclopropyl)methyl) yl)ethyl)amino)pyrimi
amino)pyrimidine-5 - dine-5 -carbonitrile
carbonitrile
(S)-2,4-Diamino-6-
(R)-2,4-Diamino-6-((l- ((l-(3-(4- (5-chloro-8-fluoro-3-(5- methylpyridin-3-yl)-4- fluoropyridin-3 -yl)-4- oxo-5-
79 Η"γΝγ Η! 113 oxo-3,4- ( trifluoromethyl) - 3 ,4 - dihydroquinazolin-2- dihydroquinazolin-2- yl)ethyl)amino)pyrimid yl)ethyl)amino)pyrimi
ine-5 -carbonitrile dine-5 -carbonitrile
Figure imgf000052_0001
[0130] In addition, the present application provides the compounds according to any of the formulae described herein or pharmaceutically acceptable salts, tautomers, isomers, prodrugs, or solvates thereof, in which from 1 to n hydrogen atoms attached to a carbon atom may be replaced by a deuterium atom or D, in which n is the number of hydrogen atoms in the molecule. It is known that the deuterium atom is a non-radioactive isotope of the hydrogen atom. Such compounds may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds of any of the formulae described herein or pharmaceutically acceptable salts, isomers, prodrugs, or solvates thereof, when administered to a mammal. See, e.g. , Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci., 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.
[0131] The present application also provides pharmaceutically acceptable salts, hydrates, solvates, tautomeric forms, polymorphs, and prodrugs of the compounds of any of the formulae described herein.
[0132] "Pharmaceutically acceptable" or "physiologically acceptable" refer to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use. "Pharmaceutically acceptable salts" or "physiologically acceptable salts" refer to salts of pharmaceutical compounds that retain the biological effectiveness and properties of the underlying compound, and which are not biologically or otherwise undesirable. There are acid addition salts and base addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Acids and bases useful for reaction with an underlying compound to form pharmaceutically acceptable salts (acid addition or base addition salts respectively) are known to one of skill in the art. Similarly, methods of preparing pharmaceutically acceptable salts from an underlying compound (upon disclosure) are known to one of skill in the art and are disclosed in for example, Berge, at al. Journal of Pharmaceutical Science, Jan. 1977 vol. 66, No. l, and other sources.
[0133] "Pharmaceutically acceptable salts" include, for example, salts with inorganic acids and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Examples of pharmaceutically acceptable salts include, but are not limited to salts with inorganic acids, such as hydrochlorate, phosphate, diphosphate, hydrobromate, sulfate, sulfinate, nitrate; as well as salts with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, benzoate, salicylate, stearate, and alkanoate such as acetate, HOOC-(CH2)n-COOH where n is 0-4. Similarly, pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium, and ammonium. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts.
[0134] A "solvate" is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds of any of the formulae described herein are also provided. Hydrates of the compounds of any of the formulae are also provided.
[0135] A "prodrug" includes any compound that becomes a compound of the formulae described herein when administered to a subject, e.g. , upon metabolic processing of the prodrug. [0136] In certain embodiments, provided are optical isomers, racemates, or other mixtures thereof, of the compounds of any of the formulae described herein or
pharmaceutically acceptable salts, prodrugs, or solvates thereof. In those situations, the single enantiomer or diastereomer, i. e. , optically active form, can be obtained by asymmetric synthesis or by resolution of the racemate. Resolution of racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high pressure liquid chromatography (HPLC) column. In addition, provided are also Z- and E- forms (or cis- and trans- forms) of the compounds of the formulae described herein or pharmaceutically acceptable salts, prodrugs, or solvates thereof with carbon-carbon double bonds. Provided are also all tautomeric forms of the compounds of any of the formulae or pharmaceutically acceptable salts, isomers, prodrugs, or solvates thereof.
[0137] In some embodiments, provided herein are the free base forms of the compounds of the formulae described herein or pharmaceutically acceptable salts, isomers, or mixture of isomers, prodrugs or solvates thereof. In certain embodiments, provided herein are the (S)- enantiomers of the compounds of the formulae described herein or pharmaceutically acceptable salts, isomers, or mixture of isomers, prodrugs or solvates thereof. In some other embodiments, provided herein are the (R)-enantiomers of the compounds of the formulae described herein or pharmaceutically acceptable salts, isomers, or mixture of isomers, prodrugs or solvates thereof. In other embodiments, provided herein are the atropisomers of the compounds of the formulae described herein or pharmaceutically acceptable salts, isomers, or mixture of isomers, prodrugs or solvates thereof.
[0138] Compositions provided herein that include a compound of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, may include racemic mixtures, or mixtures containing an enantiomeric excess of one enantiomer or single diastereomers or diastereomeric mixtures. All such isomeric forms of these compounds are expressly included herein the same as if each and every isomeric form were specifically and individually listed.
[0139] In certain embodiments, provided herein are also crystalline and amorphous forms of the compounds of the formulae described herein or pharmaceutically acceptable salts, isomer, a mixture of isomers, prodrugs, or solvates thereof. [0140] In certain embodiments, provided are also chelates, non-covalent complexes, and mixtures thereof, of the compounds of the formula described herein or pharmaceutically acceptable salts, prodrugs, or solvates thereof. A "chelate" is formed by the coordination of a compound to a metal ion at two (or more) points. A "non-covalent complex" is formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule. For example, complexation can occur through van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding).
Therapeutic Uses of the Compounds
[00141] The compounds of the formulae described herein or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof may be used for the treatment of diseases and/or conditions mediated by PI3K isomers, such as PI3K5. Thus, provided herein are methods for inhibiting one or more PI3K isomers, such as PI3K α, β, δ, and γ. In one embodiment, provided are methods for inhibiting PI3K5 activity using a compound of the formulae described herein or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof. 'ITie PI3K isomers may be selectively or specifically inhibited. Additionally, the compounds may be used to inhibit PI3K activity therapeutically or prophylactically. Also, the compounds according to the present application may be used in combination with other therapeutic agents. The therapeutic agents may be in the forms of compounds, antibodies, polypeptides, or polynucleotides. As used herein, the terms "PI3 isomers" and 'TDK isofonns" are equivalent and used interchangeably. In one embodiment, the application provides a product comprising a compound described herein and an additional therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy, e.g. a method of treating a disease, disorder, or condition that is mediated by PI3K isoforms.
[00142] Also, the therapeutic agents may be those that inhibit or modulate the activities of Bruton's tyrosine kinase, spleen tyrosine kinase, apoptosis signal-regulating kinase, Janus kinase, lysyl oxidase, lysyl oxidase-like proteins, or matrix metallopeptidase. In further embodiments, the therapeutic agents may be those that inhibit or modulate the activites of bromodomain-containing protein, adenosine A2B receptor, isocitrate dehydrogenase, serine/threonine kinase TPL2, discoidin domain receptor, serine/threonine-protein kinase, IKK, MEK, EGFR, histone deacetylase, protein kinase C, or any combination thereof. [00143] In some embodiments, the methods include administering a compound of the formula described herein or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof, in a therapeutically effective amount to a human in need thereof. The method can be employed to treat a patient who has or is believed to have a disease or condition whose symptoms or pathology is mediated by PI3K5 expression or activity. Additionally, the method can be employed to treat a patient who has or is believed to have a disease or condition whose symptoms or pathology is mediated by ΡΙ3Κβ expression or activity. The patient may be a mammal or a human.
[00144] In addition to the therapeutic uses, certain compounds of any of the formulae described herein or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof, have one or more properties selected from: (i) selectivity to any PI3K isoforms, such as PI3K5; (ii) hepatocyte stability; and (iii) potency in a cellular assay. In one embodiment, certain compounds of the formulae or a pharmaceutically acceptable salt, prodrug, isomers, or solvate thereof, have selectivity to any PI3K isoforms, such as PI3K5. In other embodiments, certain compounds of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, have selectivity to at least PI3K5. In some other embodiments, certain compounds of the formulae or a pharmaceutically acceptable salt, prodrug, isomers, or solvate thereof, have selectivity to PI3K5 and/or ΡΙ3Κβ. In yet other embodiments, certain compounds of the formulae or a pharmaceutically acceptable salt, prodrug, or solvate thereof, have one of the properties selected from: (i) selectivity to PI3K5; (ii) hepatocyte stability; and (iii) potency in a cellular assay. In yet other embodiments, certain compounds of the formulas according to the present application or a pharmaceutically acceptable salt, prodrug, or solvate thereof, have: selectivity to PI3K5 and hepatocyte stability; or selectivity to PI3K5 and potency in a cellular assay; or hepatocyte stability and potency in a cellular assay. In some embodiments, certain compounds of the formulae or a pharmaceutically acceptable salt, prodrug, or solvate thereof, have selectivity to PI3K5, hepatocyte stability, and potency in a cellular assay.
[00145] In another embodiment, certain compounds of the formulae described herein or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof have hepatocyte stability. Hepatocyte stability of a compound can be determined using any methods currently known in the art, including the methods described in the Examples below. For example, hepatocyte stability may be characterized based on half-life. In some embodiments, the half- life is greater than or about 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 1 1 hours, 12 hours, or 15 hours when incubated in human hepatocytes.
[00146] In yet another embodiment, certain compounds of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof have potency in a cellular assay. Potency in a cellular assay can be determined using any methods currently known in the art, including the methods described in the Examples below. In some embodiments, the activity in the cellular assay is less than 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, InM, 0.1 nM, or 0.01 nM.
[00147] For example, certain compounds inhibit at least one PI3K isomer, including PI3K5. For example, the compounds have an EC 50 in the described cellular assay less than 10 nM, and have a half life in hepatocytes of greater than 3 hours.
[00148] "Treatment" or "treating" is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (e.g. , decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g. , stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and/or preventing or delaying the spread (e.g. , metastasis) of the disease or condition); and/or
c) relieving the disease, that is, causing the regression of clinical symptoms (e.g. , ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival.
[0149] "Prevention" or "preventing" means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop. Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.
[0150] The terms "Subject" or "patient" refer to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in human therapy and/or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human. "Human in need thereof refers to a human who may have or is suspect to have diseases or conditions that would benefit from certain treatment; for example, being treated with the PI3K inhibitor of the compounds according to the present application.
[0151] The term "therapeutically effective amount" of a compound of the present application or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof, means an amount sufficient to effect treatment when administered to a subject, to provide a therapeutic benefit such as amelioration of symptoms or slowing of disease progression. For example, a therapeutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition responsive to inhibition of PI3K5 activity. The therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one or ordinary skill in the art.
[0152] The term "inhibition" indicates a decrease in the baseline activity of a biological activity or process. The term "inhibition of activity of PI3K isomers" or variants thereof refer to a decrease in activity in any PI3K isomer (e.g. , alpha, beta, gamma, or delta) as a direct or indirect response to the presence of a compound of any of the formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (II) or a pharmaceutically acceptable salt, isomer, a mixture of isomers, prodrug, or solvent thereof, relative to the activity of PI3K isomer in the absence of such compound or a pharmaceutically acceptable salt, isomer, a mixture of isomers, prodrug, or solvent thereof. "Inhibition of PI3K5 activity" or variants thereof refer to a decrease in PI3K5 activity as a direct or indirect response to the presence of a compound of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (II) or a pharmaceutically acceptable salt, isomer, a mixture of isomers, prodrug, or solvate thereof, relative to the activity of PI3K5 in the absence of such compound. In some embodiments, the inhibition of PI3K5 activity may be compared in the same subject prior to treatment, or other subjects not receiving the treatment. In some other embodiments, the compounds inhibit PI3K5 activity also inhibit PI3K β activity.
[0153] Without wishing to be bound to any theory, the decrease in PI3K5 activity may be due to the direct interaction of the compound with PI3K5, or due to the interaction of the compounds described herein with one or more other factors that in turn affect PI3K5 activity. For example, the presence of the compounds of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, may decrease PI3K5 activity by directly binding to the PI3K5, by causing (directly or indirectly) another factor to decrease PI3K5 activity, or by (directly or indirectly) decreasing the amount of PI3K5 present in the cell or organism.
[0154] The terms "a compound of the present application," "a compound of any of the formulae described herein," or variant thereof refers to a compound having the structure of any of the formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (II). In some embodiment, the PI3K inhibitors are the compounds having the structure of the formula (I). In one embodiment, the PI3K inhibitors are the compounds having the structure of the formula (IA). In some embodiment, the PI3K inhibitors are the compounds having the structure of the formula (IB). In certain embodiment, the PI3K inhibitors are the compounds having the structure of the formula (IC). In another embodiment, the PI3K inhibitors are the compound having the structure of formula (ID). In yet another embodiment, the PI3K inhibitors are the compounds having the structure of formula (IE). In other embodiment, the PI3K inhibitors are the compound having the structure of formula (IF).
[0155] The term "PI3K inhibitor" or variant thereof refers to a compound that inhibits the activity of PI3K. The term "PI3K isoform selective inhibitor" or variant thereof refers to a compound that inhibits the activity of one or more PI3K isoforms more effectively than the other remaining PI3K isoforms. By way of example, the term "PI3K5 selective inhibitor" generally refers to a compound that inhibits the activity of the PI3K5 isoform more effectively than other isoforms of the PI3K family (e.g. , PI3K α, β, or γ). The term "PI3Ka selective inhibitor" generally refers to a compound that inhibits the activity of the PI3Ka isoform more effectively than other isoforms of the PI3K family (e.g. , PI3K β, δ, or γ). The term "ΡΙ3Κβ selective inhibitor" generally refers to a compound that inhibits the activity of the ΡΙ3Κβ isoform more effectively than other isoforms of the PI3K family (e.g. , PI3K α, δ, or γ). The term "dual ΡΙ3Κα/β selective inhibitor generally refers to a compound that inhibits the activity of the PI3Ka and ΡΙ3Κβ isoforms more effectively than other isoforms of the PI3K family (e.g. , PI3K δ or γ).
[0156] The relative efficacies of compounds as inhibitors of an enzyme activity (or other biological activity) can be established by determining the concentrations at which each compound inhibits the activity to a predefined extent and then comparing the results. In one embodiment, the efficacy of a compound as an inhibitor of one or more PI3K isoforms can be measured by the concentration that inhibits 50% of the activity in a biochemical assay, i.e. , the 50% inhibitory concentration or "IC50". IC50 determinations can be accomplished using conventional techniques known in the art, including the techniques describes in the Examples below. In general, an IC50 can be determined by measuring the activity of a given enzyme in the presence of a range of concentrations of the compound under study. The experimentally obtained values of enzyme activity may then be plotted against the compound concentrations used. The concentration of the inhibitor that shows 50% enzyme activity (as compared to the activity in the absence of any inhibitor) is taken as the IC50 value. Analogously, other inhibitory concentrations can be defined through appropriate determinations of activity. For example, in some settings it may be desirable to establish a 90% inhibitory concentration, i.e. ,
[0157] In one embodiment, a PI3K5 selective inhibitor is a compound that exhibits a 50% inhibitory concentration (IC50) with respect to PI3K5 that is at least 10-fold, in another aspect at least 20-fold, and in another aspect at least 30-fold, lower than the IC50 value with respect to any or all of the other Class I PI3K family members. In another embodiment, a PI3K5 selective inhibitor is a compound that exhibits an IC50 with respect to PI3K5 that is at least 50-fold, in another aspect at least 100-fold, in an additional aspect at least 200-fold, and in yet another aspect at least 500-fold, lower than the IC50 with respect to any or all of the other PI3K Class I family members. A PI3K5 selective inhibitor is typically administered in an amount such that it selectively inhibits PI3K5 activity, as described above.
[0158] In one embodiment, a PI3Ka selective inhibitor is a compound that exhibits a 50% inhibitory concentration (IC50) with respect to PI3Kot that is at least 10-fold, in another aspect at least 20-fold, and in another aspect at least 30-fold, lower than the IC50 value with respect to any or all of the other Class I PI3K family members. In another embodiment, a PI3Ka selective inhibitor is a compound that exhibits an IC50 with respect to PI3Ka that is at least 50-fold, in another aspect at least 100-fold, in an additional aspect at least 200-fold, and in yet another aspect at least 500-fold, lower than the IC50 with respect to any or all of the other PI3K Class I family members. A PI3Ka selective inhibitor is typically administered in an amount such that it selectively inhibits PI3Ka activity, as described above [0159] In one embodiment, a ΡΙ3Κβ selective inhibitor is a compound that exhibits a 50% inhibitory concentration (IC50) with respect to ΡΙ3Κβ that is at least 10-fold, in another aspect at least 20-fold, and in another aspect at least 30-fold, lower than the IC50 value with respect to any or all of the other Class I PI3K family members. In another embodiment, a ΡΙ3Κβ selective inhibitor is a compound that exhibits an IC50 with respect to ΡΙ3Κβ that is at least 50-fold, in another aspect at least 100-fold, in an additional aspect at least 200-fold, and in yet another aspect at least 500-fold, lower than the IC50 with respect to any or all of the other PI3K Class I family members. A ΡΙ3Κβ selective inhibitor is typically administered in an amount such that it selectively inhibits ΡΙ3Κβ activity, as described above.
[0160] In one embodiment, a dual ΡΙ3Κα/β selective inhibitor is a compound that exhibits a 50% inhibitory concentration (IC50) with respect to PI3Ka and ΡΙ3Κβ that is at least 10- fold, in another aspect at least 20-fold, and in another aspect at least 30-fold, lower than the IC50 value with respect to any or all of the other Class I PI3K family members. In another embodiment, a dual ΡΙ3Κα/β selective inhibitor is a compound that exhibits an IC50 with respect to PI3Ka and ΡΙ3Κβ that is at least 50-fold, in another aspect at least 100-fold, in an additional aspect at least 200-fold, and in yet another aspect at least 500-fold, lower than the IC50 with respect to any or all of the other PI3K Class I family members. In another embodiment, a ΡΙ3Κβ/δ selective inhibitor is a compound that exhibits an IC50 with respect to ΡΙ3Κβ and PI3K5 that is at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 200-fold, at least 300-fold, at least 400-fold, and at least 500-fold, lower than the IC50 with respect to either PI3Ka or ΡΙ3Κγ or to both PI3Ka and ΡΙ3Κγ. A dual ΡΙ3Κα/β selective inhibitor is typically administered in an amount such that it selectively inhibits PI3Ka and ΡΙ3Κβ activity, as described above.
[0161] The methods described herein may be applied to cell populations in vivo or ex vivo. "In vivo" means within a living individual, as within an animal or human. In this context, the methods described herein may be used therapeutically in an individual. "Ex vivo" means outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. Such samples may be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and biopsies thereof. In this context, the invention may be used for a variety of purposes, including therapeutic and experimental purposes. For example, the invention may be used ex vivo to determine the optimal schedule and/or dosing of administration of a PI3K5 selective inhibitor for a given indication, cell type, individual, and other parameters. Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for in vivo treatment. Other ex vivo uses for which the invention may be suited are described below or will become apparent to those skilled in the art. The selected compounds of the formula described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, may be further characterized to examine the safety or tolerance dosage in human or non-human subjects. Such properties may be examined using commonly known methods to those skilled in the art.
[0162] Compared to other PI3K isoforms, PI3K5 is generally expressed in hematopoietic cells. Consequently, the direct effects of selective inhibitors of PI3K5 can be observed in hematopoietic cells. Hematopoietic cells typically differentiate into either lymphoid progenitor cells or myeloid progenitor cells, both of which ultimately differentiate into various mature cell types including leukocytes. Aberrant proliferation of hematopoietic cells of one type often interferes with the production or survival of other hematopoietic cell types, which can result in compromised immunity, anemia, and/or thrombocytopenia. The methods described herein may treat aberrant proliferation of hematopoietic cells by inhibiting aberrant proliferation of hematopoietic cells. As a result, these methods may also ameliorate the symptoms and secondary conditions that result from a primary effect such as excessive system or localized levels of leukocytes or lymphocytes.
[0163] In some embodiments, the compounds described herein may be used to treat subjects having various disease states, disorders, and conditions (also collectively referred to as "indications") involving aberrant proliferation of hematopoietic cells (including excessive production of lymphoid progenitor cell-derived cells and/or myeloid progenitor cell-derived cells). Such indications may include, for example, leukemias, lymphomas,
myeloproliferative disorders, myelodysplastic syndromes, and plasma cell neoplasms. In certain embodiments, the compounds described herein may be used to treat hematologic malignancies, inflammation, autoimmune disorders, allergic conditions, cardiovascular disease, and autoimmune diseases. In certain embodiments, allergic conditions may include all forms of hypersensitivity.
[0164] In other embodiments, the compounds described herein may be used to treat cancers that are mediated by, dependent on or associated with PI3K activity, such as PI3K5 activity. In certain embodiments, the disease is a hematologic malignancy. In particular embodiments, the hematologic malignancy is leukemia or lymphoma. In specific
embodiments, the disease is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), indolent non-Hodgkin' s lymphoma (iNHL), refractory iNHL, non-Hodgkin' s lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldestrom' s macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma, and diffuse large B-cell lymphoma (DLBCL). In one embodiment, the disease is T-cell acute lymphoblastic leukemia (T-ALL), or B-cell acute lymphoblastic leukemia (B-ALL). The non- Hodgkin lymphoma encompasses the indolent B-cell diseases that include, for example, follicular lymphoma, lymphoplasmacytic lymphoma, Waldenstrom macroglobulinemia, and marginal zone lymphoma, as well as the aggressive lymphomas that include, for example, Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
[0165] In other embodiments, the disease is a solid tumor. In particular embodiments, the solid tumor is from pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors (e.g. , glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, or soft tissue sarcoma. In some embodiments, the solid tumor is from non-small cell lung cancer, small- cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, or breast cancer.
[0166] In some embodiments, the disease is an autoimmune disease. In particular embodiments, the autoimmune disease is systemic lupus erythematosus (SLE), myestenia gravis, rheumatoid arthritis (RA), acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis (MS), Sjoegren' s syndrome, or autoimmune hemolytic anemia. In other embodiments, the disease is inflammation. In yet other embodiments, the disease is excessive or destructive immune reactions, such as asthma, rheumatoid arthritis, multiple sclerosis, and lupus. In yet other embodiments, the disease is excessive or destructive immune reactions, such as psoriasis or chronic obstructive pulmonary disease (COPD).
[0167] The present application also provides a method for treating a subject, who has or is suspected of having a disease or condition responsive or believed to be responsive to the inhibition of PI3K5 activity by administering to the subject a compound of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
[0168] Additionally, the application provides a method of inhibiting kinase activity of a phosphatidylinositol 3-kinase delta polypeptide by contacting the polypeptide with a compound of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
[0169] Provided is also a method of disrupting leukocyte function comprising contacting the leukocytes with an effective amount of a compound of any of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, in a subject in need thereof (e.g. , a human).
[0170] Provided is also a method of inhibiting a growth or a proliferation of cancer cells of hematopoietic origin comprising contacting the cancer cells with an effective amount of a compound of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
Kits
[0171] Provided herein are also kits that include a compound of the formulae of the present application or a pharmaceutically acceptable salt, prodrug, or solvate thereof, and suitable packaging. In one embodiment, a kit further includes instructions for use. In one aspect, a kit includes a compound of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, and a label and/or instructions for use of the compounds in the treatment of the indications, including the diseases or conditions, described herein.
[0172] Provided herein are also articles of manufacture that include a compound of any of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, in a suitable container. The container may be a vial, jar, ampoule, preloaded syringe, and intravenous bag.
Pharmaceutical Compositions and Modes of Administration
[0173] Compounds provided herein are usually administered in the form of
pharmaceutical compositions. Thus, provides herein are also pharmaceutical compositions that contain one or more of the compounds of any of the formulae, including (I), (IA), (IB), (IC), (ID), (IE), (IF), or (II), or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof, and one or more pharmaceutically acceptable vehicles selected from carriers, adjuvants and excipients. Suitable pharmaceutically acceptable vehicles may include, for example, inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants. Such
compositions are prepared in a manner well known in the pharmaceutical art. See, e.g. , Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T.
Rhodes, Eds.).
[0174] The pharmaceutical compositions may be administered in either single or multiple doses. The pharmaceutical composition may be administered by various methods including, for example, rectal, buccal, intranasal and transdermal routes. In certain embodiments, the pharmaceutical composition may be administered by intra- arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.
[0175] One mode for administration is parenteral, for example, by injection. The forms in which the pharmaceutical compositions described herein may be incorporated for administration by injection include, for example, aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.
[0176] Oral administration may be another route for administration of the compounds described herein. Administration may be via, for example, capsule or enteric coated tablets. In making the pharmaceutical compositions that include at least one compound of any of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, the active ingredient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
[0177] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose. The formulations can additionally include lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
[0178] The compositions that include at least one compound of any of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the subject by employing procedures known in the art. Controlled release drug delivery systems for oral administration include osmotic pump systems and
dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Patent Nos.
3,845,770; 4,326,525; 4,902,514; and 5,616,345. Another formulation for use in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds described herein in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
[0179] For preparing solid compositions such as tablets, the principal active ingredient may be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of any of the above formulae or a pharmaceutically acceptable salt, prodrug, or solvate thereof. When referring to these preformulation compositions as homogeneous, the active ingredient may be dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
[0180] The tablets or pills of the compounds described herein may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach. For example, the tablet or pill can include an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
[0181] Compositions for inhalation or insufflation may include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. In other embodiments, compositions in pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
Dosing
[0182] The specific dose level of a compound of the formulae described herein for any particular subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease in the subject undergoing therapy. For example, a dosage may be expressed as a number of milligrams of a compound of the formula per kilogram of the subject's body weight (mg/kg). Dosages of between about 0.01 and 150 mg/kg may be appropriate. Dosages of between about 0.001 and 10 mg/kg, between about 0.005 and 5mg/kg, and between about 0.01 and 50 mg/kg may be appropriate. In some embodiments, about 0.01 and 100 mg/kg may be appropriate. In other embodiments a dosage of between 0.05 and 60 mg/kg may be appropriate. Normalizing according to the subject's body weight is particularly useful when adjusting dosages between subjects of widely disparate size, such as occurs when using the drug in both children and adult humans or when converting an effective dosage in a non-human subject such as dog to a dosage suitable for a human subject.
[0183] The daily dosage may also be described as a total amount of a compound of the formulae administered per dose or per day. Daily dosage of a compound may be between about 1 mg and 2,000 mg, between about 1,000 to 2,000 mg/day, between about 1 to 1,000 mg/day, between about 1 to 500 mg/day, between about 5 to 400 mg/day, between about 10 to 300 mg/day, between about 25 to 250 mg/day, between about 50 to 225 mg/day, between about 75 to 200 mg/day, between about 100 to 150 mg/day, between about 1 to 100 mg/day between about between about 1 to 75 mg/day, between about 1 to 50 mg/day, between about 1 to 25 mg/day, between about 1 to 20 mg/day, between about 1 to 15 mg/day, between about 1 to 10 mg/day, between about 1 to 5 mg/day, between about 5 to 100 mg/day, between about between about 5 to 75 mg/day, between about 5 to 50 mg/day, between about 5 to 25 mg/day, between about 5 to 15 mg/day, between about 5 to 10 mg/day, between about 25 to 400 mg/day between about between about 25 to 300 mg/day, between about 25 to 200 mg/day, between about 25 to 150 mg/day, between about 25 to 125 mg/day, between about 25 to 100 mg/day, between about 25 to 75 mg/day, between about 25 to 50 mg/day, between about 25 to 40 mg/day, between about 50 to 500 mg/day, between about 50 to 400 mg/day, between about 50 to 300 mg/day, between about 50 to 250 mg/day, between 50 to 225 mg/day, between about 50 to 200 mg/day, between about 50 to 175 mg/day, between about 50 to 150 mg/day, between about 50 to 125 mg/day, between about 50 to 100 mg/day, between about 75 to 200 mg/day, between 75 to 150 mg/day, between 75 to 125 mg/day, between about 75 to 100 mg/day, between about 100 to 125 mg/day, between about 100 to 150 mg/day, between about 100 to 175 mg/day, between about 10 to 150 mg/day, between about 10 to 125 mg/day, between aboutlO to 100 mg/day, or between about 10 to 50 mg/day. In other embodiments, daily dosage of a compound may be between about 0.01 mg and 1,000 mg, between about 0.05 mg and 500 mg, between about 0.075 mg and 250 mg, between about 0.1 mg and 100 mg, between about 0.5 mg and 50 mg, between about 0.75 mg and 25mg, between about 1 mg and 10 mg, [0184] When administered orally, the total daily dosage for a human subject may be between 1 mg and 1,000 mg, between about 1 to 100 mg/day, between about 1 to 50 mg/day, between about 5 to 50 mg/day, between 5 to 25 mg/day, between about 5 to 75 mg/day, between about 10-500 mg/day, between about 10 to 150 mg/day, between about 10 to 200 mg/day, between about 50-300 mg/day, between about 75-200 mg/day, between about 75 to 150 mg/day, or between about 100-150 mg/day. In additional embodiments, daily dosage for a human may be administered between about 0.01 mg and 1,000 mg, between about 0.05 mg and 500 mg, between about 0.075 mg and 250 mg, between about 0.1 mg and 100 mg, between about 0.5 mg and 50 mg, between about 0.75 mg and 25mg, between about 1 mg and 10 mg,
[0185] The compounds of the present application or the compositions thereof may be administered once, twice, three, or four times daily, using any suitable mode described above. Also, administration or treatment with the compounds according to any of the formulae described herein may be continued for a number of days; for example, commonly treatment would continue for at least 7 days, 14 days, or 28 days, for one cycle of treatment. In some embodiments, the compounds or the composition thereof may be administered continuously, i.e. every day. Treatment cycles are well known in cancer chemotherapy, and are frequently alternated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in other embodiments, may also be continuous.
[0186] In a particular embodiment, the method comprises administering to the subject an initial daily dose of about 1 to 500 mg of a compound of the above formula and increasing the dose by increments until clinical efficacy is achieved. Increments of about 5, 10, 25, 50, or 100 mg can be used to increase the dose. In other embodiments, the methods comprising administering to the subject an initial daily dose of about 0.01 to 100 mg of the compound described herein and increasing the dose by increments of about 0.01, 0.05, 0.1, 0.5, 1, 2, 2.5, 5, 10, 25, 50, or 100 mg. The dosage can be increased daily, every other day, twice per week, or once per week.
Synthesis of the Compounds of Formula (I)
[0187] The compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (II) may be prepared using the methods disclosed herein and routine modifications thereof, which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein. The synthesis of typical compounds described herein may be accomplished as described in the following examples. If available, reagents may be purchased commercially, e.g. , from Sigma Aldrich or other chemical suppliers.
General Synthesis
[0188] Typical embodiments of compounds described herein may be synthesized using the general reaction schemes described below. It will be apparent given the description herein that the general schemes may be altered by substitution of the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Given a desired product for which the substituent groups are defined, the necessary starting materials generally may be determined by inspection. Starting materials are typically obtained from commercial sources or synthesized using published methods. For synthesizing compounds which are embodiments described in the present disclosure, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group. The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein. In general, compounds described herein are typically stable and isolatable at room temperature and pressure.
Synthetic Reaction Parameters
[0189] The terms "solvent", "inert organic solvent", or "inert solvent" refer to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like). Unless specified to the contrary, the solvents used in the reactions of the present invention are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen.
[0190] The term "q.s." means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e. , 100%). Compounds of Formula I
[0191] The compounds of formula (I) may be prepared using the method shown in Reaction Scheme I.
Figure imgf000071_0001
I
Step 1— Preparation of a compound of formula (1)
[0192] The compound of formula (1) can be made by combining compounds (A), (B) and (C) in the presence of a dehydrating agent. Compounds (A), (B) and (C) are commercially available or can be made by the methods that are commonly known or used by one skilled in the art. R1, R2, and R3 are defined as in the formula (I). Compound (A) is mixed with Compound (B) in the presence of a coupling agent such as diphenyl phosphite in a solvent such as pyridine. After stirring at a temperature between ambient and 100°C for 1 to 5 hours, compound (C) is added. The mixture is further stirred at a temperature between ambient and 100°C for 5 to 24 hours and cooled to room temperature. To extract the compound of formula (1), an organic solvent such as ethyl acetate (EtOAc) is added. Then the reaction is washed with mild acid, water, and brine. The organic phase is concentrated to obtain the compound of formula (1). The compound of formula (1) is purified by any suitable methods known in the art, such as chromatography on silica gel. Alternatively, the compound of formula (1) is used in the next step without purification. In some instance, the compound of formula (1) is purified directly without an aqueous work-up. In cases where an R1 is a cyano, the corresponding bromide can be converted to a nitrile by methods known in the art. For example, treatment of a bromide with zinc cyanide in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine)palladium, at a temperature between ambient and 100°C for 5 to 24 hours can give the compound of formula (1).
Step 2— Preparation of a compound of formula (2)
[0193] The compound of formula (2) can be made by removing the protecting group(s) from the compound of formula (1). The compound of formula (1) is dissolved in a suitable solvent and treated with a suitable acid. By way of example, suitable solvents include dichloromethane or dioxane, and suitable acids include trifluoroacetic acid, hydrochloric acid, or boron tribromide (BBr3). The reaction is carried out at temperatures between -78°C to ambient temperature. After the reaction is complete, solvent is removed to obtain the compound of formula (2).
Step 3— Preparation of a compound of formula (3)
[0194] The compound of formula (3) can be made by treating 5-substituted-2,4,6- trihalopyrimidine with ammonium hydroxide in a suitable solvent such as dioxane, where the halo is either chloro or fluoro. The reaction is carried out at an elevated temperature between 30 and 80°C between 2 and 8 hours or when the reaction was complete. Then, water is added to the cooled solution, and the precipitate is collected by filtration. If necessary, separation of regiosiomers is accomplished by standard methods, such as chromatography. The nitrile can be converted to the carboxamide under standard conditions. Step 4— Preparation of a compound of formula (I)
[0195] The compound of formula (I) can generally be prepared by coupling compound of formula (2) and compound of formula (3) in the presence of a suitable base in a suitable solvent. An example of a suitable base is diisopropylethylamine. An example of a suitable solvent is N-methylpyrrolidone (NMP), DMF, DMSO, or isopropanol. Also, an additive such as potassium fluoride may be used. The reaction is typically performed at a temperature between 50°C to 150°C for about 30 minutes to 24 hours. Alternatively the reaction can be performed in a microwave at a temperature between 100°C to 150°C for about 30 minutes to 24 hours. Water can be added to quench the reaction upon completion, and the precipitate may be filtered then dissolved in an organic solvent such as dichloromethane (DCM). The product can be isolated by methods known in the art, for example by removal of solvent under reduced pressure. The product can be purified using any suitable methods known in the art, for example, chromatography of the residue on a silica column. In certain instance, the product can be purified using recrystallization or precipitation.
[0196] It should be understood that the compounds of formula (I) can be prepared according to the methods provided in Reaction Scheme 1 , starting from materials known to one of skill in the art.
Example 1
Preparation of a Compound of Formula (1)
A. Preparation of a Compound of Formula (1) wherein n is 1, R1 is chloro, m is 0, and R3 is methyl
Figure imgf000073_0001
[0197] Diphenyl phosphite (1.9 mL, 10 mmol) was added to a solution of 2-amino-6- chlorobenzoic acid (495 mg, 2.9 mmol) and (S)-2-(tert-butoxycarbonylamino)propanoic acid (710 mg, 3.77 mmol) in pyridine (3 mL). The reaction mixture was stirred at 40°C for 2 hours. 3-Aminopyridine (274 mg, 3.48 mmol) was then added to the reaction mixture, which was then stirred at 55°C for 12 hours. The reaction mixture was cooled to room temperature and loaded onto a hexane primed Si02 column. The title compound was then purified by eluting with EtOAc in hexanes (0-50%) to afford (S)-tert-butyl l -(5-chloro-4-oxo-3-(pyridin- 3-yl)-3,4-dihydroquinazolin-2-yl)ethylcarbamate as a solid. ES/MS m/z = 401.1 (M+H+).
1 2 3
B. Preparation of a Compound of Formula (1), varying R , R , and R
[0198] Following the procedure described in Example 1 A and Reaction Scheme I with varying R1, R2 and R3 substituents, other compounds of formula ( 1) were prepared including:
[0199] (S)-tert-butyl 1 -(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)propylcarbamate,
[0200] (S)-tert-butyl (5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)(cyclopropyl)methylcarbamate,
[0201] (S)-tert-butyl l-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)-2- cyclopropylethylcarbamate,
[0202] (S)-tert-butyl 1 -(6-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylcarbamate,
[0203] (S)-tert-butyl 1 -(5-methyl-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylcarbamate,
[0204] (S)-tert-butyl l-(5-(methylsulfonyl)-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0205] (S)-tert-butyl l-(4-oxo-3-(pyridin-3-yl)-5-(trifluoromethyl)-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0206] (S)-tert-butyl l-(5-bromo-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylcarbamate;
[0207] (S)-tert-butyl l-(3-(5-fluoropyridin-3-yl)-5-methyl-4-oxo-3,4-dihydroquinazolin- 2-yl)ethylcarbamate;
(S)-tert-butyl l-(5-chloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4-dihydroquinazolin- [0209] (S)-tert-butyl 1 -(5-chloro-3-(5-chloropyridin-3-yl)-4-oxo-3,4-dihydroquinazolin- 2-yl)ethylcarbamate ;
[0210] (S)-tert-butyl l-(5-cWoro-3-(5-methoxypyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0211] (S)-tert-butyl 1 -(5-chloro-3-(5-(difluoromethyl)pyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0212] (S)-tert-butyl l-(5-chloro-3-(5-methylpyridin-3-yl)-4-oxo-3,4-dihydroquinazolin- 2-yl)ethylcarbamate ;
[0213] (S)-tert-butyl (5-chloro-3-(5-methylpyridin-3-yl)-4-oxo-3,4-dihydroquinazolin-2- yl)(cyclopropyl)methylcarbamate;
[0214] (S)-tert-butyl l-(5-chloro-4-oxo-3-(5-(trifluoromethyl)pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0215] (S)-tert-butyl l-(5-chloro-3-(5-cyclopropylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0216] (S)-tert-butyl l-(5-chloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4-dihydroquinazolin-2- yl)propylcarbamate;
[0217] (S)-tert-butyl (5-chloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4-dihydroquinazolin-2- yl)(cyclopropyl)methylcarbamate;
[0218] (S)-tert-butyl 1 -(8-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylcarbamate;
[0219] (S)-tert-butyl l-(5,8-dichloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylcarbamate;
[0220] (S)-tert-butyl 1 -(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)ethylcarbamate ;
[0221] (S)-tert-butyl l-(5,8-difluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylcarbamate; [0222] (S)-tert-butyl 1 -(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)propylcarbamate;
[0223] (S)-tert-butyl (5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)(cyclopropyl)methylcarbamate;
[0224] (S)-tert-butyl cyclopropyl(5,8-dichloro-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)methylcarbamate;
[0225] (S)-tert-butyl l-(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)-2-cyclopropylethylcarbamate;
[0226] (S)-tert-butyl l-(5,8-dichloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0227] (S)-tert-butyl l-(5-chloro-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0228] (S)-tert-butyl l-(5-chloro-8-fluoro-3-(5-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0229] (S)-tert-butyl (5-cMoro-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methylcarbamate;
[0230] (S)-tert-butyl l-(5-bromo-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)ethylcarbamate ;
[0231] (S)-tert-butyl l-(5-bromo-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)propylcarbamate;
[0232] (S)-tert-butyl l-(5-chloro-6-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)ethylcarbamate ;
[0233] (S)-tert-butyl (5-chloro-6-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)(cyclopropyl)methylcarbamate;
[0234] (S)-tert-butyl l-(5-chloro-3-(2-methylpyridin-3-yl)-4-oxo-3,4-dihydroquinazolin- 2-yl)ethylcarbamate ; [0235] (S)-tert-butyl l-(5-chloro-3-(2-methylpyridin-3-yl)-4-oxo-3,4-dihydroquinazolin- 2-yl)ethylcarbamate ;
[0236] (S)-tert-butyl l-(5-chloro-3-(4-methylpyridin-3-yl)-4-oxo-3,4-dihydroquinazolin- 2-yl)ethylcarbamate;
[0237] (S)-tert-butyl l-(5-chloro-3-(4-methylpyridin-3-yl)-4-oxo-3,4-dihydroquinazolin- 2-yl)ethylcarbamate ;
[0238] (S)-tert-butyl l-(5-chloro-6-fluoro-3-(4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0239] (S)-tert-butyl 1 -(5-chloro-6-fluoro-3-(4-me lpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0240] (S)-tert-butyl l-(5-chloro-3-(5-fluoro-2-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0241] (S)-tert-butyl l-(5-chloro-3-(5-fluoro-2-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0242] (S)-tert-butyl l-(5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0243] (S)-tert-butyl l-(5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylcarbamate;
[0244] (S)-tert-butyl (l-(5-chloro-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)carbamate;
[0245] (S)-tert-butyl (l-(3-(4-methylpyridin-3-yl)-4-oxo-5-(trifluoromethyl)-3,4- dihydroquinazolin- 2- yl)ethyl)c arbamate ;
[0246] (S)-tert-butyl ( l-(8-cyano-6-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)ethyl)carbamate;
[0247] (S)-tert-butyl (l-(8-cyano-6-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)carbamate; [0248] (S)-tert-butyl ((8-cyano-6-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)carbamate;
[0249] (S)-tert-butyl ( l-(5-chloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4-dihydroquinazolin- 2-yl)-3-methylbutyl)carbamate;
[0250] (R)-tert-butyl (l-(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)ethyl)carbamate;
[0251] (S)-tert-butyl (l-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)-3- methylbutyl)carbamate ;
[0252] (R)-tert-butyl (l-(5-chloro-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)carbamate;
[0253] (R)-tert-butyl (l-(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)propyl)carbamate;
[0254] (R)-tert-butyl ((5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- y l)(cyclopropy l)methy l)c arbamate ;
[0255] (S)-tert-butyl (l-(5-bromo-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)carbamate;
[0256] (S)-tert-butyl (l-(5-bromo-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)propyl)carbamate;
[0257] (S)-tert-butyl ( l-(5-bromo-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)ethyl)carbamate;
[0258] (S)-tert-butyl ((5-chloro-8-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)carbamate;
[0259] (S)-tert-butyl (l-(5-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)carbamate;
[0260] (S)-tert-butyl ((5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)carbamate; [0261] (S)-tert-butyl (l-(5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)carbamate;
[0262] (S)-tert-butyl (l-(5-chloro-8-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)carbamate;
[0263] (S)-tert-butyl (l-(6-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)carbamate;
[0264] (S)-tert-butyl (l-(5-chloro-3-(4,5-dimethylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)carbamate;
[0265] (S)-tert-butyl (l-(3-(6-aminopyridin-3-yl)-8-chloro-6-fluoro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)carbamate;
[0266] (S)-tert-butyl (l-(3-(6-aminopyridin-3-yl)-5,8-dichloro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)carbamate;
[0267] (S)-tert-butyl (l-(3-(6-aminopyridin-3-yl)-5-chloro-4-oxo-3,4-dihydroquinazolin- 2-yl)ethyl)carbamate;
[0268] (S)-tert-butyl (l-(3-(6-aminopyridin-3-yl)-5-chloro-4-oxo-3,4-dihydroquinazolin- 2-yl)propyl)carbamate;
[0269] (S)-tert-butyl (l-(3-(6-aminopyridin-3-yl)-5-chloro-8-fluoro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)carbamate;
[0270] (S)-tert-butyl ((3-(6-aminopyridin-3-yl)-5-chloro-4-oxo-3,4-dihydroquinazolin-2- yl) (cyclopropyl)methyl)c arbamate ;
[0271] (S)-tert-butyl (l-(3-(6-amino-4-methylpyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)carbamate;
[0272] (S)-tert-butyl (l-(3-(6-amino-4-methylpyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)carbamate;
[0273] (S)-tert-butyl (l-(3-(6-amino-4-methylpyridin-3-yl)-5,8-dichloro-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)carbamate; [0274] (S)-tert-butyl ((3-(6-amino-4-methylpyridin-3-yl)-5,8-dichloro-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)carbamate;
[0275] (S)-tert-butyl (l-(3-(6-aminopyridin-3-yl)-5-chloro-6-fluoro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)carbamate;
[0276] (S)-tert-butyl (l-(3-(6-aminopyridin-3-yl)-5-chloro-4-oxo-3,4-dihydroquinazolin- 2-yl)butyl)carbamate;
[0277] (S)-tert-butyl (l-(3-(6-aminopyridin-3-yl)-5-chloro-6-fluoro-4-oxo-3,4- dihydroquinazolin-2-yl)butyl)carbamate;
[0278] (S)-tert-butyl ((3-(6-aminopyridin-3-yl)-5-chloro-8-fluoro-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)carbamate; and
[0279] (S)-tert-butyl (l-(3-(5-aminopyridin-3-yl)-5-chloro-4-oxo-3,4-dihydroquinazolin- 2-yl)ethyl)carbamate.
C. Preparation of a Compound of Formula (1) wherein n is 1, R1 is cyano, m is 0, and R3 is methyl
Figure imgf000080_0001
[0280] To a solution of (S)-tert-butyl l-(5-bromo-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)ethylcarbamate (255 mg, 0.58 mmol) in NMP (2 mL) was added zinc cyanide (74 mg, 0.63 mmol) and (PPh3)4Pd (66 mg, 0.06 mmol). The resulting suspension was degassed under Argon and heated to 80°C for 5 hours. The reaction was poured into EtOAc, washed twice with aq. NaHCC>3 and once with brine. Purification by flash chromatography (0-75% EtOAc/hexanes) provided (S)-tert-butyl l-(5-cyano-4-oxo-3- (pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethylcarbamate 196 mg (87%). ES/MS 392.1 (M+H+). D. Preparation of a Compound of Formula (1) where one R^cyano and varying other R1, R2, and R3
[0281] (S)-tert-butyl l-(5-cyano-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)ethylcarbamate ;
[0282] (S)-tert-butyl l-(5-cyano-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)propylcarbamate;
Example 2
Preparation of a Compound of Formula (2)
A. Preparation of a Compound of Formula (2) wherein n is 1, R1 is chloro, m is 0, and R3 is methyl
Figure imgf000081_0001
[0283] Trifluoroacetic acid (3 mL) was added to a solution of (S)-tert-butyl l-(5-chloro-4- oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarbamate (1 g, 2.5 mmol) in dichloromethane (3 mL). The mixture was stirred at room temperature for 3 hours. The solvents was removed in vacuuo to obtain the title compound (S)-2-(l-aminoethyl)-5-chloro-3-(pyridin-3- yl)quinazolin-4(3H)-one. ES/MS m/z = 301.7 (M+H+).
B. Preparation of a Compound of Formula (2), varying R1, R2, and R3
[0284] Following the procedure described in Example 2A and Reaction Scheme I with varying R1, R2, and R3 substituents, other compounds of formula (2) were prepared including:
[0285] (S)-2-(l-aminopropyl)-5-chloro-3-(pyridin-3-yl)quinazolin-4(3H)-one;
[0286] (S)-2-(amino(cyclopropyl)methyl)-5-chloro-3-(pyridin-3-yl)quinazolin-4(3H)- one;
[0287] (S)-2-(l-amino-2-cyclopropylethyl)-5-chloro-3-(pyridin-3-yl)quinazolin-4(3H)- one; [0288] S)-2- l-aminoethyl)-6-fluoro-3-(pyridin-3-yl)quinazolin-4(3H)-one;
[0289] S)-2- l-aminoethyl)-5-methyl-3-(pyridin-3-yl)quinazolin-4(3H)-one;
[0290] S)-2- l-aminoethyl)-5-(methylsulfonyl)-3-(pyridin-3-yl)quinazolin-4(3H)-one;
[0291] S)-2- l-aminoethyl)-3-(pyridin-3-yl)-5-(trifluoromethyl)quinazolin-4(3H)-one;
[0292] S)-2- l-aminoethyl)-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazoline-5- carbonitrile
[0293] S)-2- l-aminoethyl)-3-(5-fluoropyridin-3-yl)-5-methylquinazolin-4(3H)-one;
[0294] S)-2- 1 - aminoethyl)- 5 -chloro- 3 - (5 -fluoropyridin- 3 -yl)quinazolin-4(3 H) -one ;
[0295] S)-2- l-aminoethyl)-5-chloro-3-(5-chloropyridin-3-yl)quinazolin-4(3H)-one;
[0296] S)-2- 1 - aminoethyl)- 5 -chloro- 3 - (5 -methoxypyridin- 3 -yl)quinazolin-4(3 H) -one ;
[0297] S)-2- l-aminoethyl)-5-chloro-3-(5-(difluoromethyl)pyridin-3-yl)quinazolin-
4(3H)-one;
[0298] S)-2- l-aminoethyl)-5-chloro-3-(5-methylpyridin-3-yl)quinazolin-4(3H)-one;
[0299] S)-2- (cyclopropyl)methyl)-5-chloro-3-(5-methylpyridin-3-yl)quinazolin-
4(3H)-one;
[0300] S)-2- 1 - aminoethyl)- 5 -chloro- 3 - (5 - (trifluoromethyl)pyridin-3 -yl)quinazolin-
4(3H)-one;
[0301] S)-2- l-aminoethyl)-5-chloro-3-(5-cyclopropylpyridin-3-yl)quinazolin-4(3H)- one;
[0302] S)-2- l-aminopropyl)-5-chloro-3-(5-fluoropyridin-3-yl)quinazolin-4(3H)-one;
[0303] S)-2- (cyclopropy l)methyl)- 5 -chloro- 3 - (5 -fluoropyridin- 3 -yl)quinazolin-
4(3H)-one;
[0304] S)-2- l-aminoethyl)-8-chloro-3-(pyridin-3-yl)quinazolin-4(3H)-one;
[0305] (S)-2-(l-aminoethyl)-5,8-dichloro-3-(pyridin-3-yl)quinazolin-4(3H)-one; [0306] (S)-2-(l-aminoethyl)-5-chloro-8-fluoro-3-(pyridin-3-yl)quinazolin-4(3H)-one;
[0307] (S)-2-(l-aminoethyl)-5,8-difluoro-3-(pyridin-3-yl)quinazolin-4(3H)-one;
[0308] (S)-2-(l-aminopropyl)-5-chloro-8-fluoro-3-(pyridin-3-yl)quinazolin-4(3H)-one;
[0309] (S)-2-(amino(cyclopropyl)methyl)-5-chloro-8-fluoro-3-(pyridin-3-yl)quinazolin- 4(3H)-one;
[0310] (S)-2-(amino(cyclopropyl)methyl)-5,8-dichloro-3-(pyridin-3-yl)quinazolin-4(3H)- one;
[0311] (S)-2-(l-amino-2-cyclopropylethyl)-5-chloro-8-fluoro-3-(pyridin-3-yl)quinazolin- 4(3H)-one;
[0312] (S)-2-(l-aminoethyl)-5,8-dichloro-3-(5-fluoropyridin-3-yl)quinazolin-4(3H)-one;
[0313] (S)-2-(l-aminoethyl)-5-chloro-8-fluoro-3-(5-fluoropyridin-3-yl)quinazolin-4(3H)- one;
[0314] (S)-2-(l-aminoethyl)-5-chloro-8-fluoro-3-(5-methylpyridin-3-yl)quinazolin- 4(3H)-one;
[0315] (S)-2-(amino(cyclopropyl)methyl)-5-chloro-8-fluoro-3-(5-fluoropyridin-3- yl)quinazolin-4(3H)-one;
[0316] (S)-2-(l-aminoethyl)-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazoline-5- carbonitrile;
[0317] (S)-2-(l-aminopropyl)-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazoline-5- carbonitrile;
[0318] (S)-2-(l-aminoethyl)-5-chloro-6-fluoro-3-(pyridin-3-yl)quinazolin-4(3H)-one;
[0319] (S)-2-(amino(cyclopropyl)methyl)-5-chloro-6-fluoro-3-(pyridin-3-yl)quinazolin- 4(3H)-one;
[0320] (S)-2-(l-aminoethyl)-5-chloro-3-(2-methylpyridin-3-yl)quinazolin-4(3H)-one;
[0321] (S)-2-(l-aminoethyl)-5-chloro-3-(2-methylpyridin-3-yl)quinazolin-4(3H)-one; [0322] (S)-2-(l-aminoethyl)-5-chloro-3-(4-methylpyridin-3-yl)quinazolin-4(3H)-one;
[0323] (S)-2-(l-aminoethyl)-5-chloro-3-(4-methylpyridin-3-yl)quinazolin-4(3H)-one;
[0324] (S)-2-(l-aminoethyl)-5-chloro-6-fluoro-3-(4-methylpyridin-3-yl)quinazolin- 4(3H)-one;
[0325] (S)-2-(l-aminoethyl)-5-chloro-6-fluoro-3-(4-methylpyridin-3-yl)quinazolin- 4(3H)-one;
[0326] (S)-2-(l-aminoethyl)-5-chloro-3-(5-fluoro-2-methylpyridin-3-yl)quinazolin- 4(3H)-one;
[0327] (S)-2-(l-aminoethyl)-5-chloro-3-(5-fluoro-2-methylpyridin-3-yl)quinazolin- 4(3H)-one;
[0328] (S)-2-(l-aminoethyl)-5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)quinazolin- 4(3H)-one;
[0329] (S)-2-(l-aminoethyl)-5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)quinazolin- 4(3H)-one;
[0330] (S)-2-(l-aminopropyl)-5-chloro-8-fluoro-3-(5-fluoropyridin-3-yl)quinazolin- 4(3H)-one;
[0331] (S)-2-(l-aminoethyl)-3-(4-methylpyridin-3-yl)-5-(trifluoromethyl)quinazolin- 4(3H)-one;
[0332] (S)-2-(l-aminoethyl)-6-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazoline-8- carbonitrile;
[0333] (S)-2-(l-aminopropyl)-6-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazoline-8-carbonitrile;
[0334] (S)-2-(amino(cyclopropyl)methyl)-6-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazoline-8-carbonitrile;
[0335] (S)-2-(l-amino-3-methylbutyl)-5-chloro-3-(5-fluoropyridin-3-yl)quinazolin- 4(3H)-one; [0336] (R)-2-(l-aminoethyl)-5-chloro-8-fluoro-3-(pyridin-3-yl)quinazolin-4(3H)-one;
[0337] (S)-2-(l-amino-3-methylbutyl)-5-chloro-3-(pyridin-3-yl)quinazolin-4(3H)-one;
[0338] (R)-2-(l-aminoethyl)-5-chloro-8-fluoro-3-(5-fluoropyridin-3-yl)quinazolin-4(3H)- one;
[0339] (R)-2-(l-aminopropyl)-5-chloro-8-fluoro-3-(pyridin-3-yl)quinazolin-4(3H)-one;
[0340] (R)-2-(amino(cyclopropyl)methyl)-5-chloro-8-fluoro-3-(pyridin-3-yl)quinazolin- 4(3H)-one;
[0341] (S)-2-(l-aminoethyl)-5-bromo-8-fluoro-3-(5-fluoropyridin-3-yl)quinazolin-4(3H)- one;
[0342] (S)-2-(l-aminopropyl)-5-bromo-8-fluoro-3-(pyridin-3-yl)quinazolin-4(3H)-one;
[0343] (S)-2-(l-aminoethyl)-5-bromo-8-fluoro-3-(pyridin-3-yl)quinazolin-4(3H)-one;
[0344] (S)-2-(l-aminoethyl)-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazoline-5- carbonitrile;
[0345] (S)-2-(l-aminoethyl)-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazoline-5- carbonitrile;
[0346] (S)-2-(amino(cyclopropyl)methyl)-5-chloro-8-fluoro-3-(5-fluoro-4-methylpyridin- 3-yl)quinazolin-4(3H)-one;
[0347] (S)-2-(l-aminoethyl)-5-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)quinazolin- 4(3H)-one;
[0348] (S)-2-(amino(cyclopropyl)methyl)-5-chloro-3-(5-fluoro-4-methylpyridin-3- yl)quinazolin-4(3H)-one;
[0349] (S)-2-(l-aminopropyl)-5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)quinazolin- 4(3H)-one;
[0350] (S)-2-(l-aminoethyl)-5-chloro-8-fluoro-3-(5-fluoro-4-methylpyridin-3- yl)quinazolin-4(3H)-one; [0351] (S)-2-(l-aminoethyl)-6-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)quinazolin-4(3H) one;
[0352] (S)-2-(l-aminoethyl)-5-chloro-3-(4,5-dimethylpyridin-3-yl)quinazolin-4(3H)-one;
[0353] (S)-2-(l-aminoethyl)-3-(6-aminopyridin-3-yl)-8-chloro-6-fluoroquinazolin-4(3H)- one;
[0354] (S)-2-(l-aminoethyl)-3-(6-aminopyridin-3-yl)-5,8-dichloroquinazolin-4(3H)-one;
[0355] (S)-2-(l-aminoethyl)-3-(6-aminopyridin-3-yl)-5-chloroquinazolin-4(3H)-one;
[0356] (S)-2-(l-aminopropyl)-3-(6-aminopyridin-3-yl)-5-chloroquinazolin-4(3H)-one;
[0357] (S)-2-(l-aminoethyl)-3-(6-aminopyridin-3-yl)-5-chloro-8-fluoroquinazolin-4(3H)- one;
[0358] (S)-2-(amino(cyclopropyl)methyl)-3-(6-aminopyridin-3-yl)-5-chloroquinazolin- 4(3H)-one;
[0359] (S)-3-(6-amino-4-methylpyridin-3-yl)-2-(l-aminopropyl)-5-chloroquinazolin- 4(3H)-one;
[0360] (S)-3-(6-amino-4-methylpyridin-3-yl)-2-(l-aminoethyl)-5-chloroquinazolin- 4(3H)-one;
[0361] (S)-3-(6-amino-4-methylpyridin-3-yl)-2-(l-aminopropyl)-5,8-dichloroquinazolin- 4(3H)-one;
[0362] (S)-2-(amino(cyclopropyl)methyl)-3-(6-amino-4-methylpyridin-3-yl)-5,8- dichloroquinazolin-4(3H)-one;
[0363] (S)-2-(l-aminoethyl)-3-(6-aminopyridin-3-yl)-5-chloro-6-fluoroquinazolin-4(3H)- one;
[0364] (S)-2-(l-aminobutyl)-3-(6-aminopyridin-3-yl)-5-chloroquinazolin-4(3H)-one;
[0365] (S)-2-(l-aminobutyl)-3-(6-aminopyridin-3-yl)-5-chloro-6-fluoroquinazolin-4(3H)- one; [0366] (S)-2-(amino(cyclopropyl)methyl)-3-(6-aminopyridin-3-yl)-5-chloro-8- fluoroquinazolin-4(3H)-one; and
[0367] (S)-2-(l-aminoethyl)-3-(5-aminopyridin-3-yl)-5-chloroquinazolin-4(3H)-one.
Example 3
Preparation of a Compound of Formula (3)
A. Preparation of a Compound of Formula (3) wherein R4 is CN and X is CI (2,4-diamino-6- chloropyrimidine-5-carbonitrile)
Figure imgf000087_0001
[0368] Ammonium hydroxide (20 mL) was added to a solution of 2,4,6- trichloropyrimidine-5-carbonitrile (5.0 g, 24 mmol) in dioxane (20 mL) at room temperature. The solution was warmed to 50°C and stirred for 3 hrs. The reaction mixture was cooled to 10°C and water (50 mL) was added. The resulting solid was filtered, washed with water, and dried under high vacuum to obtain the title compound as a white solid (4.5 g) 13H NMR (100 MHz, DMSO) 164.8, 162.6, 161.9, 115.8, 77.6. ES/MS mJz = 169.9 (M+H)+.
A. Preparation of a Compound of Formula (3), varying R3
[0369] 2,4-diamino-6-chloropyrimidine-5-carboxamide; and
[0370] 5-chloro-6-fluoropyrimidine-2,4-diamine;
Example 4
Preparation of a Compound of Formula (I)
A. Preparation of a Compound of Formula (I) wherein n is 1, R1 is chloro, m is 0, R3 is methyl, and R4 is cyano (Compound 1)
Figure imgf000088_0001
[0371] Potassium fluoride (138 mg, 2.38 mmol) was added to a solution of (S)-2-(l- aminoethyl)-5-chloro-3-(pyridin-3-yl)quinazolin-4(3H)-one (400 mg, 1.33 mmol) and 2,4- diamino-6-chloropyrimidine-5-carbonitrile (237 mg, 1.4 mmol) in diisopropylethylamine (1.0 mL, 6.0 mmol) and DMSO (3 mL). The resultant mixture was heated to 90°C for 14 hours. Then it was cooled to room temperature, filtered, and purified by HPLC eluting with 5 -95 water/acetonitrile (0.1 v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to obtain the title compound of (S)-2,4-diamino-6-((l-(5-chloro-4-oxo-3-(pyridin- 3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile as a solid (479 mg). *H NMR (400 MHz, DMSO) δ 8.74 (d, J = 2.4 Hz, 0.5H), 8.58 (dd, J = 4.8, 1.5 Hz, 0.5H), 8.51 (dd, / = 4.9, 1.7 Hz, 1.5H), 8.06 (dm, / = 8.5 Hz, 0.5H), 7.85 (dm, / = 8.0 Hz, 0.5H), 7.8 (td, 7 = 8.1, 1.4 Hz, 1H), 7.68 (ddd, / = 8.2, 3.9, 1.2 Hz, 1H), 7.60 (dt, 7 = 7.9, 1.3 Hz, 1H), 7.55 (ddd, / = 8.1, 4.8, 0.7 Hz, 0.5H), 7.48 (ddt, / = 8.1, 4.8, 0.7 Hz, 0.5H), 4.85 (m, 1H), 1.35 (d, / = 6.8 Hz, 3H). ES/MS 434.1 (M+H+).
B. Preparation of a Compound of Formula (I), varying R1, R2 and R3
[0372] Other compounds of formula (I) were prepared including:
[0373] (S)-2,4-diamino-6-(l-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)propylamino)pyrimidine-5-carbonitrile (Compound 2). 1H NMR (400 MHz, DMSO-d6) δ 8.83 - 8.35 (m, 2H), 8.00 (t, J = 9.9 Hz, 1H), 7.75 (t, J = 8.0 Hz, 1H), 7.70 - 7.38 (m, 3H), 6.75 (dd, / = 19.0, 7.5 Hz, IH), 6.57 (s, 2H), 6.39 - 5.86 (m, 2H), 4.49 (td, / = 7.5, 3.9 Hz, IH), 1.98 - 1.43 (m, 2H), 0.66 (q, / = 6.9 Hz, 3H). ES/MS 448.1 (M+H+);
[0374] (S)-2,4-diamino-6-((5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile (Compound 3). IH NMR (400 MHz, DMSO-d6) δ 8.65 (d, / = 2.5 Hz, IH), 8.58 - 8.42 (m, IH), 7.95 (ddt, / = 8.2, 2.7, 1.3 Hz, IH), 7.87 - 7.72 (m, IH), 7.66 (ddt, 7 = 8.2, 4.2, 1.1 Hz, IH), 7.63 - 7.44 (m, IH), 7.38 (dd, / = 8.1, 4.8 Hz, IH), 6.72 - 6.43 (m, 3H), 6.18 (s, 2H), 5.72 (d, J = 1.0 Hz, IH), 4.53 - 4.27 (m, IH), 1.46 - 0.95 (m, 2H), 0.07 (dd, / = 5.7, 2.8 Hz, 2H). ES/MS 460.5 (M+H+);
[0375] (S)-2,4-diamino-6-(l-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)-2-cyclopropylethylamino)pyrimidine-5-carbonitrile (Compound 4). IH NMR (400 MHz, DMSO-d6) δ 8.89 - 8.58 (m, 2H), 8.05 (dddd, J = 50.5, 8.1, 2.5, 1.5 Hz, IH), 7.82 - 7.64 (m, IH), 7.68 - 7.45 (m, 3H), 6.84 (dd, J = 7.5, 3.8 Hz, IH), 6.70 - 6.37 (m, 2H), 6.39 - 6.02 (m, 2H), 4.70 - 4.42 (m, IH), 1.91 - 1.76 (m, IH), 1.48 - 1.22 (m, IH), 0.60 (dtt, J = 16.3, 7.9, 4.3 Hz, IH), 0.26 (tt, / = 8.5, 4.4 Hz, IH), 0.20 - -0.17 (m, 2H), -0.48 - -0.92 (m, IH).
ES/MS 474.1 (M+H+);
[0376] (S)-2,4-diamino-6-(l-(6-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile (Compound 5). IH NMR (400 MHz, DMSO-d6) δ 8.80 - 8.46 (m, 2H), 7.97 (dddd, J = 25.8, 8.1, 2.5, 1.5 Hz, IH), 7.82 - 7.68 (m, 3H), 7.50 (dddd, / = 27.4, 8.1, 4.9, 0.8 Hz, IH), 6.88 (dd, / = 15.9, 7.1 Hz, IH), 6.50 (d, / = 6.5 Hz, 2H), 6.22 (s, 2H), 4.73 (dt, / = 9.6, 6.9 Hz, IH), 1.30 (dd, / = 6.7, 1.7 Hz, 3H). ES/MS 418.1 (M+H+);
[0377] (S)-2,4-diamino-6-(l-(5-methyl-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile (Compound 7). IH NMR (400 MHz, DMSO-d6) δ 8.87 - 8.32 (m, 2H), 7.96 (dddt, / = 13.4, 8.1, 2.6, 1.4 Hz, IH), 7.68 (t, 7 = 7.8 Hz, IH), 7.51 (dtd, / = 11.7, 8.1, 4.9 Hz, IH), 7.29 (dd, 7 = 7.6, 1.5 Hz, IH), 7.05 - 6.74 (m, 2H), 6.68 - 6.34 (m, 2H), 6.25 (s, IH), 4.88 - 4.48 (m, IH), 2.69 (s, 3H), 1.28 (d, / = 6.7 Hz, 3H). ES/MS 414.5 (M+H+);
[0378] (S)-2,4-diamino-6-(l-(5-(methylsulfonyl)-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 8). IH NMR (400 MHz, DMSO-d6) δ 8.76 (dd, / = 2.5, 0.7 Hz, 0.5H), 8.69 (dd, / = 2.5, 0.7 Hz, 0.5H), 8.64 (dd, / = 4.8, 1.5 Hz, 0.5H), 8.59 (dd, / = 4.8, 1.5 Hz, 0.5H), 8.35 - 8.30 (m, IH), 8.12 - 8.04 (m, 2H), 8.00 (dd, 7 = 2.5, 1.6 Hz, 0.5H), 7.98 (dd, 7 = 2.5, 1.5 Hz, 0.5H), 7.59 (ddd, 7 = 8.1, 4.8, 0.8 Hz, 0.5H), 7.52 (ddd, 7 = 8.1, 4.8, 0.8 Hz, 0.5H), 6.97 (d, 7 = 7.2 Hz, 0.5H), 6.94 (d, J = 1.2 Hz, 0.5H), 6.55 (br s, 2H), 6.26 (br s, 2H), 4.80 (dt, 7 = 8.5, 6.9 Hz, IH), 3.49 (s, 3H), 1.36 (dd, 7 = 6.6, 1.3 Hz, 3H). ES/MS 478.1 (M+H+);
[0379] (S)-2,4-diamino-6-(l-(4-oxo-3-(pyridin-3-yl)-5-(trifluoromethyl)-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 9). IH NMR (400 MHz, DMSO-d6) δ 8.75 (d, 7 = 2.5 Hz, IH), 8.67 - 8.36 (m, 2H), 8.27 - 7.92 (m, 5H), 7.94 - 7.67 (m, 2H), 7.51 (dddd, 7 = 31.6, 8.2, 4.8, 0.8 Hz, 2H), 4.89 (td, 7 = 7.0, 4.3 Hz, IH), 1.37 (d, 7 = 6.6 Hz, 3H). ES/MS 468.1 (M+H+);
[0380] (S)-2-(l-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-(pyridin-3- yl)-3,4-dihydroquinazoline-5-carbonitrile (Compound 10). *H NMR (400 MHz, DMSO-i¾) δ 8.71 (ddd, 7 = 17.0, 2.5, 0.7 Hz, IH), 8.59 (ddd, 7 = 15.9, 4.8, 1.5 Hz, IH), 8.11 - 8.03 (m, IH), 8.03 - 7.91 (m, 3H), 7.63 - 7.40 (m, IH), 6.88 (dd, 7 = 13.2, 6.9 Hz, IH), 6.52 (br. s, 2H), 6.24 (br. s, 2H), 4.70 (td, 7 = 6.8, 4.6 Hz, IH), 1.31 (d, 7 = 6.7 Hz, 3H). ES/MS 425.1 (M+H+);
[0381] (S)-2,4-diamino-6-(l-(3-(5-fluoropyridin-3-yl)-5-methyl-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 11). IH NMR (400 MHz, DMSO-d6) δ 8.67 - 8.39 (m, 2H), 8.25 - 7.95 (m, IH), 7.97 - 7.79 (m, IH), 7.69 (td, 7 = 7.8, 1.6 Hz, IH), 7.58 - 7.38 (m, IH), 7.40 - 7.18 (m, IH), 6.91 (ddd, 7 = 23.3, 7.2, 1.7 Hz, IH), 6.53 (d, 7 = 8.3 Hz, 2H), 6.21 (s, 2H), 4.96 - 4.37 (m, IH), 2.70 (d, 7 = 1.7 Hz, 3H), 1.32 (dt, 7 = 6.6, 1.6 Hz, 3H). ES/MS 432.3 (M+H+);
[0382] (S)-2,4-diamino-6-(l-(5-chloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 12). IH NMR (400 MHz, DMSO) δ 8.66 (m, 0.5H), 8.62 (d, 7 = 2.8 Hz, 0.5H), 8.55 (d, 7 = 2.6 Hz, 0.5H), 8.40 (m, 0.5H), 8.16 (dd, 7 = 2.65, 2.0 Hz, 0.5H), 8.13 (dd, 7 = 2.6, 2.0 Hz, 0.5H), 7.82 (ddd, 7 = 8.0, 8.0, 2.2 Hz, IH), 7.78(m, 0.5H), 7.69 (ddd, 8.18, 3.7, 1.2 Hz, IH), 7.61 (ddd, 7 = 7.8, 2.15, 1.2 Hz, IH), 4.86 (m, IH), 1.37 (d, 7 = 6.7 Hz, 1.5H), 1.36 (d, 7 = 6.5 Hz, 1.5H).
ES/MS 452.8 (M+H+);
[0383] (S)-2,4-diamino-6-(l-(5-chloro-3-(5-chloropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 13). IH NMR (400 MHz, DMSO) δ 8.52 (d, 7 = 5.6 Hz, IH), 7.82 (t, 7 = 8.0 Hz, IH), 7.70 (dd, 7 = 8.2, 1.0 Hz, IH), 7.62 (dd, 7 = 8.0, 1.1 Hz, IH), 7.55 (dm, 7 = 5.6 Hz, IH), 5.03 (m, IH), 1.38 (d, 7 = 6.6 Hz, 3H). ES/MS 469.3 (M+H+);
[0384] (S)-2,4-diamino-6-(l-(5-chloro-3-(5-methoxypyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 14). IH NMR (400 MHz, DMSO) δ 8.35 (d, 7 = 1.9 Hz, 0.5H), 8.31 (d, 7 = 2.8 Hz, 0.5H), 8.24 (d, 7 = 2.7 Hz, 0.5H), 8.13 (d, 7 = 1.9 Hz, 0.5H), 7.84 (t, 7 = 8.3 Hz, IH), 7.78 (dd, 7 = 2.7, 1.9 Hz, 0.5H), 7.72 (ddd, 7 = 8.2, 1.8, 1.2 Hz, IH), 7.64 (ddd, 7 = 7.8, 1.3, 0.6 Hz, IH), 7.41 (dd, 7 = 2.8, 2.0 Hz, IH), 4.98 (m, IH), 3.85 (s, 1.5H), 3.79 (s, 1.5H), 1.40 (d, 3H). ES/MS 464.8 (M+H+);
[0385] (S)-2,4-diamino-6-(l-(5-chloro-3-(5-(difluoromethyl)pyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 15). IH NMR (400 MHz, DMSO) δ 8.9 (s, 0.5H), 8.75 (s, 0.5H), 8.69 (s, 0.5H), 8.67 (s, 0.5H), 8.33 (s, 0.5H), 7.96 (s, 0.5H), 7.81 (ddd, 7 = 8.0, 8.0, 4.0 Hz, 0.5H), 7.70(ddd, 7 = 9.3, 8.2, 1.15 Hz, 0.5H), 7.61 (ddd, 7.8, 3.2, 1.2 Hz, 0.5H), 7.3 (m, 0.5H), 7.15 (m, IH), 4.86 (m, IH), 1.37 (d, 7 = 6.7 Hz, 1.5H), 1.34 (d, 7 = 6.8 Hz, 1.5H). ES/MS 484.8 (M+H+);
[0386] (S)-2,4-diamino-6-(l-(5-chloro-3-(5-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 16). IH NMR (400 MHz, DMSO-d6) δ 8.55 - 8.23 (m, 2H), 7.91 - 7.70 (m, IH), 7.73 - 7.44 (m, 3H), 6.92 (dd, 7 = 22.9, 7.2 Hz, IH), 6.51 (d, 7 = 5.1 Hz, 2H), 6.20 (d, 7 = 17.4 Hz, 2H), 4.78 (h, 7 = 6.6 Hz, IH), 2.40 - 2.11 (m, 3H), 1.39 - 1.19 (m, 3H). ES/MS 448.1 (M+H+);
[0387] (S)-2,4-diamino-6-((5-chloro-3-(5-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile (Compound 17). IH NMR (400 MHz, DMSO-d6) δ 8.54 - 8.17 (m, 2H), 7.88 - 7.47 (m, 3H), 6.71 (dd, 7 = 57.5, 7.7 Hz, IH), 6.51 (s, 2H), 6.10 (s, 2H), 4.48 (dt, 7 = 26.1, 7.8 Hz, IH), 2.42 - 2.02 (m, 3H), 1.61 - 1.28 (m, IH), 0.64 - 0.30 (m, 3H), 0.25 - -0.11 (m, IH). ES/MS 474.1 (M+H+);
[0388] (S)-2,4-diamino-6-(l-(5-chloro-4-oxo-3-(5-(trifluoromethyl)pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 18). IH NMR (400 MHz, DMSO-d6) δ 9.24 - 8.72 (m, 2H), 8.58 (td, 7 = 2.2, 0.7 Hz, IH), 7.90 - 7.47 (m, 3H), 6.92 (dd, 7 = 40.0, 7.3 Hz, IH), 6.47 (d, 7 = 21.5 Hz, 2H), 6.14 (s, 2H), 4.76 (dp, 7 = 26.9, 6.6 Hz, IH), 1.32 (dd, 7 = 12.3, 6.5 Hz, 3H). ES/MS 502.1 (M+H+); [0389] (S)-2,4-diamino-6-(l-(5-chloro-3-(5-cyclopropylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 19). 1H NMR (400 MHz, DMSO-d6) δ 8.54 - 8.15 (m, 2H), 7.84 - 7.70 (m, 1H), 7.70 - 7.44 (m, 3H), 6.88 (dd, 7 = 6.9, 4.8 Hz, 1H), 6.51 (s, 2H), 6.19 (s, 2H), 4.64 (dt, 7 = 12.6, 6.7 Hz, 1H), 2.05 - 1.77 (m, 1H), 1.28 (dd, 7 = 9.0, 6.7 Hz, 3H), 1.05 - 0.88 (m, 2H), 0.80 - 0.56 (m, 2H). ES/MS 474.1 (M+H+);
[0390] (S)-2,4-diamino-6-(l-(5-chloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)propylamino)pyrimidine-5-carbonitrile (Compound 20). 1H NMR (400 MHz, DMSO-d6) δ 8.74 - 8.45 (m, 2H), 8.02 (ddt, 7 = 103.9, 9.0, 2.1 Hz, 2H), 7.78 (td, 7 = 8.0, 0.8 Hz, 1H), 7.61 (ddt, 7 = 25.7, 8.0, 1.1 Hz, 1H), 6.77 (d, 7 = 31.6 Hz, 1H), 6.55 (s, 2H), 6.19 (s, 2H), 4.77 - 4.39 (m, 1H), 2.05 - 1.57 (m, 2H), 0.82 - 0.44 (m, 3H). ES/MS 468.1 (M+H+);
[0391] (S)-2,4-diamino-6-((5-chloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile (Compound 21). 1H NMR (400 MHz, DMSO-d6) δ 8.65 - 8.17 (m, 2H), 8.19 - 7.25 (m, 4H), 6.85 - 6.24 (m, 3H), 6.13 (s, 2H), 4.45 (dt, 7 = 20.2, 8.0 Hz, 1H), 1.42 (h, 7 = 7.3 Hz, 1H), 0.58 - 0.25 (m, 3H), 0.08 (dq, 7 = 10.0, 5.5, 5.1 Hz, 1H). ES/MS 478.1 (M+H+);
[0392] (S)-2,4-diamino-6-(l-(8-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile (Compound 22). 1H NMR (400 MHz, DMSO-d6) δ 8.75 (d, 7 = 2.5 Hz, 1H), 8.65 - 8.42 (m, 2H), 8.16 - 7.94 (m, 3H), 7.92 - 7.58 (m, 1H), 7.65 - 7.47 (m, 2H), 7.51 - 7.38 (m, 1H), 7.31 (s, 2H), 4.94 (h, 7 = 6.7 Hz, 1H), 1.39 (dd, 7 = 6.6, 2.6 Hz, 3H). ES/MS 434.9 (M+H+);
[0393] (S)-2,4-diamino-6-(l-(5,8-dichloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 23). 1H NMR (400 MHz, DMSO-d6) δ 8.87 - 8.38 (m, 4H), 8.02 (tdd, 7 = 7.4, 6.6, 5.6, 2.9 Hz, 2H), 7.89 - 7.65 (m, 2H), 7.65 - 7.32 (m, 3H), 5.03 - 4.68 (m, 1H), 1.57 - 1.15 (m, 3H). ES/MS 469.2 (M+H+);
[0394] (S)-2,4-diamino-6-(l-(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 24). 1H NMR (400 MHz, DMSO-d6) δ 8.80 - 8.42 (m, 2H), 8.12 - 7.81 (m, 1H), 7.80 - 7.68 (m, 1H), 7.62 - 7.51 (m, 1H), 7.46 (dt, 7 = 10.6, 5.3 Hz, 1H), 6.87 (dd, 7 = 16.8, 7.0 Hz, 1H), 6.51 (d, 7 = 5.7 Hz, 2H), 6.21 (d, 7 = 21.8 Hz, 2H), 4.76 - 4.60 (m, 1H), 1.30 (dd, J = 6.6, 1.5 Hz, 3H).
ES/MS 452.1 (M+H+);
[0395] (S)-2,4-diamino-6-(l-(5,8-difluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 25). 1H NMR (400 MHz, DMSO-d6) δ 8.73 (d, / = 2.5 Hz, 1H), 8.65 - 8.36 (m, 1H), 8.02 (dt, / = 8.2, 2.0 Hz, 1H), 8.02 - 7.70 (m, 6H), 7.55 (dd, / = 8.1, 4.8 Hz, 1H), 7.47 (dd, / = 8.1, 4.8 Hz, 1H), 7.47 - 7.25 (m, 1H), 4.83 (q, / = 6.7 Hz, 1H), 1.48 - 1.26 (m, 3H). ES/MS 436.4 (M+H+);
[0396] (S)-2,4-diamino-6-(l-(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)propylamino)pyrimidine-5-carbonitrile (Compound 26). 1H NMR (400 MHz, DMSO-d6) δ 8.81 - 8.46 (m, 2H), 8.10 - 7.80 (m, 1H), 7.71 (dd, / = 9.7, 8.7 Hz, 1H), 7.64 - 7.38 (m, 2H), 6.76 (dd, J = 20.9, 7.5 Hz, 1H), 6.58 (s, 2H), 6.19 (d, / = 38.7 Hz, 2H), 4.54 (tt, / = 7.8, 5.3 Hz, 1H), 1.91 - 1.59 (m, 2H), 0.69 (td, / = 7.2, 4.4 Hz, 3H). ES/MS 466.1 (M+H+);
[0397] (S)-2,4-diamino-6-((5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile (Compound 27). 1H NMR (400 MHz, DMSO-d6) δ 8.76 - 8.39 (m, 2H), 8.00 - 7.64 (m, 2H), 7.68 - 7.22 (m, 2H), 6.74 - 6.41 (m, 3H), 6.15 (d, / = 24.2 Hz, 2H), 4.48 (td, / = 7.8, 1.5 Hz, 1H), 1.54 - 1.24 (m, 1H), 0.53 - 0.21 (m, 3H), 0.07 - -0.13 (m, 1H). ES/MS 478.1 (M+H+);
[0398] (S)-2,4-diamino-6-(cyclopropyl(5,8-dichloro-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)methylamino)pyrimidine-5-carbonitrile (Compound 28). 1H NMR (400 MHz, DMSO-d6) δ 8.78 - 8.39 (m, 2H), 8.10 - 7.70 (m, 2H), 7.66 - 7.13 (m, 2H), 6.74 - 6.33 (m, 3H), 6.19 (s, 2H), 4.60 (t, 7 = 7.6 Hz, 1H), 1.48 - 1.21 (m, 1H), 0.49 - 0.23 (m, 2H), 0.14 - -0.04 (m, 2H). ES/MS 494.1 (M+H+);
[0399] (S)-2,4-diamino-6-(l-(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)-2-cyclopropylethylamino)pyrimidine-5-carbonitrile (Compound 29). 1H NMR (400 MHz, DMSO-d6) δ 9.00 - 8.41 (m, 2H), 8.25 - 7.82 (m, 1H), 7.80 - 7.38 (m, 3H), 6.86 (t, / = 6.9 Hz, 1H), 6.58 (s, 2H), 6.25 (d, / = 26.1 Hz, 2H), 4.59 (qd, / = 7.7, 3.9 Hz, 1H), 2.02 - 1.68 (m, 1H), 1.38 (dddd, / = 34.1, 13.0, 7.9, 4.1 Hz, 1H), 0.61 (h, 7 = 6.3 Hz, 1H), 0.42 - -0.23 (m, 2H), -0.65 (ddq, / = 72.7, 9.9, 4.8 Hz, 2H). ES/MS 492.1 (M+H+); [0400] (S)-2,4-diamino-6-(l -(5,8-dichloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 30). 1H NMR (400 MHz, DMSO-d6) δ 8.78 - 8.30 (m, 2H), 8.25 - 7.64 (m, 2H), 7.59 (dt, / = 8.5, 1.2 Hz, 1H), 6.87 (dd, 7 = 24.3, 7.4 Hz, 1H), 6.51 (d, / = 11.3 Hz, 2H), 6.23 (s, 2H), 4.87 (ddd, / = 13.5, 9.8, 6.7 Hz, 1H), 1.43 - 1.32 (m, 3H). ES/MS 486.0 (M+H+);
[0401] (S)-2,4-diamino-6-(l -(5-chloro-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 31). 1H NMR (400 MHz, DMSO-d6) δ 8.83 - 8.25 (m, 2H), 8.23 - 7.66 (m, 2H), 7.59 (dd, / = 8.8, 4.5 Hz, 1H), 6.90 (dd, J = 23.2, 7.2 Hz, 1H), 6.52 (d, J = 9.2 Hz, 2H), 6.24 (s, 2H), 4.97 - 4.46 (m, 1H), 1.33 (dd, / = 6.6, 1.6 Hz, 3H). ES/MS 470.1 (M+H+);
[0402] (S)-2,4-diamino-6-(l -(5-chloro-8-fluoro-3-(5-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 32). 1H NMR (400 MHz, DMSO-d6) δ 8.60 - 8.15 (m, 2H), 7.93 - 7.66 (m, 1H), 7.64 - 7.31 (m, 2H), 7.03 - 6.67 (m, 1H), 6.51 (d, / = 8.2 Hz, 2H), 6.18 (s, 2H), 4.81 (td, / = 6.8, 4.8 Hz, 1H), 2.27 (ddd, / = 63.2, 1.3, 0.7 Hz, 3H), 1.32 (dd, / = 1 1.5, 6.6 Hz, 3H). ES/MS 466.1 (M+H+);
[0403] (S)-2,4-diamino-6-((5-chloro-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile (Compound 33). 1H NMR (400 MHz, DMSO-d6) δ 8.67 - 8.25 (m, 2H), 8.07 (ddd, / = 9.3, 2.7, 1.8 Hz, 1H), 7.93 - 7.47 (m, 2H), 6.83 - 6.41 (m, 3H), 6.14 (s, 2H), 4.48 (dt, / = 20.2, 7.9 Hz, 1H), 1.67 - 1.32 (m, 1H), 0.65 - 0.29 (m, 3H), 0.27 - 0.01 (m, 1H). ES/MS 496.1 (M+H+);
[0404] (S)-2-(l-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-8-fluoro-4-oxo-3- (pyridin-3-yl)-3,4-dihydroquinazoline-5-carbonitrile (Compound 34). 1H NMR (400 MHz, DMSO-i¾) δ 8.74 (ddd, / = 20.2, 2.4, 0.7 Hz, 1H), 8.64 (ddd, / = 16.5, 4.8, 1.5 Hz, 1H), 8.14 (dd, J = 8.4, 4.5 Hz, 1H), 8.09 - 7.91 (m, 2H), 7.65 - 7.49 (m, 1H), 6.93 (dd, J = 15.4, 6.9 Hz, 1H), 6.57 (br. s, 2H), 6.37 - 6.14 (m, 2H), 4.82 - 4.69 (m, 1H), 1.35 (d, / = 6.7 Hz, 3H). ES/MS 443.1 (M+H+);
[0405] (S)-2-(l-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)propyl)-8-fluoro-4-oxo-3- (pyridin-3-yl)-3,4-dihydroquinazoline-5-carbonitrile (Compound 35). JH NMR (400 MHz, DMSO-i¾) δ 8.72 (ddd, / = 7.6, 2.5, 0.7 Hz, 1H), 8.64 (ddd, / = 10.1 , 4.8, 1.5 Hz, 1H), 8.10 (dd, / = 8.4, 4.5 Hz, 1H), 8.01 (dddd, / = 11.2, 8.1 , 2.5, 1.5 Hz, 1H), 7.92 (ddd, / = 9.6, 8.5, 1.0 Hz, 1H), 7.64 - 7.50 (m, 1H), 6.85 - 6.71 (m, 1H), 6.55 (br. s, 2H), 6.23 (br. s, 2H), 4.63
- 4.46 (m, 1H), 1.92 - 1.61 (m, 2H), 0.68 (td, 7 = 7.3, 5.4 Hz, 3H). ES/MS 457.1 (M+H+);
[0406] (S)-2,4-diamino-6-(l-(5-chloro-6-fluoro-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 36). 1H NMR (400 MHz, DMSO-d6) δ 8.74 - 8.43 (m, 2H), 8.08 - 7.82 (m, 2H), 7.71 (ddd, 7 = 9.1, 5.0, 3.2 Hz, 1H), 7.51 (dddd, 7 = 28.0, 8.1, 4.8, 0.8 Hz, 1H), 6.85 (dd, 7 = 14.4, 7.0 Hz, 1H), 6.52 (s, 2H), 6.20 (d, 7 = 25.5 Hz, 2H), 4.67 (h, 7 = 6.7 Hz, 1H), 1.29 (d, 7 = 6.7 Hz, 3H). ES/MS 452.1 (M+H+);
[0407] (S)-2,4-diamino-6-((5-chloro-6-fluoro-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile (Compound 37). 1H NMR (400 MHz, DMSO-d6) δ 8.74 - 8.32 (m, 2H), 8.04 - 7.86 (m, 1H), 7.82 - 7.58 (m, 1H), 7.44 (dddd, 7 = 60.7, 8.1, 4.8, 0.8 Hz, 1H), 6.72 - 6.46 (m, 4H), 6.16 (s, 2H), 4.44 (td, 7 = 7.9, 1.7 Hz, 1H), 1.52 - 1.19 (m, 1H), 0.39 (dddd, 7 = 16.8, 9.7, 7.4, 4.2 Hz, 3H), 0.12
- -0.19 (m, 1H). ES/MS 478.1 (M+H+);
[0408] (S)-2,4-diamino-6-(l-(5-chloro-3-(2-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 38). 1H NMR (400 MHz, DMSO) 5 8.31 (dd, 7 = 5.2, 1.5 Hz, 1H), 7.94(dd, 7 = 7.8, 1.3 Hz, 1H), 7.82 (t, 8.11 Hz, 1H), 7.72 (dd, 7 = 8.11 , 1.16 Hz, 1H), 7.61 (dd, 7 = 7.94, 1.04 Hz, 1H), 7.34 (dd, 7 = 7.85, 4.85 Hz, 1H), 5.18 (m, 1H), 2.23 (s, 3H), 1.38 (d, 7 = 6.7 Hz, 3H). ES/MS 448.8 (M+H+);
[0409] (S)-2,4-diamino-6-(l-(5-chloro-3-(2-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 39). 1H NMR (400 MHz, DMSO) δ 8.4 (dd, 7 = 4.7, 1.6 Hz, 1H), 7.81 (dd, 7 = 8.0, 1.6 Hz, 1H), 7.80 (t, 8.03 Hz, 1H), 7.66 (dd, 7 = 8.21 , 1.17 Hz, 1H), 7.59 (dd, 7 = 7.8, 1.17 Hz, 1H), 7.27 (dd, 7 = 7.9,
4.8 Hz, 1H), 4.68 (m, 1H), 2.25 (s, 3H), 1.26 (d, 7 = 6.67 Hz, 3H). ES/MS 448.8 (M+H+);
[0410] (S)-2,4-diamino-6-(l-(5-chloro-3-(4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 40). 1H NMR (400 MHz, DMSO) δ 8.68 (s, 1H), 8.37 (d, 7 = 4.9 Hz, 1H), 8.31 (bs, 1H), 7.90 (bs, 1H), 7.83 (t,
8.09 Hz, 1H), 7.74 (dd, 7 = 8.09, 1.22 Hz, 1H), 7.62 (dd, 7 = 7.75, 1.22 Hz, 1H), 7.30 (d, 7 = 5.25 Hz, 1H), 5.25 (m, 1H), 2.13 (s, 3H), 1.40 (d, 7 = 6.4 Hz, 3H). ES/MS 448.8 (M+H+); [0411] (S)-2,4-diamino-6-(l-(5-chloro-3-(4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 41). 1H NMR (400 MHz, DMSO) δ 8.4 (s, 1H), 8.38 (d, 7 = 5.0 Hz, 1H), 8.11 (bs, 1H), 7.90 (bs, 1H), 7.83 (t, 7.86 Hz, 1H), 7.71 (dd, 7 = 7.9, 1.25 Hz, 1H), 7.63 (dd, 7 = 7.9, 1.25 Hz, 1H), 7.44 (d, 7 = 5.0 Hz, 1H), 4.75 (m, 1H), 2.12 (s, 3H), 1.34 (d, 7 = 6.6 Hz, 3H). ES/MS 448.8 (M+H+);
[0412] (S)-2,4-diamino-6-(l-(5-chloro-6-fluoro-3-(4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 42). 1H NMR (400 MHz, DMSO-d6) δ 8.54 (s, 1H), 8.41 - 8.26 (m, 1H), 7.93 (t, 7 = 9.0 Hz, 1H), 7.84 - 7.66 (m, 1H), 7.19 (dt, 7 = 5.0, 0.7 Hz, 1H), 6.93 (d, 7 = 8.6 Hz, 1H), 6.47 (s, 2H), 5.73 (s, 2H), 5.25 - 4.90 (m, 1H), 2.09 (s, 3H), 1.46 - 1.22 (m, 3H). ES/MS 466.1 (M+H+);
[0413] (S)-2,4-diamino-6-(l-(5-chloro-6-fluoro-3-(4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 43). 1H NMR (400 MHz, DMSO-d6) δ 8.58 - 8.30 (m, 2H), 7.93 (td, 7 = 9.0, 1.3 Hz, 1H), 7.75 (ddd, 7 =
9.0, 5.0, 1.4 Hz, 1H), 7.41 (d, 7 = 5.0 Hz, 1H), 6.94 (d, 7 = 7.4 Hz, 1H), 6.53 (s, 2H), 6.23 (s, 2H), 4.69 (qd, 7 = 7.3, 5.8 Hz, 1H), 2.11 (d, 7 = 1.5 Hz, 3H), 1.26 (dd, 7 = 6.6, 1.5 Hz, 3H). ES/MS 466.1 (M+H+);
[0414] (S)-2,4-diamino-6-(l-(5-chloro-3-(5-fluoro-2-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 44). 1H NMR (400 MHz, DMSO) δ 8.3 (d, 7 = 2.5 Hz, 2H), 8.16 (bs, 1H), 8.04 (dd, 8.8, 2.6 Hz, 1H), 7.83 (t, 7 = 8.24 Hz, 1H), 7.74 (d, 7 = 8.2 Hz, 1H), 7.66 (d, 7 = 7.7 Hz, 1H), 5.25 (m, 1H), 2.20 (s, 3H), 1.40 (d, 7 = 6.5 Hz, 3H). ES/MS 466.1 (M+H+);
[0415] (S)-2,4-diamino-6-(l-(5-chloro-3-(5-fluoro-2-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 45). 1H NMR (400 MHz, DMSO) δ 8.5 (d, 7 = 2.8 Hz, 2H), 7.83 (t, 7 = 8.15 Hz, 1H), 7.7 (dd, 7 = 8.15, 1.3 Hz, 1H), 7.66 (dd, 7 = 8.8, 2.7 Hz, 1H), 7.63 (dd, 7 = 7.8, 1.4 Hz, 1H), 7.38 (m, 1H), 7.2 (ddt, 7 =
8.1 , 6.7, 1.13 Hz, 1H), 7.16 (ddd, 7 = 6.4, 2.0, 1.2 Hz, 1H), 6.90 (bs, 1H), 4.77 (m, 1H), 2.25 (s, 3H), 1.36 (d, 7 = 6.5 Hz, 3H). ES/MS 466.1 (M+H+);
[0416] (S)-2,4-diamino-6-(l-(5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 46). 1H NMR (400 MHz, DMSO) δ 8.60 (s, 1H), 8.45 (s, 1H), 8.33 (bs, 1H), 7.87 (t, 7 = 8.0 Hz, 1H), 7.78 (dd, 7 = 8.2, 1.2 Hz, IH), 7.67 (dd, / = 7.8, 1.2 Hz, IH), 7.31 (bs, IH), 5.30 (m, IH), 2.08 (s, 3H), 1.44 (d, / = 6.5 Hz, 3H). ES/MS 466.8 (M+H+);
[0417] (S)-2,4-diamino-6-(l-(5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 47). IH NMR (400 MHz, DMSO) δ 8.49 (s, IH), 8.32 (s, IH), 7.87 (t, / = 8.0 Hz, 2H), 7.76 (dd, / = 8.2, 1.2 Hz, IH), 7.67 (dd, / = 7.9, 1.25 Hz, IH), 4.86 (m, IH), 2.14 (s, 3H), 1.39 (d, / = 6.67 Hz, 3H). ES/MS 466.8 (M+H+);
[0418] (S)-2,4-Diamino-6-((l-(5-chloro-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile (Compound 48). JH NMR (400 MHz, DMSO-d6) δ 8.80 - 8.36 (m, 2H), 7.94 - 7.38 (m, 3H), 6.94 - 6.63 (m, IH), 6.53 (d, J = 8.1 Hz, 2H), 6.16 (s, 2H), 4.62 (t, J = 7.8 Hz, IH), 2.10 - 1.42 (m, 2H), 1.04 - 0.64 (m, 3H). ES/MS 484.1 (M+H+);
[0419] (S)-2-(l-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-5-(methylsulfonyl)- 3-(pyridin-3-yl)quinazolin-4(3H)-one (Compound 49): *H NMR (400 MHz, DMSO) δ 8.79 - 8.73 (m, IH), 8.69 - 8.63 (m, IH), 8.35 - 8.26 (m, IH), 8.13 - 7.99 (m, 3H), 7.66 - 7.53 (m, IH), 6.34 - 6.28 (m, IH), 5.99 (br s, 2H), 5.54 (br s, IH), 5.48 (br s, IH), 4.71 - 4.60 (m, IH), 3.48 (s, 3H), 1.36 - 1.32 (m, 3H). ES/MS 487.1 (M+H+);
[0420] (S)-2,4-Diamino-6-((l-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethyl)amino)pyrimidine-5-carboxamide (Compound 50). JH NMR (400 MHz, DMSO-i¾) δ 8.71 (dd, J = 27.8, 8.2 Hz, IH), 8.20 - 7.86 (m, IH), 7.76 - 7.42 (m, 2H), 7.02 (d, J = 23.4 Hz, IH), 6.27 (d, J = 7.8 Hz, IH), 5.96 - 5.52 (m, IH), 4.57 (dd, J = 7.5, 6.7 Hz, IH), 4.08 (d, / = 5.2 Hz, IH), 3.13 (d, / = 4.4 Hz, 2H), 1.34 - 1.03 (m, 3H). ES/MS 482.1 (M+H+);
[0421] (S)-5-Chloro-2-(l-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-3-(5- fluoropyridin-3-yl)quinazolin-4(3h)-one (Compound 51). *H NMR (400 MHz, DMSO- ) δ 8.81 - 8.44 (m, 2H), 7.78 - 7.47 (m, 3H), 6.27 (dd, / = 7.5, 5.0 Hz, IH), 5.98 - 5.84 (m, IH), 5.47 (s, IH), 4.87 - 4.36 (m, IH), 1.56 - 1.17 (m, 3H). ES/MS 462.2 (M+H+);
[0422] (S)-2-(l-((2,6-Diamino-5-chloropyrimidin-4-yl)amino)ethyl)-5-fluoro-3-(pyridin- 3-yl)quinazolin-4(3H)-one (Compound 52). *H NMR (400 MHz, DMSO-d6) δ 8.90 - 8.34 (m, 2H), 8.10 - 7.62 (m, 2H), 7.66 - 7.42 (m, IH), 7.29 (dd, / = 11.0, 8.2 Hz, IH), 6.18 (d, J = 110.3 Hz, 2H), 5.59 (s, IH), 4.72 - 4.21 (m, IH), 1.39 - 1.12 (m, 3H). ES/MS 426.9 (M+H+);;
[0423] (S)-5-Chloro-2-(l -((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-3-(pyridin- 3-yl)quinazolin-4(3H)-on (Compound 53). *H NMR (400 MHz, DMSO-d6) δ 8.83 - 8.51 (m, 2H), 8.25 - 7.88 (m, IH), 7.86 - 7.37 (m, 3H), 6.25 (t, / = 8.2 Hz, IH), 5.97 (s, 2H), 5.50 (d, J = 18.3 Hz, 2H), 4.65 - 4.45 (m, IH), 1.27 (dd, / = 6.7, 1.8 Hz, 3H). ES/MS 444.1 (M+H+);
[0424] (S)-2-(l-((2,6-Diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-6-fluoro-4-oxo-3- (pyridin-3-yl)-3,4-dihydroquinazoline-8-carbonitrile (Compound 54): JH NMR (400 MHz, DMSO) δ 8.78 (d, / = 2.4 Hz, 0.5H), 8.59 (m, IH), 8.57 (t, / = 2.8 Hz, 0.5H), 8.51 (dd, / = 4.8, 1.6 Hz, 0.5H), 8.48 (d, / = 2.4 Hz, 0.5H), 8.22 (m, IH), 8.06 (m, 0.5H), 7.88 (bm, 4H), 7.79 (m, 0.5H), 7.58 (dd, / = 8.0, 4.8 Hz, 0.5H), 7.47 (dd, / = 8.0, 4.8 Hz, 0.5H), 5.02 (m, IH), 1.46 (d, / = 6.4 Hz, 3H). ES/MS 443.1 (M+H+);
[0425] (S)-2-(l-((2,6-Diamino-5-cyanopyrimidin-4-yl)amino)propyl)-6-fluoro-3-(5- fluoropyridin-3-yl)-4-oxo-3,4-dihydroquinazoline-8-carbonitrile (Compound 55): JH NMR (400 MHz, DMSO) δ 8.71 (s, IH), 8.64 (d, / = 2.8 Hz, IH), 8.58 (m, 3H), 8.34 (s, IH), 8.23 (m, 2 H), 8.18 (m, IH), 7.84 (bs, IH), 7.71 (m, IH), 4.92 (m, IH), 2.08 (m, IH), 1.88 (m, IH), 0.90 (m, 3H). ES/MS 475.1 (M+H+);
[0426] (S)-2-(Cyclopropyl((2,6-diamino-5-cyanopyrimidin-4-yl)amino)methyl)-6-fluoro- 3-(5-fluoropyridin-3-yl)-4-oxo-3,4-dihydroquinazoline-8-carbonitrile (Compound 56): 1H NMR (400 MHz, DMSO) δ 8.69 (s, 0.5H), 8.60 (m, 1.5H), 8.49 (d, / = 2.4 Hz, 0.5H), 8.23 (m, 1.5H), 8.17 (m, 0.5H), 7.95 (bs, IH), 7.78 (bs, IH), 7.71 (bs, IH), 7.59 (m, 0.5H), 4.60 (m, IH), 1.64 (m, IH), 0.60 (m, IH), 0.50 (m, 2H), 0.29 (m, IH). ES/MS 487.1 (M+H+);
[0427] (S)-2,4-Diamino-6-((l -(5-chloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)-3-methylbutyl)amino)pyrimidine-5-carbonitrile (Compound 57). 1H NMR (400 MHz, DMSO) δ 8.83 - 8.58 (m, 2H), 8.24 (dd, / = 9.3, 2.2 Hz, IH), 8.09 (m, IH), 7.83 - 7.70 (m, IH), 7.70 - 7.49 (m, 2 H), 4.70 (m, IH), 4.01-3.29 (br m, 5H) 1.81 (m, IH), 1.50 (m , 2H), 0.78 (m, 3H), 0.48 - 0.33 (m, 3H). ES/MS 494.2 (M+H+);
[0428] (R)-2,4-Diamino-6-((l-(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 110). 'll NlVIR (400 MHz, DMSO) δ 8.75-8.51 (m, 2H), 8.05-7.89 (m, IH), 7.84 - 7.75 (m, IH), 7.67 - 7.45 (m, 2H), 4.83 (m, IH) 4.42-3.27 (br m, 5H) 1.36 (d, / = 6.6 Hz, 3H). ES/MS 452.1 (M+H+);
[0429] (S)-2,4-Diamino-6-((l -(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)-3-methylbutyl)amino)pyrimidine-5-carbonitrile (Compound 58). 1H NMR (400 MHz, DMSO) δ 8.82 - 8.75 (m, IH), 8.67 (ddd, J = 13.2, 4.8, 1.5 Hz, IH), 8.09 (ddd, J = 8.3, 5.3, 3.3 Hz, IH), 7.78 (td, / = 8.1 , 2.0 Hz, IH), 7.69 - 7.55 (m, 3H), 7.51 -6.88 (br m, 5H) 4.70 (m, IH), 1.83 (d, / = 9.8 Hz, IH), 1.50 - 1.37 (m, 2H), 0.76 (dd, / = 9.3, 5.9 Hz, 3H), 0.37- 0.25 (m, 3H). ES/MS 476.1 (M+H+);
[0430] (R)-2,4-Diamino-6-((l-(5-chloro-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 113). 1H NMR (400 MHz, DMSO) δ 8.68 (m, IH), 8.58-8.42 (m, IH), 8.15-7.81 (m, 2H), 7.66 (d, / = 8.5 Hz, 1 H), 7.56-7.37 (br m, 2H), 7.26-7.00 (br m, 2H), 6.83-6.67 (m, IH) 4.92 (m, IH), 1.39 (m, 3H). ES/MS 470.1 (M+H+);
[0431] (S)-5-Chloro-2-(l -((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-8-fluoro-3- (pyridin-3-yl)quinazolin-4(3h)-one;
[0432] (R)-2,4-Diamino-6-((l-(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile (compound 11 1). 1H NMR (400 MHz, DMSO) δ 8.82 - 8.50 (m, 2H), 8.15 - 7.93 (m, IH), 7.91 - 7.74 (m, 2H), 7.71 - 7.48 (m, 3H), 7.41 (ddd, 7 = 8.6, 7.4, 1.4 Hz, 1 H), 7.28 - 7.12 (m, 2H), 6.79 - 6.69 (m, IH), 4.71 (m, IH), 2.05 - 1.90 (m, IH), 1.90 - 1.74 (m, IH), 0.82 - 0.68 (m, 3H). ES/MS 466.1 (M+H+);
[0433] (R)-2,4-Diamino-6-(((5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile (Compound 112). *H NMR (400 MHz, DMSO) δ 8.78 - 8.32 (m, 2H), 8.12 - 7.88 (m, 5H), 7.82 (m, IH), 7.74 - 7.62 (m, 2H), 7.39 (m, IH), 6.77 - 6.70 (m, IH), 4.54 - 4.42 (m, IH), 1.63 - 1.47 (m, IH), 0.62 - 0.08 (m, 4H). ES/MS 478.1 (M+H+);
[0434] (S)-2,4-diamino-6-((l -(5-bromo-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 60). JH NMR (400 MHz, DMSO- ) δ 8.65 - 8.43 (m, 2H), 8.15 - 8.06 (m, IH), 7.84 - 7.76 (m, IH), 7.68 (t, / = 9.2 Hz, 1H), 6.95 - 6.81 (m, 1H), 6.51 (d, / = 10.8 Hz, 2H), 6.22 (s, 2H), 4.88 - 4.71 (m, 1H), 1.39 - 1.27 (m, 3H). ES/MS 514.0 (M+H+);
[0435] (S)-2,4-diamino-6-((l-(5-bromo-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile (Compound 61). JH NMR (400 MHz, DMSO- ) δ 8.81 - 8.61 (m, 1H), 8.60 - 8.48 (m, 1H), 8.11 - 7.64 (m, 3H), 7.64
- 7.48 (m, 2H), 7.33 (br. s, 4H), 4.76 - 4.58 (m, 1H), 2.05 - 1.69 (m, 2H), 0.84 - 0.66 (m, 3H). ES/MS 510.1 (M+H+);
[0436] (S)-2-(l-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-8-fluoro-3-(5- fluoropyridin-3-yl)-4-oxo-3,4-dihydroquinazoline-5-carbonitrile (Compound 62). JH NMR (400 MHz, DMSO- ) δ 8.73 - 8.45 (m, 2H), 8.24 - 7.83 (m, 3H), 7.83 - 7.01 (br. m, 5H),
5.03 - 4.87 (m, 1H), 1.42 (d, / = 6.6 Hz, 3H). ES/MS 461.1 (M+H+);
[0437] (S)-2-(l-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-4-oxo-3-(pyridin-3- yl)-3,4-dihydroquinazoline-5-carbonitrile (Compound 63). !H NMR (400 MHz, DMSO-d6) δ 8.82 - 8.75 (m, 1H), 8.72 - 8.62 (m, 1H), 8.15 - 7.92 (m, 4H), 7.67 - 7.52 (m, 1H), 6.32 - 6.24 (m, 1H), 6.00 (s, 2H), 5.53 (d, / = 17.8 Hz, 2H), 4.67 - 4.51 (m, 1H), 1.40 - 1.25 (m, 3H). ES/MS 434.1 (M+H+);
[0438] (S)-2,4-diamino-6-((l-(5-bromo-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 64). 1H NMR (400 MHz, DMSO- ) δ 8.77 - 8.64 (m, 1H), 8.64 - 8.51 (m, 1H), 8.08 - 7.89 (m, 1H), 7.85
- 7.76 (m, 1H), 7.69 (t, / = 9.2 Hz, 1H), 7.61 - 7.45 (m, 1H), 6.97 - 6.82 (m, 1H), 6.55 (d, / = 5.4 Hz, 2H), 6.25 (br. d, / = 16.7 Hz, 2H), 4.80 - 4.65 (m, 1H), 1.33 (d, / = 6.6 Hz, 3H). ES/MS 496.1 (M+H+);
[0439] (S)-2,4-Diamino-6-(((5-chloro-8-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-
3.4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile
(Compound 65): *H NMR (400 MHz, DMSO- ) δ 8.55 (m, 1H), 8.38 (m, 1H), 7.82 (dd, J = 9.6, 8.8 Hz, 1H), 7.65 (dd, / = 8.8, 4.5 Hz, 1H), 4.63 (t, / = 8.7 Hz, 1H), 2.01 (s, 3H), 1.63 (m, 1H), 0.61 (m, 1H), 0.41 (m, 2H), 0.30 (m, 1H). ES/MS 510.1 (M+H+);
[0440] (S)-2,4-Diamino-6-(((5-chloro-8-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo- 3,4-dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile
(Compound 66): *H NMR (400 MHz, DMSO- ) δ 8.38 (s, 1H), 8.15 (s, 1H), 7.80 (dd, J = 9.6, 8.8 Hz, IH), 7.65 (dd, 7 = 8.8, 4.5 Hz, IH), 4.24 (t, 7 = 8.34 Hz, IH), 2.09 (s, 3H), 1.59 (m, IH), 0.55 (m, IH), 0.44 (m, 2H), 0.07 (m, IH). ES/MS 510.1 (M+H+);
[0441] (S)-2,4-diamino-6-((l-(5-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 67): 1H NMR (400 MHz, DMSO- ) δ 8.55 (s, IH), 8.39 (s, IH), 7.90 (td, J = 8.2, 8.2, 5.5 Hz, IH), 7.62 (dd, J = 8.3, 1.0 Hz, IH) 7.37 (ddd, 7 = 10.9, 8.2, 1.0 Hz, IH), 5.28 (dd, 7 = 8.6, 6.5 Hz, IH), 2.05 (s, 3H), 1.40 (d, J = 6.5 Hz, 3H). ES/MS 450.1 (M+H+);
[0442] (S)-2,4-diamino-6-((l-(5-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 68): JH NMR (400 MHz, DMSO- ) δ 8.44 (s, IH), 8.31 (s, IH), 7.90 (td, J = 8.2, 8.2, 5.5 Hz, IH), 7.59 (dd, J = 8.2, 1.0 Hz, IH) 7.37 (ddd, 7 = 11.0, 8.3, 1.1 Hz, IH), 4.82 (p, 7 = 6.8, 6.7 Hz, IH), 2.08 (s, 3H), 1.36 (d, J = 6.6 Hz, 3H). S/MS 450.1 (M+H+);
[0443] (S)-2,4-diamino-6-(((5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile (Compound
69) : *H NMR (400 MHz, DMSO-i¾) δ 8.54 (s, IH), 8.38 (s, IH), 7.84 (t, J = 8.0 Hz, IH), 7.75 (d, J = 8.0 Hz, IH), 7.64 (d, 7 = 7.8 Hz, IH), 4.60 (t, 7 = 8.8 Hz, IH), 2.00 (s, 3H), 1.62 (m, IH), 0.61 (m, IH), 0.41 (m, 2H), 0.30 (m, IH) . ES/MS 492.1 (M+H+);
[0444] (S)-2,4-diamino-6-(((5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile (Compound
70) : *H NMR (400 MHz, DMSO-i¾) δ 8.39 (s, IH), 8.16 (s, IH), 7.84 (t, J = 8.0 Hz, IH), 7.75 (dd, J = 8.0, 1.2 Hz, IH), 7.65 (dd, 7 = 7.8, 1.2 Hz, IH), 4.21 (t, 7 = 8.4 Hz, IH), 2.07 (s, 3H), 1.59 (m, IH), 0.57 (m, IH), 0.43 (m, 2H), 0.02 (m, IH) . ES/MS 492.1 (M+H+);
[0445] (S)-2,4-diamino-6-((l-(5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile (Compound 71): 1H NMR (400 MHz, DMSO- ) δ 8.56 (s, IH), 8.42 (s, IH), 7.83 (t, J = 8.0 Hz, IH), 7.73 (dd, J = 8.1, 1.3 Hz, IH), 7.63 (dd, 7 = 7.8, 1.3 Hz, IH), 5.09 (q, 7 = 7.8 Hz, IH), 2.13 (dt, J = 13.9, 7.0 Hz, IH), 2.00 (s, 3H), 1.79 (dt, J = 14.5, 7.5 Hz, IH), 0.82 (t, J = 7.4 Hz, IH). ES/MS 480.1 (M+H+);
[0446] (S)-2,4-diamino-6-((l-(5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile (Compound 72): 1H NMR (400 MHz, DMSO- ) δ 8.44 (s, IH), 8.23 (s, IH), 7.83 (t, J = 8.0 Hz, IH), 7.73 (d, J = 8.0 Hz, IH), 7.63 (d, 7 = 8.0 Hz, IH), 4.63 (q, 7 = 7.1 Hz, IH), 2.1 (s, 3H), 2.04 (dq, J = 13.9, 7.0 Hz, IH), 1.67 (dp, J = 14.3, 7.4, 7.2 Hz, IH), 0.80 (t, J = 7.3 Hz, IH). ES/MS 480.1 (M+H+);
[0447] (S)-2,4-diamino-6-((l-(5-chloro-8-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4- oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 73): 1H NMR (400 MHz, DMSO- ) 58.57 (s, IH), 8.42 (s, IH), 7.82 (dd, J = 9.6, 8.8 Hz, IH), 7.65 (dd, 7 = 8.8, 4.5 Hz, IH), 5.28 (m, IH), 2.05 (s, 3H), 1.42 (d, J = 6.5 Hz, 3H). ES/MS 484.1 (M+H+);
[0448] (S)-2,4-diamino-6-((l-(5-chloro-8-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4- oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 74): 1H NMR (400 MHz, DMSO- ) δ 8.45 (s, IH), 8.28 (s, IH), 7.81 (dd, J = 9.6, 8.8 Hz, IH), 7.65 (dd, 7 = 8.8, 4.5 Hz, IH), 4.83 (m, IH), 2.12 (s, 3H), 1.36 (d, J = 6.6 Hz, 3H). ES/MS 484.1 (M+H+);
[0449] (S)-2,4-diamino-6-((l-(6-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 75): 1H NMR (400 MHz, DMSO-i¾) δ 8.57 (s, IH), 8.41 (s, IH), 7.9-7.8 (m, 3H), 5.32 (m, IH), 2.03 (s, 3H), 1.42 (d, J = 6.5 Hz, 3H). ES/MS 450.1 (M+H+);
[0450] (S)-2,4-diamino-6-((l-(6-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 76): 1H NMR (400 MHz, DMSO- ) δ 8.45 (s, IH), 8.29 (s, IH), 7.9-7.8 (m, 3H), 4.86 (m, IH), 2.08 (s, 3H), 1.37 (d, J = 6.6 Hz, 3H). ES/MS 450.1 (M+H+);
[0451] (S)-2,4-diamino-6-((l-(5-chloro-3-(4,5-dimethylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 77): JH NMR (400 MHz, DMSO- ) δ 8.57 (s, IH), 8.29 (s, IH), 7.83 (t, J = 8.2 Hz, IH), 7.74 (dd, J = 8.2, 1.3 Hz, IH) 7.62 (dd, 7 = 7.8, 1.3 Hz, IH), 5.28 (m, IH), 2.12 (s, 3H), 2.03 (s, 3H), 1.40 (d, J = 6.5 Hz, 3H). ES/MS 462.1 (M+H+);
[0452] (S)-2,4-diamino-6-((l-(5-chloro-3-(4,5-dimethylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 78): JH NMR (400 MHz, DMSO- ) δ 8.24 (s, IH), 8.21 (s, IH), 7.82 (t, J = 8.2 Hz, IH), 7.71 (dd, J = 8.2, 1.2 Hz, 1H) 7.62 (dd, / = 7.8, 1.2 Hz, 1H), 4.83 (m, 1H), 2.30 (s, 3H), 2.05 (s, 3H), 1.33 (d, J = 6.6 Hz, 3H). ES/MS 462.1 (M+H+);
[0453] (S)-2,4-Diamino-6-((l-(3-(4-methylpyridin-3-yl)-4-oxo-5-(trifluoromethyl)-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 79). 1H NMR (400 MHz, DMSO-d6) δ 8.57 (d, J = 0.9 Hz, 1H), 8.33 (dd, J = 4.9, 1.0 Hz, 1H), 8.17 - 7.90 (m, 3H), 7.36 - 7.07 (m, 1H), 6.97 (d, J = 8.7 Hz, 1H), 6.46 (s, 2H), 5.31 - 4.94 (m, 1H), 2.07 (s, 3H), 1.37 (d, J = 6.4 Hz, 3H). ES/MS 482.2 (M+H+);
[0454] (S)-2,4-Diamino-6-((l-(3-(4-methylpyridin-3-yl)-4-oxo-5-(trifluoromethyl)-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 80). JH NMR (400 MHz, DMSO-d6) δ 8.52 (s, 1H), 8.41 (d, J = 5.0 Hz, 1H), 7.42 (dt, J = 5.1, 0.7 Hz, 1H), 6.98 (d, J = 7.1 Hz, 1H), 6.52 (s, 2H), 4.74 (p, J = 6.7 Hz, 1H), 2.08 (s, 3H), 1.27 (d, J = 6.7 Hz, 3H). ES/MS 482.2 (M+H+);
[00432] (S)-3-(6-aminopyridin-3-yl)-8-chloro-2-(l-((2,6-diamino-5-chloropyrimidin- 4-yl)amino)ethyl)-6-fluoroquinazolin-4(3H)-one (Compound 81). *H NMR (400 MHz, DMSO-i¾) δ 8.11 (dt, / = 9.6, 3.2 Hz, 1H), 8.06 - 7.96 (m, 1H), 7.80 (dd, / = 8.0, 2.9 Hz, 1H), 7.53 (ddd, / = 8.6, 5.3, 2.8 Hz, 1H), 6.59 (dd, / = 8.7, 6.1 Hz, 1H), 6.39 (d, / = 9.0 Hz, 2H), 6.03 (d, / = 7.2 Hz, 2H), 5.62 (d, / = 12.1 Hz, 2H), 4.79 (dt, / = 30.2, 7.2 Hz, 1H), 1.36 - 1.21 (m, 3H). ES/MS 476.1 (M+H+);
[00433] (S)-2,4-diamino-6-((l-(3-(6-aminopyridin-3-yl)-8-chloro-6-fluoro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 82). 1H NMR (400 MHz, DMSO- ) δ 8.12 (dt, / = 8.7, 2.3 Hz, 1H), 8.01 (dd, / = 21.8, 2.6 Hz, 1H), 7.81 (dd, / = 8.3, 3.0 Hz, 1H), 7.51 (ddd, / = 9.0, 6.3, 2.7 Hz, 1H), 6.89 (dd, / = 42.5, 6.9 Hz, 2H), 6.62 - 6.52 (m, 2H), 6.37 (d, / = 6.6 Hz, 3H), 4.86 (dt, / = 23.9, 6.6 Hz, 1H), 1.38 - 1.21 (m, 3H). ES/MS 467.1 (M+H+);
[00434] (S)-3-(6-aminopyridin-3-yl)-5,8-dichloro-2-(l-((2,6-diamino-5- chloropyrimidin-4-yl)amino)ethyl)quinazolin-4(3H)-one (Compound 83). *H NMR (400 MHz, DMSO-i¾) δ 8.05 - 7.92 (m, 1H), 7.54 (ddt, / = 11.5, 8.0, 3.4 Hz, 1H), 6.69 - 6.47 (m, 1H), 6.39 (dd, / = 8.4, 4.1 Hz, 1H), 6.02 (d, / = 6.5 Hz, 1H), 5.62 (d, / = 10.2 Hz, 1H), 4.74 (dt, / = 33.1, 7.0 Hz, 1H), 2.54 (s, 2H), 1.35 - 1.21 (m, 3H). ES/MS 492.1 (M+H+); [00435] (S)-2,4-diamino-6-((l-(3-(6-aminopyridin-3-yl)-5,8-dichloro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 84). JH NMR (400 MHz, DMSO- ) δ 8.06 - 7.90 (m, 2H), 7.60 - 7.47 (m, 2H), 6.88 (dd, / = 44.9, 6.9 Hz, 2H), 6.63 - 6.52 (m, 2H), 6.37 (d, / = 8.0 Hz, 3H), 4.83 (dq, / = 26.5, 6.7 Hz, 1H), 1.38 - 1.21 (m, 3H). ES/MS 483.1 (M+H+);
[00436] (S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(l-((2,6-diamino-5-chloropyrimidin- 4-yl)amino)ethyl)quinazolin-4(3H)-one (Compound 85). *H NMR (400 MHz, DMSO-i¾) δ 8.01 (dt, 7 = 39.3, 2.5 Hz, 2H), 7.79 - 7.67 (m, 1H), 7.64 - 7.47 (m, 4H), 6.58 (ddd, / = 11.5, 8.8, 2.0 Hz, 1H), 6.38 - 6.21 (m, 3H), 6.02 (d, J = 8.8 Hz, 1H), 5.56 (d, 7 = 13.9 Hz, 1H), 4.81 - 4.49 (m, 1H), 1.31 (ddd, / = 12.4, 7.1 , 2.2 Hz, 3H). ES/MS 458.1 (M+H+);
[00437] (S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(l-((2,6-diamino-5-chloropyrimidin- 4-yl)amino)propyl)quinazolin-4(3H)-one (Compound 86). *H NMR (400 MHz, DMSO-i¾) δ 8.16 - 7.89 (m, 1H), 7.73 (td, / = 8.0, 2.7 Hz, 1H), 7.62 - 7.47 (m, 4H), 6.61 (ddd, / = 19.4, 8.8, 0.8 Hz, 1H), 6.35 (d, / = 1 1.5 Hz, 1H), 6.18 - 6.01 (m, 3H), 5.56 (d, J = 15.9 Hz, 1H), 4.59 (dtd, J = 35.7, 8.3, 3.6 Hz, 1H), 1.86 - 1.58 (m, 2H), 0.76 - 0.68 (m, 3H). ES/MS 472.1 (M+H+);
[00438] (S)-2,4-diamino-6-((l-(3-(6-aminopyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile (Compound 87). 1H NMR (400 MHz, DMSO- ) δ 8.19 - 7.89 (m, 1H), 7.76 (td, / = 8.0, 2.4 Hz, 1H), 7.65 - 7.45 (m, 2H), 6.91 - 6.50 (m, 3H), 6.37 (s, 3H), 4.66 (dtd, / = 30.1 , 7.7, 3.9 Hz, 1H), 1.93 - 1.59 (m, 2H), 0.71 (td, / = 7.3, 4.8 Hz, 3H). ES/MS 463.1 (M+H+);
[00439] (S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(l-((2,6-diamino-5-chloropyrimidin- 4-yl)amino)ethyl)-8-fluoroquinazolin-4(3H)-one (Compound 88). *H NMR (400 MHz, DMSO-i¾) δ 8.01 (d, J = 37.3 Hz, 1H), 7.70 (t, J = 9.3 Hz, 1H), 7.68 - 7.35 (m, 1H), 6.58 (t, / = 8.4 Hz, 2H), 6.49 - 6.20 (m, 1H), 6.01 (s, 1H), 5.57 (d, / = 12.7 Hz, 2H), 4.73 (s, 1H), 1.42 - 1.11 (m, 3H). ES/MS 476.1 (M+H+);
[00440] (S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(cyclopropyl((2,6-diamino-5- chloropyrimidin-4-yl)amino)methyl)quinazolin-4(3H)-one (Compound 89). *H NMR (400 MHz, DMSO-i¾) δ 8.08 - 7.88 (m, 1H), 7.83 - 7.68 (m, 1H), 7.69 - 7.40 (m, 2H), 6.59 (dd, J = 8.6, 3.1 Hz, 1H), 6.46 - 6.27 (m, 1H), 6.16 - 5.86 (m, 2H), 5.57 (d, 7 = 6.6 Hz, 1H), 4.67 (q, 7 = 8.1 Hz, 1H), 1.21 (d, 7 = 22.0 Hz, 2H), 0.54 - 0.34 (m, 2H), 0.34 - 0.19 (m, 1H). ES/MS 484.1 (M+H+);
[00441] (S)-2,4-diamino-6-(((3-(6-aminopyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile (Compound 90). *H NMR (400 MHz, DMSO-i¾) δ 8.01 - 7.91 (m, 1H), 7.78 (td, 7 = 8.0, 2.0 Hz, 1H), 7.66 - 7.54 (m, 2H), 7.48 (dd, 7 = 8.9, 3.0 Hz, 1H), 6.66 (d, 7 = 9.5 Hz, 2H), 6.56 (dd, 7 = 12.7, 8.7 Hz, 2H), 6.35 (s, 2H), 4.70 (dt, 7 = 10.0, 7.3 Hz, 1H), 1.22 (d, 7 = 11.5 Hz, 1H), 0.45 - 0.37 (m, 2H), 0.18 - 0.02 (m, 2H). ES/MS 475.1 (M+H+);
[00442] (S)-2,4-diamino-6-((l-(3-(6-amino-4-methylpyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile (Compound 91): JH NMR (400 MHz, DMSO- ) δ 7.87 (s, 1H), 7.80 (t, 7 = 8.0 Hz, 1H), 7.61 (ddd, 7 = 17.6, 7.9, 1.3 Hz, 1H), 6.67 (s, 1H), 6.49 - 6.41 (m, 2H), 6.21 (s, 1H), 4.82 (td, 7 = 8.2, 4.2 Hz, 1H), 1.90 (s, 3H), 1.67 (dp, 7 = 14.4, 7.2 Hz, 1H), 1.25 (dd, 7 = 11.4, 5.0 Hz, 1H), 0.74 (t, 7 = 7.3 Hz, 3H). ES/MS 477.1 (M+H+);
[00443] (S)-2,4-diamino-6-((l-(3-(6-amino-4-methylpyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile (Compound 92): 1H NMR (400 MHz, DMSO- ) δ 7.94 (s, 1H), 7.80 (t, 7 = 8.0 Hz, 1H), 7.61 (ddd, 7 = 16.0, 8.0, 1.2 Hz, 2H), 6.86 (d, 7 = 7.0 Hz, 1H), 6.63 (s, 2H), 6.45 (s, 1H), 6.35 (s, 2H), 6.27 (s, 2H), 4.78 (td, 7 = 6.8, 4.8 Hz, 1H), 1.94 (s, 3H), 1.84 - 1.69 (m, 1H), 1.60 (dp, 7 = 13.7, 7.0 Hz, 1H), 0.73 (t, 7 = 7.3 Hz, 3H). ES/MS 477.1 (M+H+);
[00444] (S)-2,4-diamino-6-((l-(3-(6-amino-4-methylpyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 93): JH NMR (400 MHz, DMSO- ) δ 7.98 (s, 1H), 7.79 (t, 7 = 8.0 Hz, 1H), 7.60 (ddd, 7 = 13.9, 8.1, 1.2 Hz, 2H), 6.99 (d, 7 = 6.6 Hz, 1H), 6.62 (s, 2H), 6.43 (s, 1H), 6.37 (s, 2H), 6.22 (s, 2H), 4.83 (p, 7 = 6.6 Hz, 1H), 1.93 (s, 3H), 1.24 (d, 7 = 6.7 Hz, 3H). ES/MS 463.1 (M+H+);
[00445] (S)-2,4-diamino-6-((l-(3-(6-amino-4-methylpyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 94): JH NMR (400 MHz, DMSO- ) δ 7.98 (s, 1H), 7.80 (dd, 7 = 7.8 Hz, 1H), 7.66 - 7.55 (m, 2H), 6.98 (d, 7 = 6.6 Hz, 1H), 6.61 (s, 2H), 6.43 (t, 7 = 0.8 Hz, 1H), 6.37 (s, 2H), 6.22 (s, 2H), 4.83 (p, 7 = 6.6 Hz, 1H), 1.93 (d, 7 = 0.7 Hz, 3H), 1.24 (d, 7 = 6.7 Hz, 3H). ES/MS 463.1 (M+H+); [00446] (S)-2,4-diamino-6-((l-(3-(6-amino-4-methylpyridin-3-yl)-5,8-dichloro-4-oxo- 3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 95): JH NMR (400 MHz, DMSO- ) δ 8.13 (s, 1H), 8.04 (d, / = 8.5 Hz, 1H), 7.62 (d, / = 8.5 Hz, 2H), 7.32 (s, 1H), 6.83 (s, 1H), 6.58 (s, 1H), 6.5 (s, 1H), 5.39 (q, / = 7.1, 6.6 Hz, 1H), 2.05 (s, 3H), 1.45 (d, / = 6.5 Hz, 3H). ES/MS 498.1 (M+H+);
[00447] (S)-2,4-diamino-6-((l-(3-(6-amino-4-methylpyridin-3-yl)-5,8-dichloro-4-oxo- 3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 96): 1H NMR (400 MHz, DMSO- ) δ 8.05 (d, / = 8.5 Hz, 1H), 7.92 (s, 1H), 7.65 (d, / = 8.5 Hz, 1H), 6.84 (s, 1H), 4.98 (p, / = 6.7 Hz, 1H), 2.12 (s, 3H), 1.39 (d, / = 6.6 Hz, 3H). ES/MS 498.1 (M+H+);
[00448] (S)-2,4-diamino-6-((l-(3-(6-aminopyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 97): JH NMR (400 MHz, DMSO-i¾) δ 8.09 - 8.03 (m, 0.5H), 7.98 - 7.92 (m, 0.5H), 7.77 (td, / = 8.0, 2.3 Hz, 1H), 7.58 (ddt, / = 12.1, 7.9, 1.3 Hz, 1H), 6.89 (d, / = 6.8 Hz, 0.5H), 6.81 (d, / = 6.9 Hz, 0.5H), 6.64 - 6.52 (m, 2H), 6.33 (d, / = 7.1 Hz, 2H), 4.73 (dp, / = 30.3, 6.7 Hz, 1H), 1.32 (dd, / = 14.1, 6.7 Hz, 3H). ES/MS 449.1 (M+H+);
[00449] (S)-2,4-diamino-6-(((3-(6-amino-4-methylpyridin-3-yl)-5,8-dichloro-4-oxo- 3,4-dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile
(Compound 98): *H NMR (400 MHz, DMSO- ) δ 7.99 (d, / = 8.5 Hz, 1H), 7.87 (s, 1H), 7.58 (d, / = 8.5 Hz, 1H), 6.66 (s, 2H), 6.43 (ddd, / = 8.4, 1.9, 1.2 Hz, 1H), 6.22 (s, 2H), 4.95 (dd, / = 8.6, 6.2 Hz, 1H), 1.86 (d, / = 0.8 Hz, 3H), 1.36 - 1.21 (m, 1H), 0.47 - 0.32 (m, 3H), 0.18 - 0.06 (m, 1H). ES/MS 524.1 (M+H+);
[00450] (S)-2,4-diamino-6-(((3-(6-amino-4-methylpyridin-3-yl)-5,8-dichloro-4-oxo- 3,4-dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile
(Compound 99): *H NMR (400 MHz, DMSO- ) δ 8.06 (d, / = 8.5 Hz, 1H), 7.84 (s, 1H), 7.77 (s, 1H), 7.65 (d, / = 8.5 Hz, 1H), 7.58 (s, 1H), 6.88 (s, 1H), 4.49 (t, / = 8.1 Hz, 1H), 2.11 (s, 3H), 1.56 (tq, / = 8.3, 5.2, 4.3 Hz, 1H), 0.63 - 0.40 (m, 3H), 0.14 - 0.03 (m, 1H). ES/MS 524.1 (M+H+);
[00451] (S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(l-((2,6-diamino-5-chloropyrimidin- 4-yl)amino)ethyl)-6-fluoroquinazolin-4(3H)-one (Compound 100). !H NMR (400 MHz, DMSO-i¾) δ 8.01 (m, 1H), 7.93 - 7.82 (m, 1H), 7.72 - 7.46 (m, 2H), 6.58 (m, 1H), 6.35 (d, / = 8.4 Hz, 2H), 6.25 (dd, / = 21.7, 7.5 Hz, 2H), 6.02 (d, / = 7.5 Hz, 2H), 5.56 (d, / = 14.0 Hz, 2H), 4.81 - 4.55 (m, 1H), 1.30 (m, 3H). ES/MS 536.1 (M+H+);
[00452] (S)-2,4-diamino-6-((l-(3-(6-aminopyridin-3-yl)-5-chloro-6-fluoro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 101). 'll NMR (400 MHz, DMSO- ) δ 8.42 - 7.84 (m, 3H), 7.84 - 7.46 (m, 3H), 7.75 - 7.50 (m, 4H), 7.01
- 6.63 (m, 1H), 5.00 (m, 1H), 1.38 (dd, / = 19.7, 6.6 Hz, 3H). ES/MS 467.1 (M+H+);
[00453] (S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(l-((2,6-diamino-5-chloropyrimidin- 4-yl)amino)butyl)quinazolin-4(3H)-one (Compound 102). *H NMR (400 MHz, DMSO-i¾) δ 8.02 (ddd, J = 52.2, 2.7, 0.7 Hz, 1H), 7.87 - 7.41 (m, 3H), 6.61 (ddd, J = 27.6, 8.7, 0.7 Hz, 1H), 6.49 - 5.85 (m, 4H), 5.53 (d, / = 21.9 Hz, 1H), 4.69 (dtd, / = 45.0, 8.8, 3.3 Hz, 1H), 2.01 - 1.55 (m, 2H), 1.35 - 0.77 (m, 2H), 0.61 (dt, / = 20.1, 7.4 Hz, 3H). ES/MS 486.1 (M+H+);
[00454] (S)-2,4-diamino-6-((l-(3-(6-aminopyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)butyl)amino)pyrimidine-5-carbonitrile (Compound 103). 'll NlVIR (400 MHz, DMSO- ) δ 8.21 - 7.87 (m, 1H), 7.82 - 7.19 (m, 3H), 6.95 - 6.46 (m, 3H), 6.32 (d, J = 6.8 Hz, 4H), 5.08 - 4.39 (m, 1H), 1.71 (dd, J = 40.5, 13.9 Hz, 2H), 1.40 - 0.94 (m, 2H), 0.80 - 0.38 (m, 3H). ES/MS 477.1 (M+H+);
[00455] (S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(l-((2,6-diamino-5-chloropyrimidin- 4-yl)amino)butyl)-6-fluoroquinazolin-4(3H)-one (Compound 104). *H NMR (400 MHz, DMSO-i¾) δ 8.09 (dd, J = 2.1, 0.7 Hz, 1H), 7.85 (td, / = 9.0, 3.2 Hz, 1H), 7.72 - 7.37 (m, 3H), 6.62 (ddd, / = 27.1, 8.7, 0.7 Hz, 1H), 6.34 (d, / = 8.8 Hz, 2H), 6.16 - 5.84 (m, 4H), 5.53 (d, / = 21.7 Hz, 2H), 4.69 (dtd, / = 44.3, 9.0, 3.2 Hz, 1H), 1.68 (m, 2H), 1.43 - 0.87 (m, 2H), 0.61 (dt, / = 20.1, 7.4 Hz, 3H). ES/MS 504.1 (M+H+);
[00456] (S)-2,4-diamino-6-((l-(3-(6-aminopyridin-3-yl)-5-chloro-6-fluoro-4-oxo-3,4- dihydroquinazolin-2-yl)butyl)amino)pyrimidine-5-carbonitrile (Compound 105). 'll NlVIR (400 MHz, DMSO- ) δ 8.03 (dd, / = 57.4, 2.5 Hz, 1H), 7.93 - 7.34 (m, 3H), 6.88 - 6.42 (m, 3H), 6.33 (d, / = 23.6 Hz, 3H), 4.74 (m, 1H), 1.82 - 1.54 (m, 2H), 1.43 - 0.87 (m, 2H), 0.74
- 0.45 (m, 3H). ES/MS 495.1 (M+H+); [00457] (S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(cyclopropyl((2,6-diamino-5- chloropyrimidin-4-yl)amino)methyl)-8-fluoroquinazolin-4(3H)-one (Compound 106). *H NMR (400 MHz, DMSO- ) δ 8.10 (s, IH), 7.89 - 7.57 (m, 2H), 7.60 - 7.12 (m, 3H), 6.61 (s, IH), 4.57 (s, IH), 1.49 (d, 7 = 22.8 Hz, IH), 1.37 - 1.01 (m, 3H), 0.45 (s, 2H), 0.18 (d, / = 21.1 Hz, IH). ES/MS 502.1 (M+H+);
[00458] (S)-2,4-diamino-6-(((3-(6-aminopyridin-3-yl)-5-chloro-8-fluoro-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile (Compound 107). *H NMR (400 MHz, DMSO-i¾) δ 7.96 (dd, J = 20.6, 2.6 Hz, IH), 7.80 - 7.64 (m, IH), 7.67 - 7.36 (m, 2H), 6.65 (d, / = 7.5 Hz, 2H), 6.62 - 6.24 (m, 6H), 4.72 (dt, / = 10.3, 7.2 Hz, IH), 1.24 (tt, / = 12.5, 5.8 Hz, IH), 0.50 - 0.25 (m, 3H), 0.15 - 0.03 (m, IH). ES/MS 493.1 (M+H+);
[00459] (S)-2,4-diamino-6-((l-(3-(5-aminopyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 108). Exists as a -11 mixture of diastereomers. IH NMR (400 MHz, DMSO-d6) δ 7.97 - 7.90 (m, 1.5H), 7.85 (d, J = 2.0 Hz, 0.5H), 7.78 (td, J = 8.0, 2.4 Hz, IH), 7.66 - 7.56 (m, 2H), 7.24 (s, 0.5H), 7.11 (s, 0.5H), 4.91 (p, J = 7.3 Hz, 0.5H), 4.80 (p, J = 6.8 Hz, 0.5H), 1.34 (dd, J = 6.7, 1.4 Hz, 3H). ES/MS 449.1 (M+H+); and
[00460] (S)-4-amino-6-((l-(3-(5-aminopyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 109). Exists as a ~11 mixture of diastereomers. IH NMR (400 MHz, DMSO-d6) δ 8.09 (s, 0.5H), 8.00 (d, J = 2.5 Hz, 0.5H), 7.94 (s, 0.5H), 7.89 (d, J = 2.4 Hz, 0.5H), 7.87 (s, 0.5H), 7.77 (td, J = 8.0, 2.5 Hz, IH), 7.72 (d, J = 6.9 Hz, 0.5H), 7.67 - 7.55 (m, 2.5H), 7.44 (s, 0.5H), 7.32 (d, J = 14.0 Hz, 2.5H), 4.87 (p, J = 7.1 Hz, 0.5H), 4.81 (p, J = 6.7 Hz, 0.5H), 1.37 (dd, J = 6.7, 3.1 Hz, 3H).. ES/MS 434.1 (M+H+).
C. Preparation of a Compound of Formula (I) wherein n is 2, R1 is cyano, Rl is fluoro, m is 0, R3 is cyclopropyl, and R4 is chloro
Figure imgf000109_0001
[0461] (S)-5-chloro-2-(l-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-8-fluoro-3- (pyridin-3-yl)quinazolin-4(3H)-one (141 mg, 0.3 mmol), Zn(CN)2 (40 mg, 0.35 mmol), and Pd(PPh3)4 (34 mg, 0.03 mmol) were dissolved in NMP (3 mL). Argon was bubbled through (1 min.) and then heated to 120°C using microwave for lh. The reaction mixture was purified by HPLC to give (S)-2-(cyclopropyl((2,6-diamino-5-chloropyrimidin-4- yl)amino)methyl)-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazoline-5-carbonitrile (Compound 59). 1H NMR (400 MHz, DMSO-d6) δ 8.80 - 8.54 (m, 1H), 8.51 - 8.31 (m, 1H), 8.19 (ddd, J = 8.5, 4.5, 1.5 Hz, 1H), 8.09 - 7.89 (m, 2H), 7.83 - 7.50 (m, 5H), 7.46 - 7.26 (m, 2H), 4.48 (dt, J = 14.0, 8.2 Hz, 1H), 1.66 - 1.48 (m, 1H), 0.63 - 0.38 (m, 3H), 0.16 (ddt, J = 15.4, 9.2, 4.4 Hz, 1H). ES/MS 478.1 (M+H+).
Example 5
Characterization of Compounds of Formula (I)
[0462] This Example characterizes the biological activity of the compounds of formula (I) and further compares with Compounds X, Y and Z having the following structures:
Figure imgf000109_0002
Compound X Compound Y Compound Z
[0463] Enzymatic activity of PI3K isoforms was measured to determine the inhibitory activities to the PI3K isoforms selectivity of the compounds tested, including the activities against PI3K5. A cellular assay measuring the inhibition of basophil activation was used to assess the potency of the compounds in a cellular assay. Stability in human hepatocytes was also measured to assess the half-life of the tested compounds in human subjects. i. Enzymatic activity ofPI3K isoforms
[0464] Enzymatic activity of the class I PI3K isoforms in the presence of the compounds of Table 1 and Compounds X, Y and Z was measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. The TR-FRET assay was used to monitor formation of the product 3,4,5-inositol triphosphate molecule (PIP3) as it competed with fluorescently labeled PIP3 for binding to the GRP- 1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product results in a decrease in TR-FRET signal as the labeled fluorophore is displaced from the GRP- 1 protein binding site.
[0465] Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2 X Km ATP (75-500 μΜ), 2 μΜ PIP2, 5% glycerol, 5 mM MgC12, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1 % (v/v) DMSO at the following concentrations for each isoforms: ΡΙ3Κα, ΡΙ3Κβ, and PI3K5 between 25 and 50 pM, and ΡΙ3Κγ at 2 nM. After an assay reaction time of 30 minutes at 25°C, reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled- PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100μ8 delay and 500 μ8 read window).
[0466] Data were normalized based on positive (ΙμΜ wortmanin) and negative (DMSO) controls, α, β, δ, and γ ICso values were calculated from the fit of the dose-response curves to a four-parameter equation. All IC50 values represent geometric mean values if more than one value was obtained. IC50 values were reported in units of nM.
[0467] Table 2 below summarizes the IC50 values (nM) that were collected for PI3K5 for compounds in the Example. Table 2a summarizes the IC50 (nM) values for ΡΙ3Κβ and half life (hours) values in cryopreserved human hepatocytes. Table 2. The PI3K5 IC50 Values for Representive Compounds
Figure imgf000111_0001
43 4 100 48
44 34 101 8
45 6 102 15
46 38 103 1
47 0.5 104 94
48 4 105 9
49 67 106 31
50 2 107 1
51 7 108 0.6
52 63 109 2
53 4 110 61
54 10 111 9
55 60 112 7
56 30 113 620
57 14 114 220
58 14 115 4
Table 2a. The ΡΙ3Κβ ICso and the Half-Life Values for Representive Compounds
Figure imgf000112_0001
ND: not determined. ii. Activity on Basophils
[0468] Effect on basophil activation was measured in human whole blood using the Flow2 CAST® kit (Buhlmann Laboratories AG, Baselstrasse, Switzerland) following the protocol provided by the manufacturer with minor modifications. Human whole blood was collected into K2-EDTA venipuncture tubes. Whole blood samples were treated with either DMSO (0.3% final) or a serial dilution of compounds in DMSO for 60 minutes at 37°C. Basophils were then activated either with anti-FceRI mAb or with fMLP. To activate basophils using the anti-FceRI mAb; 50 μL· of whole blood was mixed with 110 of stimulation buffer (B-BAT-STB) and 20 μΐ of anti-FceRI (B-BAT-STCON). To activate basophils with fMLP; 50 μL· of whole blood was mixed with 80 μL· of stimulation buffer (B- BAT-STB) and 50 μΐ. of fMLP (B-CCR-FMLP). Stimulation buffer was used as a negative control. 20 μL· of the staining reagent (combination of anti-human CD63-FITC and anti- human CCR3-PE mAbs) was then added to each tube. The tubes were mixed gently and incubated for 25 minutes at 37°C. Subsequently, erythrocytes were lysed and fixed by the addition of 2 mL of lysing solution (B-BAT-LYR) for 10 minutes at room temperature. Cells were pelleted by centrifugation at 1200 rpm for 10 minutes at room temperature in a swing- out rotor. Supernatant was aspirated and cell pellet resuspended in 400 μL· of wash buffer. Flow cytometric analysis of the basophil activation was performed on a FC500MPL flow cytometer (Beckman Coulter Inc., Fullerton, CA). CCR3-staining and side scatter were applied to gate at least 200 basophils that expressed a high density of CCR3. The percent CD63 positive cells within the gated basophil population were determined in different treatment groups and normalized to the vehicle control (0.3% DMSO) with anti-FceRI mAb of fMLP stimulus as 100%. Final compound concentration was adjusted to correct for dilution effect of added reagents. The EC50 values were calculated from the analysis of the dose-response curves to a four-parameter equation. All EC50 values represented geometric mean values and were reported in units of nM. Table 3 below summarizes the EC50 data collected in the Example.
Hi. Hepatocyte stability
[0469] This assay was used to evaluate the metabolic stability of test articles (TA) following incubation in cryopreserved hepatocytes by monitoring parent drug disappearance via LC/MC. The TA was incubated with 1 million hepatocytes/mL at 2 μΜ substrate in duplicate. The incubation was carried out at 37°C with 5% C02 and saturating humidity. Samples were taken at 0, 1 , 2, and 4 hours to monitor the disappearance of TA and a half-life (t 2) was determined. Table 3 below summarizes the human hepatocyte t 2 values (hours) collected in the Example. [0470] The symbols used in Table 3 below are as follows:
#### =<1 nM *=<1 h
### =>1 nM AND <10 nM **>lAND<3h
## =>10 nM AND <50 nM ***=>3 AND <6 h
#=>50nM ****=>6 AND<10h
*****_->1Q
Table 3. The EC50 and the Half-Life Values for Representative Compounds
Figure imgf000114_0001
44 ND ND ND ND
45 ### 7 4
46 ND ND # ## # 8
47 #### 0.4 ***** >10
ND: not determined.
[0471] The results from the above Example indicate that certain compounds of formula (I) have greater stability in human hepatocytes and longer half-life compared to compounds X, Y and Z. By way of example, Table 4 below summarizes the ti/2 and EC50 values of compounds 1 , X, Y and Z.
Table 4. The Comparisons of the EC50 And the Half-Life Values.
Figure imgf000115_0001

Claims

CLAIMS is claimed is:
A compound having the structure of formula (I)
Figure imgf000116_0001
or a pharmaceutically acceptable salt, isomer, or a mixture thereof, wherein:
n is 0, 1, 2, 3, or 4;
each R1 is independently selected from halo, cyano, alkyl, or alkylsulfonyl, wherein the alkyl moiety may be optionally substituted with 1 to 3 halogen;
m is 0, 1, 2, or 3;
each R2 is independently selected from halo, -NH2, alkoxy, alkyl, or cycloalkyl, wherein the alkyl moiety may be optionally substituted with 1 to 3 halogen;
R3 is hydrogen, alkyl, or cycloalkyl, wherein the alkyl moiety may be optionally substituted with cycloalkyl; and
R4 is cyano, halo, or CONH2.
2. The compound of claim 1 , wherein
n is 1 or 2;
each R1 is independently selected from halo, cyano, alkyl, or alkylsulfonyl, wherein the alkyl moiety may be optionally substituted with 1 to 3 halogen;
m is 0, 1, or 2;
each R2 is independently selected from halo, alkoxy, alkyl, or cycloalkyl, wherein the alkyl moiety may be optionally substituted with 1 to 3 halogen;
R3 is hydrogen, alkyl, or cycloalkyl, wherein the alkyl moiety may be optionally substituted with cycloalkyl; and
R4 is cyano.
3. The compound of any of claims 1-2, wherein each R1 is independently selected from halo, cyano, Ci-4alkyl, Ci-4 haloalkyl, or Ci-4alkylsulfonyl.
4. The compound of any of claims 1-3, wherein each R is independently selected from fluoro, chloro, iodo, bromo, cyano, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methylsulfonyl, ethylsulfonyl, or propylsulfonyl.
5. The compound of any of claims 1, 3-4, wherein each R2 is independently selected from halo, -NH2, C^alkoxy, Ci-4alkyl, Ci-4haloalkyl, or C3_6cycloalkyl.
6. The compound of any of claims 1, 3-5, wherein each R2 is independently selected from -NH2, fluoro, chloro, iodo, bromo, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, methyl, ethyl, propyl, butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
7. The compound of any of claims 1-6, wherein R3 is selected from hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl.
8. The compound of any of claims 1-7, wherein R3 is selected from hydrogen, Ci^alkyl, C3_6cycloalkyl, or C3_6cycloalkylCi_4alkyl.
9. The compound of any of claims 1-8, wherein R3 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, or cyclopropylbutyl.
10. The compound of any of claims 1, 3-9, wherein R4 is selected from cyano, fluoro, chloro, bromo, or CONH2.
11. The compound of any of claims 1-10, wherein n is 1.
12. The compound of any of claims 1-10, wherein n is 2.
13. The compound of any of claims 1-10, wherein m is 0.
14. The compound of any of claims 1-10, wherein m is 1.
15. The compound of any of claims 1-10, wherein m is 2.
16. The compound of any of claims 1-15, wherein the compound is a (S)-enantiomer.
17. The compound of any of claims 1-15, wherein the compound is a (R)-enantiomer.
18. The compound of any of claims 1-17, wherein the compound is an atropisomer.
19. The compound of claim 1, wherein the compound is selected from the group consisting of:
(S)-2,4-diamino-6-(l-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)propylamino)pyrimidine- 5 -carbonitrile ;
(S)-2,4-diamino-6-((5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)-2- cyclopropylethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(6-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-methyl-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-(methylsulfonyl)-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(4-oxo-3-(pyridin-3-yl)-5-(trifluoromethyl)-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2-(l-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazoline- 5 -carbonitrile ;
(S)-2,4-diamino-6-(l-(3-(5-fluoropyridin-3-yl)-5-methyl-4-oxo-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile; (S)-2,4-diamino-6-(l-(5-chloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-3-(5-chloropyridin-3-yl)-4-oxo-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-3-(5-methoxypyridin-3-yl)-4-oxo-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-3-(5-(difluoromethyl)pyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-3-(5-methylpyridin-3-yl)-4-oxo-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((5-chloro-3-(5-methylpyridin-3-yl)-4-oxo-3,4-dihydroquinazolin-2- yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-4-oxo-3-(5-(trifluoromethyl)pyridin-3-yl)-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-3-(5-cyclopropylpyridin-3-yl)-4-oxo-3,4-dihydroquinazolin- 2-yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4-dihydroquinazolin-2- yl)propylamino)pyrimidine- 5 -carbonitrile ;
(S)-2,4-diamino-6-((5-chloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4-dihydroquinazolin-2- yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(8-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5,8-dichloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile; (S)-2,4-diamino-6-(l-(5,8-difluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)propylamino)pyrimidine- 5 -carbonitrile ;
(S)-2,4-diamino-6-((5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(cyclopropyl(5,8-dichloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin- 2-yl)methylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)- 2-cyclopropylethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5,8-dichloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-8-fluoro-3-(5-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((5-chloro-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4-dihydroquinazolin- 2-yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile;
(S)-2-(l-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-8-fluoro-4-oxo-3-(pyridin-3-yl)- 3,4-dihydroquinazoline-5-carbonitrile;
(S)-2-(l-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)propyl)-8-fluoro-4-oxo-3-(pyridin-3- yl)-3, 4-dihydroquinazoline-5 -c arbonitrile ;
(S)-2,4-diamino-6-(l-(5-chloro-6-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((5-chloro-6-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile; (S)-2,4-diamino-6-(l-(5-chloro-3-(2-methylpyridin-3-yl)-4-oxo-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-3-(4-methylpyridin-3-yl)-4-oxo-3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-6-fluoro-3-(4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-3-(5-fluoro-2-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(l-(5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile;
(R)-2,4-Diamino-6-((l-(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethyl) amino)pyrimidine- 5 -carbonitrile ;
(R)-2,4-Diamino-6-((l-(5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)propyl)amino)pyrimidine-5-carbonitrile;
(R)-2,4-Diamino-6-(((5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile;
(R)-2,4-Diamino-6-((l-(5-chloro-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(R)-2,4-diamino-6-((l-(5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(R)-2,4-diamino-6-((l-(5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-Diamino-6-((l-(5-chloro-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2-(l-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-5-(methylsulfonyl)-3-(pyridin- 3-yl)quinazolin-4(3H)-one; (S)-2,4-Diamino-6-((l-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethyl) amino)pyrimidine- 5 -carboxamide ;
(S)-5-Chloro-2-(l-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-3-(5-fluoropyridin-3- yl)quinazolin-4(3h)-one;
(S)-2-(l-((2,6-Diamino-5-chloropyrimidin-4-yl)amino)ethyl)-5-fluoro-3-(pyridin-3- yl)quinazolin-4(3H)-one;
(S)-5-Chloro-2-(l-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-3-(pyridin-3- yl)quinazolin-4(3H)-one;
(S)-2-(l-((2,6-Diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-6-fluoro-4-oxo-3-(pyridin-3-yl)- 3,4-dihydroquinazoline-8-carbonitrile;
(S)-2-(l-((2,6-Diamino-5-cyanopyrimidin-4-yl)amino)propyl)-6-fluoro-3-(5-fluoropyridin-3- yl)-4-oxo-3,4-dihydroquinazoline-8-carbonitrile;
(S)-2-(Cyclopropyl((2,6-diamino-5-cyanopyrimidin-4-yl)amino)methyl)-6-fluoro-3-(5- fluoropyridin-3-yl)-4-oxo-3,4-dihydroquinazoline-8-carbonitrile;
(S)-2,4-Diamino-6-((l-(5-chloro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)- 3 -methylbutyl)amino)pyrimidine- 5 -carbonitrile ;
(S)-2,4-Diamino-6-((l-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)-3- methylbutyl)amino)pyrimidine-5-carbonitrile;
(S)-5-Chloro-2-(l-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-8-fluoro-3-(pyridin-3- yl)quinazolin-4(3h)-one;
(S)-2,4-diamino-6-((l-(5-bromo-8-fluoro-3-(5-fluoropyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(5-bromo-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2-(l-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-8-fluoro-3-(5-fluoropyridin-3- yl)-4-oxo-3,4-dihydroquinazoline-5-carbonitrile; (S)-2-(l-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-4-oxo-3-(pyridin-3-yl)-3,4- dihydroquinazoline- 5 -carbonitrile ;
(S)-2,4-diamino-6-((l-(5-bromo-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2- yl)ethyl) amino)pyrimidine- 5 -carbonitrile ;
(S)-2,4-Diamino-6-(((5-chloro-8-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-Diamino-6-(((5-chloro-8-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(5-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(5-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(((5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(((5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(5-chloro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(5-chloro-8-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(5-chloro-8-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(6-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile; (S)-2,4-diamino-6-((l-(6-fluoro-3-(5-fluoro-4-methylpyridin-3-yl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(5-chloro-3-(4,5-dimethylpyridin-3-yl)-4-oxo-3,4-dihydroquinazolin- 2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(5-chloro-3-(4,5-dimethylpyridin-3-yl)-4-oxo-3,4-dihydroquinazolin- 2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-Diamino-6-((l-(3-(4-methylpyridin-3-yl)-4-oxo-5-(trifluoromethyl)-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-Diamino-6-((l-(3-(4-methylpyridin-3-yl)-4-oxo-5-(trifluoromethyl)-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-3-(6-aminopyridin-3-yl)-8-chloro-2-(l-((2,6-diamino-5-chloropyrimidin-4- yl)amino)ethyl)-6-fluoroquinazolin-4(3H)-one;
(S)-2,4-diamino-6-((l-(3-(6-aminopyridin-3-yl)-8-chloro-6-fluoro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-3-(6-aminopyridin-3-yl)-5,8-dichloro-2-(l-((2,6-diamino-5-chloropyrimidin-4- yl)amino)ethyl)quinazolin-4(3H)-one;
(S)-2,4-diamino-6-((l-(3-(6-aminopyridin-3-yl)-5,8-dichloro-4-oxo-3,4-dihydroquinazolin-2- yl)ethyl) amino)pyrimidine- 5 -carbonitrile ;
(S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(l-((2,6-diamino-5-chloropyrimidin-4- yl)amino)ethyl)quinazolin-4(3H)-one;
(S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(l-((2,6-diamino-5-chloropyrimidin-4- yl)amino)propyl)quinazolin-4(3H)-one;
(S)-2,4-diamino-6-((l-(3-(6-aminopyridin-3-yl)-5-chloro-4-oxo-3,4-dihydroquinazolin-2- yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(l-((2,6-diamino-5-chloropyrimidin-4- yl)amino)ethyl)-8-fluoroquinazolin-4(3H)-one; (S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(cyclopropyl((2,6-diamino-5-chloropyrimidin-4- yl)amino)methyl)quinazolin-4(3H)-one;
(S)-2,4-diamino-6-(((3-(6-aminopyridin-3-yl)-5-chloro-4-oxo-3,4-dihydroquinazolin-2- yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(3-(6-amino-4-methylpyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(3-(6-amino-4-methylpyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(3-(6-amino-4-methylpyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(3-(6-amino-4-methylpyridin-3-yl)-5-chloro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(3-(6-amino-4-methylpyridin-3-yl)-5,8-dichloro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(3-(6-amino-4-methylpyridin-3-yl)-5,8-dichloro-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(3-(6-aminopyridin-3-yl)-5-chloro-4-oxo-3,4-dihydroquinazolin-2- yl)ethyl) amino)pyrimidine- 5 -carbonitrile ;
(S)-2,4-diamino-6-(((3-(6-amino-4-methylpyridin-3-yl)-5,8-dichloro-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(((3-(6-amino-4-methylpyridin-3-yl)-5,8-dichloro-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile;
(S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(l-((2,6-diamino-5-chloropyrimidin-4- yl)amino)ethyl)-6-fluoroquinazolin-4(3H)-one;
(S)-2,4-diamino-6-((l-(3-(6-aminopyridin-3-yl)-5-chloro-6-fluoro-4- dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile; (S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(l-((2,6-diamino-5-chloropyrimidin-4- yl)amino)butyl)quinazolin-4(3H)-one;
(S)-2,4-diamino-6-((l-(3-(6-aminopyridin-3-yl)-5-chloro-4-oxo-3,4-dihydroquinazolin-2- yl)butyl) amino)pyrimidine- 5 -carbonitrile ;
(S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(l-((2,6-diamino-5-chloropyrimidin-4- yl)amino)butyl)-6-fluoroquinazolin-4(3H)-one;
(S)-2,4-diamino-6-((l-(3-(6-aminopyridin-3-yl)-5-chloro-6-fluoro-4-oxo-3,4- dihydroquinazolin-2-yl)butyl)amino)pyrimidine-5-carbonitrile;
(S)-3-(6-aminopyridin-3-yl)-5-chloro-2-(cyclopropyl((2,6-diamino-5-chloropyrimidin-4- yl)amino)methyl)-8-fluoroquinazolin-4(3H)-one;
(S)-2,4-diamino-6-(((3-(6-aminopyridin-3-yl)-5-chloro-8-fluoro-4-oxo-3,4- dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((l-(3-(5-aminopyridin-3-yl)-5-chloro-4-oxo-3,4-dihydroquinazolin-2- yl)ethyl) amino)pyrimidine- 5 -carbonitrile ; and
(S)-4-amino-6-((l-(3-(5-aminopyridin-3-yl)-5-chloro-4-oxo-3,4-dihydroquinazolin-2- yl)ethyl) amino)pyrimidine- 5 -carbonitrile ; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.
20. The compound of claim 19, wherein the compound is an atropisomer.
21. A pharmaceutical composition comprising:
the compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof of any of claims 1-20; and at least one pharmaceutically acceptable vehicle.
22. A method for treating a disease or condition in a human in need thereof, comprising administering to the human a therapeutic effective amount of the compound, a
pharmaceutically acceptable salt, isomer, or a mixture thereof of any of claims 1-20.
23. The method of claim 22, wherein the disease or condition is an inflammatory disorder, an autoimmune disease, or a cancer.
24. The method of claim 22-23, wherein the disease or condition is lymphoma, multiple myeloma, or leukemia.
25. The method of any of claims 22-23, wherein the disease or condition is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), non-Hodgkin' s lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldestrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small cell lung cancer, small-cell lung cancer, colon cancer, systemic lupus erythematosus (SLE), myestenia gravis, rheumatoid arthritis (RA), acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis (MS), Sjoegren' s syndrome, autoimmune hemolytic anemia, psoriasis, chronic obstructive pulmonary disease (COPD) or asthma.
26. The method of claim 22-25, wherein the compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof, is administered intravenously, intramuscularly, parenterally, nasally or orally.
27. A kit comprises the compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof of any of claims 1-20, or a label and/or instructions for use.
28. The compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof of any of claims 1 -20 for use in therapy.
29. The compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof of any of claims 1-20 for use in a method of treating of any of claims 18-22.
30. Use of the compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof of any of claims 1 -20 for the manufacture of a medicament for treatment of a disease or condition of any of claims 22-26.
PCT/US2014/042392 2013-06-14 2014-06-13 Phosphatidylinositol 3-kinase inhibitors WO2014201409A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
NZ714710A NZ714710A (en) 2013-06-14 2014-06-13 Phosphatidylinositol 3-kinase inhibitors
EP14738957.1A EP3008053B1 (en) 2013-06-14 2014-06-13 Phosphatidylinositol 3-kinase inhibitors
MX2015017192A MX347988B (en) 2013-06-14 2014-06-13 Phosphatidylinositol 3-kinase inhibitors.
PL14738957T PL3008053T3 (en) 2013-06-14 2014-06-13 Phosphatidylinositol 3-kinase inhibitors
SG11201509910YA SG11201509910YA (en) 2013-06-14 2014-06-13 Phosphatidylinositol 3-kinase inhibitors
KR1020157035901A KR101709436B1 (en) 2013-06-14 2014-06-13 Phosphatidylinositol 3-kinase inhibitors
CN201480033119.7A CN105308034B (en) 2013-06-14 2014-06-13 The kinase inhibitor of phosphatidylinositols 3
EA201592182A EA028319B1 (en) 2013-06-14 2014-06-13 Phosphatidylinositol 3-kinase inhibitors
SI201430672T SI3008053T1 (en) 2013-06-14 2014-06-13 Phosphatidylinositol 3-kinase inhibitors
ES14738957.1T ES2667173T3 (en) 2013-06-14 2014-06-13 Phosphatidylinositol 3-kinase inhibitors
AU2014277950A AU2014277950B2 (en) 2013-06-14 2014-06-13 Phosphatidylinositol 3-kinase inhibitors
JP2015563142A JP6030783B2 (en) 2013-06-14 2014-06-13 Phosphatidylinositol 3-kinase inhibitor
CA2915129A CA2915129C (en) 2013-06-14 2014-06-13 Phosphatidylinositol 3-kinase inhibitors
BR112015031475A BR112015031475A2 (en) 2013-06-14 2014-06-13 compound, pharmaceutical composition, method for treating a disease or condition, kit, and use of compound.
IL242677A IL242677B (en) 2013-06-14 2015-11-19 Phosphatidylinositol 3-kinase inhibitors
AU2016201584A AU2016201584B2 (en) 2013-06-14 2016-03-11 Phosphatidylinositol 3-kinase inhibitors
HK16108969.2A HK1220968A1 (en) 2013-06-14 2016-07-27 Phosphatidylinositol 3-kinase inhibitors 3-
HK16110710.0A HK1223911A1 (en) 2013-06-14 2016-09-09 Phosphatidylinositol 3-kinase inhibitors 3-

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361835333P 2013-06-14 2013-06-14
US61/835,333 2013-06-14

Publications (1)

Publication Number Publication Date
WO2014201409A1 true WO2014201409A1 (en) 2014-12-18

Family

ID=51177160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/042392 WO2014201409A1 (en) 2013-06-14 2014-06-13 Phosphatidylinositol 3-kinase inhibitors

Country Status (24)

Country Link
US (2) US9221795B2 (en)
EP (1) EP3008053B1 (en)
JP (1) JP6030783B2 (en)
KR (1) KR101709436B1 (en)
CN (1) CN105308034B (en)
AR (1) AR096621A1 (en)
AU (2) AU2014277950B2 (en)
BR (1) BR112015031475A2 (en)
CA (1) CA2915129C (en)
EA (1) EA028319B1 (en)
ES (1) ES2667173T3 (en)
HK (2) HK1220968A1 (en)
IL (1) IL242677B (en)
MX (1) MX347988B (en)
NO (1) NO2994608T3 (en)
NZ (1) NZ714710A (en)
PL (1) PL3008053T3 (en)
PT (1) PT3008053T (en)
SG (1) SG11201509910YA (en)
SI (1) SI3008053T1 (en)
TR (1) TR201806822T4 (en)
TW (1) TWI644909B (en)
UY (1) UY35617A (en)
WO (1) WO2014201409A1 (en)

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9115141B2 (en) 2011-08-29 2015-08-25 Infinity Pharmaceuticals, Inc. Substituted isoquinolinones and methods of treatment thereof
US9181221B2 (en) 2010-05-21 2015-11-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2016126552A1 (en) 2015-02-03 2016-08-11 Gilead Sciences, Inc. Combination therapies for treating cancers
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9512114B2 (en) 2013-09-22 2016-12-06 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
WO2017059224A2 (en) 2015-10-01 2017-04-06 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
WO2017106556A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
WO2017152062A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
WO2017177179A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
WO2017215590A1 (en) 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof
WO2018026835A1 (en) 2016-08-04 2018-02-08 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
US9944639B2 (en) 2014-07-04 2018-04-17 Lupin Limited Quinolizinone derivatives as PI3K inhibitors
WO2018085069A1 (en) 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
WO2018097977A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
WO2018137598A1 (en) 2017-01-24 2018-08-02 I-Mab Anti-cd73 antibodies and uses thereof
WO2018156901A1 (en) 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
WO2018156895A1 (en) 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
WO2018195321A1 (en) 2017-04-20 2018-10-25 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
JP2019511452A (en) * 2016-03-05 2019-04-25 ハンチョウ ヂョンシャン ファーマシューティカルズ カンパニー リミテッドＨａｎｇｚｈｏｕ Ｚｈｅｎｇｘｉａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． Quinoline analogues as phosphatidylinositol 3-kinase inhibitors
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019193542A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
WO2019193533A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2'-cyclic dinucleotides
US10442799B1 (en) 2018-04-07 2019-10-15 Fuqiang Ruan Heterocyclic compounds and uses thereof
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2019217780A1 (en) 2018-05-11 2019-11-14 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
WO2019222112A1 (en) 2018-05-14 2019-11-21 Gilead Sciences, Inc. Mcl-1 inhibitors
WO2020014643A1 (en) 2018-07-13 2020-01-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020214663A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214652A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
WO2021011544A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
WO2021076908A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
WO2021087064A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
WO2021096860A1 (en) 2019-11-12 2021-05-20 Gilead Sciences, Inc. Mcl1 inhibitors
WO2021130638A1 (en) 2019-12-24 2021-07-01 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2021222522A1 (en) 2020-05-01 2021-11-04 Gilead Sciences, Inc. Cd73 inhibiting 2,4-dioxopyrimidine compounds
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2022221304A1 (en) 2021-04-14 2022-10-20 Gilead Sciences, Inc. CO-INHIBITION OF CD47/SIRPα BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023147418A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. Parp7 inhibitors
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023196784A1 (en) 2022-04-05 2023-10-12 Gilead Sciences, Inc. Combinations of antibody therapies for treating colorectal cancer
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AR096621A1 (en) * 2013-06-14 2016-01-20 Gilead Sciences Inc 3-QUINASA PHOSFATIDYLINOSITOL (PI3K) PHOSFATIDYLINOSITOL INHIBITORS
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
CN106459005A (en) 2014-06-13 2017-02-22 吉利德科学公司 Phosphatidylinositol 3-kinase inhibitors
CA2952037A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
SG11201609527PA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
MX2016016528A (en) 2014-06-13 2017-03-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors.
GB201506786D0 (en) * 2015-04-21 2015-06-03 Ucb Biopharma Sprl Therapeutic use
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
CN109640999A (en) 2016-06-24 2019-04-16 无限药品股份有限公司 Combination treatment
TW201813963A (en) 2016-09-23 2018-04-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201825465A (en) 2016-09-23 2018-07-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201815787A (en) * 2016-09-23 2018-05-01 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
CN108017641B (en) * 2016-11-02 2021-01-05 深圳铂立健医药有限公司 Pyrazolopyrimidine compound as PI3K inhibitor and application thereof
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
KR20200112900A (en) 2018-01-20 2020-10-05 선샤인 레이크 파르마 컴퍼니 리미티드 Substituted aminopyrimidine compounds and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035075A1 (en) * 2001-10-19 2003-05-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2011146882A1 (en) * 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
ATE303997T1 (en) 1997-06-09 2005-09-15 Pfizer Prod Inc CHINAZOLIN-4-ON AMPA ANTAGONISTS
EP1216234B1 (en) 1999-09-16 2004-12-29 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE60028227T2 (en) 1999-10-27 2007-03-29 Cytokinetics, Inc., South San Francisco CHINAZOLINONE USING METHODS AND COMPOSITIONS
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
SI2223922T1 (en) 2000-04-25 2016-04-29 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
FR2828206B1 (en) 2001-08-03 2004-09-24 Centre Nat Rech Scient USE OF LYSYL OXIDASE INHIBITORS FOR CELL CULTURE AND TISSUE ENGINEERING
WO2003076418A1 (en) 2002-03-07 2003-09-18 X-Ceptor Therapeutics, Inc. Quinazolinone modulators of nuclear receptors
WO2004037176A2 (en) 2002-10-21 2004-05-06 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
DK1689724T3 (en) 2003-11-25 2012-02-27 Novartis Ag Quinazolinone compounds as anticancer agents
DK1761540T3 (en) 2004-05-13 2016-11-21 Icos Corp Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase DELTA
BRPI0512075A (en) 2004-06-15 2008-02-06 Astrazeneca Ab compound, process for the preparation thereof, pharmaceutical composition, use of a compound, and methods for producing a b-raf inhibiting effect, and an anticancer effect on a warm-blooded animal, and for treating a disease
US7939538B2 (en) 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
DE102005024017A1 (en) 2005-05-25 2006-11-30 Merck Patent Gmbh quinazolinones
EP2139882B1 (en) 2007-03-23 2013-12-25 Amgen Inc. 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
US20110217300A1 (en) 2007-06-22 2011-09-08 Arqule, Inc. Quinazolinone Compounds and Methods of Use Thereof
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
US8513284B2 (en) 2009-02-13 2013-08-20 Ucb Pharma, S.A. Fused pyridine and pyrazine derivatives as kinase inhibitors
JP5789252B2 (en) 2009-05-07 2015-10-07 インテリカイン， エルエルシー Heterocyclic compounds and uses thereof
TW201111362A (en) 2009-06-25 2011-04-01 Amgen Inc Heterocyclic compounds and their uses
JP2012531435A (en) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 4H-pyrido [1,2-a] pyrimidin-4-one derivatives as PI3K inhibitors
CA2773848A1 (en) 2009-09-09 2011-03-17 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
EP2499126B1 (en) 2009-11-12 2015-01-07 UCB Pharma, S.A. Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors
WO2011075699A2 (en) 2009-12-18 2011-06-23 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
AU2010330875B2 (en) 2009-12-18 2013-08-01 Amgen Inc. Heterocyclic compounds and their uses
UY33304A (en) 2010-04-02 2011-10-31 Amgen Inc HETEROCYCLIC COMPOUNDS AND THEIR USES
AU2011258217B2 (en) 2010-05-26 2016-12-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US20130085131A1 (en) 2010-07-01 2013-04-04 Amgen Inc. Heterocyclic compounds and their uses
MX2012015134A (en) 2010-07-02 2013-05-06 Amgen Inc Heterocyclic compounds and their use as inhibitors of pi3k activity.
US9670212B2 (en) 2010-09-14 2017-06-06 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
US8765773B2 (en) 2010-10-18 2014-07-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
AU2011323243A1 (en) 2010-11-04 2013-05-23 Amgen Inc. Heterocyclic compounds and their uses
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2816144A1 (en) 2010-11-17 2012-05-24 Amgen Inc. Quinoline derivatives as pik3 inhibitors
US20130267526A1 (en) 2010-12-23 2013-10-10 Amgen, Inc. Heterocyclic compounds and their uses
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
BR112013020329A2 (en) 2011-02-09 2016-08-02 Hoffmann La Roche heterocyclic compounds as pi3 kinase inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2751093A1 (en) * 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9202145B2 (en) 2012-11-30 2015-12-01 Safety Management Services, Inc. System and method of determining material reaction or sensitivity using high-speed video frames
EP2935246B1 (en) 2012-12-21 2018-07-25 Gilead Calistoga LLC Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
AU2013364068B2 (en) * 2012-12-21 2016-10-20 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
AR096621A1 (en) * 2013-06-14 2016-01-20 Gilead Sciences Inc 3-QUINASA PHOSFATIDYLINOSITOL (PI3K) PHOSFATIDYLINOSITOL INHIBITORS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035075A1 (en) * 2001-10-19 2003-05-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2011146882A1 (en) * 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMERIKS M K ET AL: "Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) .delta. and .gamma", CURRENT TOPICS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD, HILVERSUM; NL, vol. 9, no. 8, 1 May 2009 (2009-05-01), pages 738 - 753, XP002556393, ISSN: 1568-0266, DOI: 10.2174/156802609789044434 *

Cited By (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738644B2 (en) 2010-05-21 2017-08-22 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9181221B2 (en) 2010-05-21 2015-11-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9115141B2 (en) 2011-08-29 2015-08-25 Infinity Pharmaceuticals, Inc. Substituted isoquinolinones and methods of treatment thereof
US9546180B2 (en) 2011-08-29 2017-01-17 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9657007B2 (en) 2013-09-22 2017-05-23 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
US9670194B2 (en) 2013-09-22 2017-06-06 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
US9518046B2 (en) 2013-09-22 2016-12-13 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
US9512114B2 (en) 2013-09-22 2016-12-06 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
US9944639B2 (en) 2014-07-04 2018-04-17 Lupin Limited Quinolizinone derivatives as PI3K inhibitors
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
WO2016126552A1 (en) 2015-02-03 2016-08-11 Gilead Sciences, Inc. Combination therapies for treating cancers
WO2017059224A2 (en) 2015-10-01 2017-04-06 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
WO2017106556A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
WO2017152062A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
JP2019511452A (en) * 2016-03-05 2019-04-25 ハンチョウ ヂョンシャン ファーマシューティカルズ カンパニー リミテッドＨａｎｇｚｈｏｕ Ｚｈｅｎｇｘｉａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． Quinoline analogues as phosphatidylinositol 3-kinase inhibitors
JP7201992B2 (en) 2016-03-05 2023-01-11 ナンキン ヂョンシャン ファーマシューティカルズ カンパニー リミテッド Quinoline analogues as phosphatidylinositol 3-kinase inhibitors
US11446301B2 (en) 2016-03-05 2022-09-20 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Quinoline analogs as phosphatidylinositol 3-kinase inhibitors
WO2017177179A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
WO2017215590A1 (en) 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof
WO2018026835A1 (en) 2016-08-04 2018-02-08 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
WO2018085069A1 (en) 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
WO2018097977A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
WO2018137598A1 (en) 2017-01-24 2018-08-02 I-Mab Anti-cd73 antibodies and uses thereof
EP4050030A1 (en) 2017-01-24 2022-08-31 I-Mab Biopharma US Limited Anti-cd73 antibodies and uses thereof
US10314844B2 (en) 2017-02-24 2019-06-11 Gilead Sciences, Inc. Inhibitors of Bruton's tyrosine kinase
US10370381B2 (en) 2017-02-24 2019-08-06 Gilead Sciences, Inc. Inhibitors of bruton'S tyrosine kinase
WO2018156895A1 (en) 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
WO2018156901A1 (en) 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
WO2018195321A1 (en) 2017-04-20 2018-10-25 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP4026835A2 (en) 2017-04-20 2022-07-13 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP4227302A1 (en) 2018-02-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019193542A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides
US11149052B2 (en) 2018-04-06 2021-10-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides
US11292812B2 (en) 2018-04-06 2022-04-05 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotides
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
WO2019193533A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2'-cyclic dinucleotides
US10442799B1 (en) 2018-04-07 2019-10-15 Fuqiang Ruan Heterocyclic compounds and uses thereof
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2019217780A1 (en) 2018-05-11 2019-11-14 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
EP4029868A1 (en) 2018-05-14 2022-07-20 Gilead Sciences, Inc. Mcl-1 inhibitors
WO2019222112A1 (en) 2018-05-14 2019-11-21 Gilead Sciences, Inc. Mcl-1 inhibitors
EP4234030A2 (en) 2018-07-13 2023-08-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020014643A1 (en) 2018-07-13 2020-01-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020214663A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214652A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
WO2021011544A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
WO2021076908A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
WO2021087064A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
WO2021096860A1 (en) 2019-11-12 2021-05-20 Gilead Sciences, Inc. Mcl1 inhibitors
WO2021130638A1 (en) 2019-12-24 2021-07-01 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2021222522A1 (en) 2020-05-01 2021-11-04 Gilead Sciences, Inc. Cd73 inhibiting 2,4-dioxopyrimidine compounds
WO2022221304A1 (en) 2021-04-14 2022-10-20 Gilead Sciences, Inc. CO-INHIBITION OF CD47/SIRPα BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023147418A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. Parp7 inhibitors
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023196784A1 (en) 2022-04-05 2023-10-12 Gilead Sciences, Inc. Combinations of antibody therapies for treating colorectal cancer
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY

Also Published As

Publication number Publication date
IL242677B (en) 2018-06-28
EP3008053A1 (en) 2016-04-20
CN105308034A (en) 2016-02-03
NO2994608T3 (en) 2018-09-08
JP2016523223A (en) 2016-08-08
EA201592182A1 (en) 2016-06-30
PT3008053T (en) 2018-04-26
AU2014277950B2 (en) 2016-02-04
AR096621A1 (en) 2016-01-20
SI3008053T1 (en) 2018-06-29
UY35617A (en) 2014-12-31
CA2915129A1 (en) 2014-12-18
US9221795B2 (en) 2015-12-29
TWI644909B (en) 2018-12-21
KR20160005128A (en) 2016-01-13
US20160039793A1 (en) 2016-02-11
HK1223911A1 (en) 2017-08-11
HK1220968A1 (en) 2017-05-19
MX2015017192A (en) 2016-04-06
TR201806822T4 (en) 2018-06-21
TW201536772A (en) 2015-10-01
EP3008053B1 (en) 2018-03-21
MX347988B (en) 2017-05-19
NZ714710A (en) 2016-11-25
ES2667173T3 (en) 2018-05-09
BR112015031475A2 (en) 2017-07-25
JP6030783B2 (en) 2016-11-24
EA028319B1 (en) 2017-11-30
KR101709436B1 (en) 2017-02-22
AU2016201584B2 (en) 2017-04-13
CA2915129C (en) 2021-07-27
PL3008053T3 (en) 2018-08-31
CN105308034B (en) 2017-10-31
SG11201509910YA (en) 2016-01-28
AU2016201584A1 (en) 2016-03-31
US20140371246A1 (en) 2014-12-18
AU2014277950A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
AU2016201584B2 (en) Phosphatidylinositol 3-kinase inhibitors
AU2013364068B2 (en) Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
JP5336606B2 (en) Antitumor effect enhancer
AU2015274628B2 (en) Phosphatidylinositol 3-kinase inhibitors
US10611777B2 (en) Imidazopyridazine compounds and their use
CA2952018A1 (en) Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
WO2014187319A1 (en) Substituted pyrazolopyrimidines as kinases inhibitors
TWI523856B (en) BCR-ABL kinase inhibitor and its application
US20150210702A1 (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
US9388165B2 (en) Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase
US20190365752A1 (en) Quinoline analogs as phosphatidylinositol 3-kinase inhibitors
US20210155604A1 (en) Quinazoline compound serving as egfr triple mutation inhibitor and applications thereof
KR101684950B1 (en) Furan-containing fused cyclic compound or its salt and pharmaceutical composition comprising the same
CN114591335B (en) Indazole compound, preparation method and application thereof
KR20170074380A (en) Dihydropteridin-one derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating PI3 kinase related diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480033119.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14738957

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 242677

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2915129

Country of ref document: CA

Ref document number: 2015563142

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/017192

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201592182

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20157035901

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014277950

Country of ref document: AU

Date of ref document: 20140613

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014738957

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015031475

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015031475

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20151210